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Abstract
A b s t r a c t
Intranasal challenge of allergic individuals with allergen causes symptoms of nasal 
blockage and airway hyper-reactivity (AHR). A group of inflammatory peptides, 
known as kinins, are synthesised in the nasal airway, in response to challenge with 
allergen and their production coincides with symptom severity. These effects can be 
modelled in non-allergic individuals with the inflammatory phospholipid platelet- 
activating factor (PAF). Antagonism of kinin B2 receptors in vivo reduces the 
recovery of kinins from the nasal airway of allergic individuals challenged with 
allergen and non-allergic individuals challenged with PAF, and inhibits AHR in both 
allergic and non-allergic individuals.
In this thesis, the mechanism by which, icatibant, a kinin B2 receptor antagonist, 
reduces the recovery of kinins from the nasal airway of non-allergic individuals 
challenged with PAF has been investigated. In addition, the mechanism by which 
PAF enhances the congestive responses to intranasal challenge with the kinin, 
bradykinin, and the mast cell-derived mediator, histamine, has been investigated.
The effect of various kinin receptor antagonists on the recovery of albumin and 
kinins, by nasal lavage, from individuals challenged with PAF were determined by 
ELISA and radioimmunoassay respectively.
The effect of various kinin receptor antagonists on the enzyme activity of tissue 
kallikrein, plasma kallikrein and crude nasal lavage fluid were investigated by 
spectrophotmetry with the chromogenic substrates S-2266 and S-2302.
Nasal blockage was measured objectively using acoustic rhinometry.
The data in this thesis has shown that icatibant potently inhibits the recovery of 
kinins from PAF challenged non-atopic individuals in vivo. This effect does not 
appear to be dependant on the inhibition of plasma or tissue kallikrein activity, or 
the antagonism of kinin B2 receptors which control the influx of prekallikrein and 
kininogen into the nasal airway. In addition, there is evidence to suggest that nerves 
within the human nasal airway may play a role in PAF-induced AHR.
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CHAPTER 1
INTRODUCTION
1.1 Introduction
The kinins, bradykinin and kallidin, are agonists of kinin B2 receptors and these 
receptors are present on the microvasculature of the human nasal airway. With 
the aid of selective, high affinity antagonists, such as icatibant, bradykinin has 
been shown to cause nasal blockage and rhinorrhea in non-allergic individuals 
via the kinin B2 receptor. However, introduction of icatibant into the nasal airway 
of individuals with allergic rhinitis has shown that it inhibits allergen-induced 
kinin production in addition to inhibiting allergen-induced nasal blockage. In this 
thesis the mechanism by which icatibant inhibits the recovery of kinins from 
human nasal airways has been determined using non-allergic individuals to 
model allergic rhinitis by intranasal challenge with the phospholipid platelet 
activating factor (PAF).
1.2 Anatomy and physiology of the human nasal airway
1.2.1 The nasal cavity
To assist breathing, the nose must heat, humidify and filter air of foreign 
particles on entry into the airway (Atkinson and Kaliner, 1995; Mygind and Dahl, 
1998; Dykewicz, 2003). Filtration begins in the nasal vestibule, the outermost 
region of the nose. This region contains a copious amount of hairs, which seize 
and deposit potentially noxious particles (greater than 10 pM in diameter) in the 
nasal cavity where they enter the mucociliary transport system (figure 1 .1 ) 
(Naclerio and Solomon, 1997).
The nasal cavity is a framework of bone and cartilage, lined with soft mucosal 
tissue. Entry into the nasal cavity occurs via two oblong shaped apertures, 
which form canals that project dorsally into the airway. These canals join to form 
a region known as the nasopharynx. The anterior ends of both canals are 
segregated from each other by a wall of cartilage and bone known as the nasal
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septum, while the bases of the canals are situated directly above a bone known 
as the hard palate (figure 1.1).
Protruding from the lateral walls of both nasal cavities are three bones, known 
as the superior, the middle and the inferior nasal turbinates (or conchae) (figure 
1.1) (Mygind and Dahl, 1998). These structures significantly increase the 
surface area of the nasal airway and therefore improve its ability to heat and 
humidify air (figure 1.1)
Figure 1.1) The lateral wall of the human nasal cavity (Gray’s Anatomy, 2000).
The respiratory mucosa consists of a layer of ciliated pseudostratified columnar 
epithelial cells, intermittently penetrated by goblet cells, basal cells and non- 
ciliated epithelial cells (figure 1.2) (Thaete et al., 1981; Atkinson and Kaliner, 
1995; Christodoulopoulos et al., 2000; Salib et al., 2003; Dykewicz, 2003). Both 
ciliated and non-ciliated cells contain 300 to 400 small cytoplasmic extensions 
on their apical surfaces called microvilli and like cilia, the function of the 
micorvilli is to increase the surface area of the nasal airway to help maintain a 
constant temperature and humidity.
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Situated directly beneath the mucosal lining is the basement membrane, a 
fibrous layer composed of type I, III and IV collagen (Christodoulopoulos et al., 
2000). It forms a stable surface for cells of the mucosal lining to grow on, and 
prevents cellular detachment during a chemical or inflammatory insult. Beneath 
the basement membrane is a relatively cell free zone, called the submucosa (or 
lamina propia). The major constituents of this zone are glands, blood vessels, 
nerves, interstitial cells and inflammatory cells.
1.2.2 Nasal glands and secretions
There are two types of glands found in the nasal mucosa, serous glands and 
mucous glands. Serous glands predominantly reside near the surface of the 
submucosa, where they produce non-viscous secretions which contain 
antimicrobial proteins such as lactoferrin, lysozyme, secretory IgA and secretory 
component (Mygind and Dahl, 1998; Kaliner, 2005; Thaete et al., 1981). Each 
nostril is thought to contain approximately 100 to 150 of these glands. Mucous 
glands are situated further away from the mucosal surface and they are around 
10 times more abundant than their serous counterparts. They produce a more 
viscous secretion (as a result of a higher glycoprotein content) and are thought 
to be one of the major contributors to nasal secretions during nasal allergy.
Secretions from both of these glands combine with mucous glycoproteins from 
the goblet cells, condensed water from inspired air and plasma exudate to 
produce a bilayered blanket which lines the respiratory epithelium (Salib et al., 
2003; Kaliner, 1991). The inner layer is serous in nature, while the outer layer 
has a high mucus content, and acts a barrier responsible for catching 
microorganisms and particles found within the inspired air. Epithelial cilia pass 
through the inner layer to penetrate the outer layer of the blanket. Movement of 
the cilia causes the mucous layer to move posteriorly towards the nasopharynx 
where it can be swallowed. The ciliated epithelia, mucosal and submucosal 
glands work in unity to form the first line of defence against foreign particles and 
microorganisms.
1.2.3 The microvasculature
Arterioles of the respiratory mucosa receive a large amount of blood from the 
ethmoidal arteries (branches of the ophthalmic artery) and the sphenopalatine 
artery (a branch of the maxillary artery) (Dawes and Prichard, 1953; Atkinson
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and Kaliner, 1995). The blood leaves the arterioles to enter arterio-venous 
anastamoses, capillaries and venous sinusoids of the nasal mucosa.
Arterio-venous anastamoses (AVA) are structures that bypass capillary beds 
and venous sinusoids present within the nasal airway, and directly join arterioles 
to venules at the surface of the submucosa (figure 1.2). In doing so, it is thought 
they allow an increase in blood flow, which helps to cool the nasal airway down 
in hot ambient temperatures, without causing nasal congestion (Widdicombe, 
1997).
Postcapillary venules are potentially very porous in nature, this is because their 
endothelial cells contract (in response to exposure to certain inflammatory 
mediators) to form gaps in the junctions between endothelial cells (figure 1.2) 
(Cauna, 1970; Atkinson and Kaliner, 1995; Widdicombe, 1997; Mygind and 
Dahl, 1998). Consequently, postcapillary venules are deemed a major site of 
plasma leakage during inflammatory events. It must be noted that the leakage of 
plasma into the interstitial space may also cause nasal congestion due to 
submucosal swelling (oedema).
There are three types of capillary beds found in the nasal airway, all of which 
are distinguished from each other by their position within the lamina propia 
(subepithelial capillary beds, glandular capillary beds and periosteal capillary 
beds). They all contain an endothelial lining with fenestrae (figure 1.2) (Cauna, 
1970; Atkinson and Kaliner, 1995; Mygind and Dahl, 1998; Grevers and 
Kastenbauer, 1996). The fenestrations aid the humidification and heating of the 
surrounding tissues, increase the efficiency of gaseous exchange, and increase 
the efficiency of nutrient transfer between the capillaries, the epithelium and the 
glands of the nasal airway.
Venous sinusoids are the capacitance vessels of the microvasculature, they are 
extremely prominent in the nasal turbinates. They are responsible for generating 
the symptom of nasal blockage. When engorged with blood, they distend into 
the nasal airway (because they are encased in bone), and obstruct airflow 
(figure 1.2). Sphincter muscles, called throttle veins, are situated at the site 
where the sinusoids adjoin to venules. It is thought that their contraction 
increases the level of sinusoidal filling (Widdicombe, 1997). Sinusoid filling is 
also thought to be controlled by the degree of sympathetic tone regulating the
30
Chapter 1 Introduction
activity of smooth muscle in sinusoidal walls and the degree of venular 
compression by adjacent dilated arteries.
Ciliated-columnar 
epithelial cell
Non-clliated 
columnar 
epithelial cell
Basal cell
Submucosal
Basement
membrane
.....
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Arteriovenous anastamoses
Postcapillary
venule
Figure 1.2) The anatomy of the human nasal mucosa adapted from 
Naclerio et al., 1993 and Baraniuk, 1995.
1.2.4 The autonomic and sensory nervous system
The human nasal airway has an extensive neuronal network, comprising of the 
autonomic nervous system (the sympathetic nervous and the parasympathetic 
nervous system) and the non-adrenergic non-cholinergic nervous (NANC) 
system.
Parasympathetic innervation of the respiratory mucosa of the nasal cavity is 
derived from the greater superficial petrosal nerves which synapse in the 
sphenopalatine ganglion (SPG) (figure 1.3). The entire sympathetic nervous 
input of the nasal airway originates from the superior cervical ganglion (SCG), 
which emits three main clusters of nerve fibre; the ethmoid nerves; the deep 
petrosal nerves and another nerve/(s) which are thought to innervate the 
arterioles of the contralateral and ipsilateral nasal cavities (Wilson and Yates, 
1978; Su et al., 1988; Atkinson and Kaliner, 1995; Rinder, 1996).
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Figure 1.3) A schematic diagram of the neuronal arrangement within the nasal mucosa 
adapted from Wilson and Yates, 1978; Su et al., 1988; Atkinson and Kaliner, 1995 and 
Widdicombe, 1990. A signifies the arterioles, V signifies the postcapillary venules, a = 
SCG nerve fibres, b = the vidian nerve, c = the greater superficial petrosal nerve, d = 
the deep petrosal nerve, e = the caudal nasal nerve.
After leaving the SCG, the ethmoidal nerves directly innervate the nasal 
mucosa. Prior to entry into the SPG, the deep petrosal nerves become closely 
associated with the greater superficial petrosal nerves as they traverse the
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pterygoid canal. Subsequently, they are given the collective name, the vidian 
nerve (figure 1.3).
As the vidian nerve enters the SPG, the deep petrosal nerve passes through the 
ganglion but does not form any synapses. The emerging postganglionic 
parasympathetic fibres remain in close proximity with the deep petrosal nerves, 
and are given the name, the caudal nasal nerve (figure 1.3).
The caudal nasal nerve, along with sympathetic fibres traversing from the 
contralateral nasal cavity provide the remainder of the autonomic input of the 
nasal airway (Wilson and Yates, 1978; Su et al., 1988; Atkinson and Kaliner,
1995).
Sensory neurones of the nasal airway originate from axons of the maxillary 
division of the trigeminal cranial nerve. It branches off into two divisions, one 
forms a varicosity with the parasympathetic branch of the vidian/caudal nasal 
nerve in the SPG, and the other branch directly innervates the mucosa and 
submucosa of the nasal airway (figure 1.3) (Widdicombe, 1990; Atkinson and 
Kaliner, 1995).
1.2.5 The sympathetic nervous system
The degranulation of mast cells after allergen challenge results in the production 
of an array of humoral mediators, most of which influence the dynamics and 
integrity of the microvasculature within the nose. However, under non­
inflammatory conditions the sympathetic nervous system is predominantly 
responsible for controlling vascular tone. This has been shown by the severance 
of sympathetic fibres emanating from the SCG. Cervical sympathectomy causes 
ipsilateral nasal blockage, suggesting that nasal patency is maintained by a 
continuous stream of impulses from the sympathetic nervous system (Mygind, 
1982; Takanashi et al., 2003). The principal neurotransmitter in this stream of 
impulses is noradrenaline.
Three adrenoceptor subtypes for noradrenaline are present within the nasal 
airway: ar, a2- and (32-adrenoceptors (van Megen et al., 1991a). a-r 
adrenoceptors are post-synaptic receptors, which when activated cause 
vasoconstriction including constriction of venous sinusoids. While, on the other 
hand, a2-adrenoceptors were originally thought to be exclusively pre-synaptic,
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and therefore autoinhibitory. This is no longer the case since pharmacological 
studies on human nasal mucosa and blood vessels have shown that (1) the 
tissue contracts in response to the application of a2-adrenoceptor agonists, and 
(2) this response is inhibited by pre-treatment with a selective a2-adrenoceptor 
antagonist (Ichimura and Chow, 1988).
These findings brought the following question to light, “what is the precise 
subanatomical location of the a2-adrenoceptor?”. Andersson and Bende, (1984) 
found that intranasal application of a2-agonists into the nasal airway caused a 
significant reduction in blood flow, while application of clinically efficacious 
doses of an di-agonist (for relief of nasal congestion) did not significantly affect 
nasal blood flow (Andersson and Bende. 1984). It was therefore concluded that 
a2-adrenoceptors are the predominant a-adrenoceptor found on resistance 
vessels. Another group performed studies on pre-capillary (resistance) vessels 
in vitro and found that the application of phenylephrine (a selective a-r 
adrenoceptor agonist) to the preparation caused dose-dependent 
vasoconstriction (which was inhibited by prazosin, a selective ai-adrenoceptor 
antagonist), while oxymetazoline (a non-selective a-adrenoceptor agonist) had 
very little effect on the vascular tone (Johannssen et al., 1997). A possible 
reason for the discrepancy between these results could be because the study 
performed in vitro was carried out using only arterioles dissected from the nose 
(and not AVAs or venous sinusoids), therefore any contribution of the AVAs and 
capacitance vessels to the rate of blood flow in vivo were overlooked.
Nonetheless, it is unanimously agreed that (1) functional forms of a-r and a2- 
adrenoceptor are present within the nasal airway, (2) under non-inflammatory 
conditions it is likely that d r  and a2-adrenoceptors are both responsible for 
maintenance of nasal patency and, (3) the exogenous application of their 
agonists to the nasal airway reduces nasal congestion.
Expression of p2-adrenoceptors within the human nasal mucosa of allergic 
individuals is thought to be downregulated in comparison to that of non-allergic 
individuals (Ishibe et al., 1983; van Megen et al., 1991a). The biological 
significance of this finding is not known, as their physiological role within the 
human nasal airway is not understood (Svensson et al., 1980; Andersson and 
Bende. 1984; van Megen et al., 1991a; Stewart et al., 1993). p2.adrenoceptors 
have been identified on the nasal turbinates of non-allergic individuals. It is
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speculated that they cause nasal blockage by their ability to dilate resistance 
vessels (Widdicombe, 1997). However, intranasal challenge with selective p2. 
adrenoceptor agonists does not produce significant nasal blockage (Svensson 
et al., 1980; Andersson et al., 1984). It has also been speculated that because 
these receptors are found on post-capillary venules, they may play a role in 
controlling the vascular permeability of the nasal vasculature. However, 
Svensson et al., (1994) found that intravenous administration of |32.adrenoceptor 
agonists does not alter the albumin or plasma-derived protein content of nasal 
lavages from non-allergic individuals challenged with histamine.
1.3 Allergic rhinitis
Allergic rhinitis is a condition in which the nasal airway mounts an inflammatory 
response against foreign particles found on the mucosal surface. It currently 
affects millions of people worldwide and its prevalence is thought to be 
increasing dramatically, especially in industrialised nations. During 2001, in the 
UK alone, it was estimated that 22% of the population suffered from clinically 
diagnosable forms of allergic rhinitis (Bauchau and Durham, 2004).
Allergic individuals usually experience symptoms of pruitis (nasal itching), 
excessive sneezing, nasal blockage, rhinorrhea (a runny nose) and airway 
hyper-reactivity. Symptoms can be extremely debilitating and it is not 
uncommon for them to spread to other regions of the body such as the eyes 
(conjunctivitis), the lower airway (allergic asthma) or even the skin (dermatitis or 
utricaria). In severe cases symptoms can cause insomnia.
Broadly speaking, there are two forms of allergic rhinitis, a perennial form and a 
seasonal form (Skoner, 2001). The perennial form is prevalent all year around 
and is triggered by exposure to indoor allergens such as house dust mite, 
animal dander and mould spores. The seasonal form of allergic rhinitis tends to 
arise during the spring and summer months as a result of rises in ambient levels 
of tree, grass and flower pollens.
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1.3.1 Pathophysiology
Under normal conditions, in non-allergic individuals, the nasal mucosa functions 
effortlessly, maintaining homeostasis and preventing the entry of foreign 
particles into the nasal mucosa. However, in sufferers of allergic rhinitis, this 
system fails, resulting in an inflammatory response, which manifests itself in the 
form of the symptoms mentioned above.
Allergic rhinitis is composed of two phases, a sensitisation phase and an 
effector phase. Sensitisation is the first of the two phases and is responsible for 
allergen recognition, the production of CD4+ T-helper 2 (TH2) lymphocytes and 
immunoglobulin E (IgE) antibodies specific for the invading particle.
1.3.1.1 Sensitisation
Allergen(s) capable of evading the nose’s first line of defence against foreign 
particles are usually encountered by one of three types of antigen presenting 
cell (APC): monocytes/macrophages, B-lymphocytes and dendritic cells (DCs) 
(Kalb et al., 1991; van Cauwenberge, 1997). A pre-requisite for being able to act 
as an APC, is that the cell must be able to express class II major 
histocompatibility complexes (MHC II). However, of the three leukocytes 
mentioned above DCs are the dominant cell type responsible for mediating 
primary immune responses against allergens (Fokkens, 1999; Howarth et al., 
2000). The reason for this is not known but large numbers of their 
undifferentiated predecessors are abundant within the nasal epithelium and 
mucosa (Jahnsen et al., 2004).
Recognised allergens are endocytosed by local dendrite cells and passed 
through an intracellular pathway responsible for processing exogenous 
antigens. This pathway involves cleaving the allergen into 4-7 amino acid long 
peptides, binding to MHC II molecules and then transportation to the cell 
membrane for extracellular expression (Fokkens, 1999).
While processing the antigen, the DC down regulates the expression of 
chemokine receptors that direct it towards the nasal mucosa, and upregulates 
the expression of receptors such as CCR7 and CCR8 (Qu et al., 2004). These 
receptors cause the DC to leave the nasal mucosa, via lymphatic system, and 
enter a local lymphoid tissue organ in which the chemokines CCL21 and CCL1,
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ligands for CCR7 and CCR8 respectively, are produced (Fokkens, 1999; Upham 
and Stumbles, 2003).
Once in the lymph node, the DC binds to T-cell receptors (TCRs) of 
undifferentiated CD4+ T-cells via their MHC class II receptors, with the peptide 
still bound. CD4+ cells differentiate into one of two cellular subtypes: a TH1 
subtype, which generates a delayed hyper-sensitivity response to invading 
allergens, or, a TH2 subtype, which is necessary for a type I and type IV 
hypersensitivity reaction. In order for the immunoincompetent T-cells to 
differentiate into a CD4+ TH2 lymphocyte a variety of other co-stimulatory 
signals are generated, such as the binding of CD4 to MHC II (Lydard et al., 
2000), the release of TH2-cell promoting cytokines by the DC (Upham and 
Stumbles, 2003), the release of TH1 impeding cytokines by the DC (Upham and 
Stumbles, 2003) and the interaction of the two cell types via other surface 
receptors (Lydard et al., 2000). Unfortunately, the reason why DC cells promote 
a Th2 subtype as opposed to TH1 in allergic disorders is not known (Eisenbarth 
et al., 2003).
In addition to DCs, B-lymphocytes found within the nasal mucosa also act as 
APC. Allergen which enters the nasal mucosa is captured by the Fab region of 
antibodies bound to the surface of B-lymphocytes via their Fc regions (Fokkens, 
1999). Cross-linkage of two immunoglobulin receptors (by allergen) causes 
allergen-immunoglobulin complexes to be endocytosed. They are passed 
through a series of endosomes until they reach specialised endosomes known 
as the MIIC (MHC-class-ll-containing endosome compartments) (Jelinek, 2000; 
Clark et al., 2004). In the MIIC, the allergen is cleaved into short amino acid 
sequences and binds to the antigen recognition domain of MHC class II 
molecules. The MHC class II molecule-allergen complexes are then passed to 
the plasma membrane for extracellular expression.
Like DCs, antigen processing B-cells travel down a chemokine gradient which 
cause them to leave the nasal mucosa and enter a local lymphoid tissue organ 
(Clark et al., 2004).
Once in the local lymphoid organ, B-lymphocytes bind to the T-cell receptors of 
naive T-lymphocytes, via their MHC class ll-allergen complexes (Clark et al.,
2004). This interaction promotes the differentiation of naive T-lymphocytes into 
Th2 lymphocytes.
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Newly formed CD4+ TH2 cells release IL-2 to promote further growth and 
differentiation of naive T-lymphocytes into TH2 lymphocytes (van Cauwenberge,
1997).
Naive B-cells present within the local lymphoid organ become activated by 
binding to antigen-receptor complexes found on the surface of follicular dendritic 
cells, which are also present within the lymphoid organ. This ultimately results in 
the differentiation of the B-cells into non-immunoglobulin E (non-lgE) secreting 
plasma cells. However, it is believed that the plethora of TH2 cytokines (including 
IL-3, IL-4, IL-5, IL-6, IL- 7, IL-10 and IL-13) and TH2 co-stimulatory signals (such 
as B-cell CD40 binding with CD40L/CD154, and B-cell CD28 binding with 
CD80/CD86) cause the B-cells to grow and differentiate into IgE-secreting 
plasma and memory cells (van Cauwenberge, 1997; Fokkens, 1999; Lydard et 
al., 2000; Jelinek, 2000; Baraniuk, 1997).
IgE produced by the plasma cells leaves the lymph node and enters the 
circulation. Subsequently, a rise of specific-lgE titre is thought to be indicative of 
atopy (or allergy) (Prussin and Metcalfe, 2006). Immonhistochemical 
examination of nasal biopsies from sensitised individuals has shown that 
approximately 64% of the IgE observed co-localises with mast cells 
(Rajakulasingam et al., 1997a). This interaction occurs via high affinity cell 
surface FceRI receptors, which are found on both mast cells and basophils. IgE 
binds to these receptors (via its Fc region), leaving its antigen-binding Fab 
region exposed to the extracellular environment, awaiting further allergen 
invasion.
1.3.1.2 The immediate response
Sensitised individuals remain asymptomatic until they encounter allergen again, 
in which case, a variety of different inflammatory mediators are produced. A 
handful of these mediators induce an immediate response, which results in the 
manifestation of rhinitic symptoms for a period of approximately 40 minutes. A 
key event in the development of the immediate response is mast cell 
degranulation.
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1.3.1.2.1 Mast cell activation
Mast cells usually reside in the submucosa of non-allergic individuals. However, 
in allergic rhinitis, they traverse the lamina propia and mucosa to enter the 
epithelium, where they proliferate in anticipation of another invasion of allergen 
(Howarth, 1995; Baraniuk, 1997; Howarth et al., 2000; Skoner, 2001; Salib et 
al., 2003).
All subsequent IgE-specific allergen that infiltrates the nasal epithelium/mucosa 
binds to the high affinity FceRI receptors. IgE binding is translated into an 
intracellular signal by the activation of two tyrosine kinases, Syk and Fyn (Blank 
and Rivera, 2004). The combined activity of Fyn (which ultimately activates 
protein kinase C) and Syk (which simultaneously generates a phospholipase Cy- 
dependent rise in intracellular [Ca2+]) is mandatory for mast cell degranulation 
(Blank and Rivera, 2004).
Degranulation is a term which refers specifically to the exocytosis of storage 
granules. These granules contain carboxypeptidases, tryptase, chymase (in 
mast cells found in connective tissue only) and histamine, which is bound to the 
proteoglycans, chondritin and heparin (Naclerio et al., 1985; Togias et al., 1988; 
Dykewicz, 2003; Hansen et al., 2004). Receptor cross-linkage also acts as a 
signal for the release of lipid mediators, but because they are synthesised on 
demand their release is delayed, and also prolonged by their diffusion out into 
the extracellular space. Lipid mediators produced include platelet activating 
factor (PAF), prostaglandin D2 (PGD2), leukotriene B4 (LTB4), leukotriene C4 
(LTC4) and leukotriene D4 (LTD4) (Baraniuk, 1997; Christodoulopoulos et al., 
2000; Dykewicz, 2003). Cytokines are the third and final type of mediator 
released as a result of receptor cross-linkage. Examples include tumour 
necrosis factor-a (TNFa), transforming growth factor-p (TGFp), IL-4, IL-5, IL-6 
and IL-13 (Howarth, 1995; Baraniuk, 1997; Christodoulopoulos et al., 2000; 
Salib et al., 2003).
It is thought that mast cell degranulation only occurs in cells in which one 
allergen molecule simultaneously binds to two surface FceRI receptors (cross- 
linking) (Blank and Rivera, 2004). However, it has recently been discovered that 
intracellular signalling occurs in the absence of receptor cross-linkage and
antigen binding (Kalesnikoff et al., 2001). Binding of IgE to FcsRI (without cross­
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linkage) activates specific mitogen-activated protein kinase (MAPK) pathways, 
which cause the cytokine synthesis and secretion (IL-6, IL-13 and TNFa) 
without mast cell degranulation or lipid mediator synthesis (Kalesnikoff et al., 
2001; Prussin and Metcalfe, 2006).
1.3.1.2.2 Change in vascular dynamics
The blood vessels within the nasal airway contain receptors for a variety of 
different inflammatory mediators produced during, and as a result of mast cell 
degranulation. It is generally thought that receptors for these mediators are 
found on endothelial cells, which line the lumen of the vasculature, and 
production of their agonists causes vasodilation and/or plasma extravasation 
(Behrendt and Ganz, 2002).
Vasodilation is an increase in the luminal diameter of a blood vessel. It is a 
receptor-dependent and receptor-independent event brought about by the 
activation of the Ca2+-dependent enzyme, endothelial nitric oxide synthase 
(eNOS) (Behrendt and Ganz, 2002). Receptor dependent activation of eNOS 
can be triggered by mediators such as bradykinin, histamine and acetylcholine, 
while shear stress, on endothelial cells, can cause receptor independent 
activation of eNOS (Arnal et al., 1999) . eNOS is responsible for the conversion 
of the amino acid, L-arginine, into nitric oxide (NO) and L-citrulline. NO diffuses 
into adjacent vascular smooth muscle cells and activates another enzyme called 
guanylate cyclase. Guanylate cyclase converts guanosine triphosphate into 
cyclic guanosine monophosphate, which in turn goes on to activate a series of 
other enzymes that cause the relaxation of vascular smooth muscle (Behrendt 
and Ganz, 2002).
Objectively, vasodilation is detected as an increase in blood flow through the 
arterioles and AVAs (Birchall et al., 1993). While subjectively, vasodilation is 
observed as nasal blockage due to engorgement of the venous sinusoids with 
blood (which occurs when the rate of blood flow through the arterioles and/or 
AVAs supplying the sinusoids is greater than that through the venules 
responsible for emptying them) (Birchall et al., 1993).
Under non-inflammatory conditions, postcapillary blood vessels within the nasal 
airway are slightly porous in nature and therefore allow the fluid to exit from the 
microvasculature. However, these pores impede the extravasation of large
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proteins (such as albumin and a 2 -macroglobulin) into the lamina propia 
(Persson et al., 1991; Persson et al., 1996; Persson et al., 1997). Under 
inflammatory conditions the endothelial cells of these blood vessels contract in 
response to exposure to mediators such as histamine and PAF. This contraction 
results in the formation inter-endothelial gaps, which do not impede the 
transition of plasma proteins out of the microvasculature (Greiff et al., 2002; 
Greiff et al., 2003). Consequently, exudate accumulates in the lamina propia 
and then traverses the mucosa to enter the nasal lumen.
Increases in vascular permeability are potentiated by a simultaneous occurrence 
of vasodilation. This is because an increase in blood flow, also increases the 
hydrostatic pressure in post-capillary blood vessels, therefore forcing exudate 
out of the microvasculature at a faster rate (Berg et al., 2003; Greiff et al., 2003). 
An increase in vascular permeability also contributes to nasal blockage, due to 
oedema formation (Persson et al., 1991; Persson et al., 1996).
Objective measurements of an increase in vascular permeability are made by 
detecting increases of extravasation, using markers such as albumin and ot2 - 
macroglobulin (Svensson et al., 1989; Svensson et al., 1995; Berg 2003; Greiff 
et al., 2005).
1.3.1.2.3 Activation of sensory-parasympathetic reflex
While some of the symptoms of allergic rhinitis are caused by changes in 
vascular tone (nasal blockage), it has been established that the majority are 
caused by neural activity. Intranasal challenge with mediators such as 
bradykinin and histamine induces symptoms of rhinorrhea, pruritus and 
sneezing, all of which may be mediated partly by neural activation. The common 
starting point in the generation of all these symptoms is the sensory nervous 
system.
Sensory nerves fibres innervating the nasal mucosa are unmyelinated small 
diameter C-fibres. Their activation causes the production of an orthodromic 
signal, which passes, via the trigeminal sensory root, and diverges on entry into 
the central nervous system (CNS). Impulses are propagated along ascending 
neural pathways into higher regions of the CNS where sensations of itch and 
pain are acknowledged. Impulses also travel via interneurones within the CNS,
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until they synapse with parasympathetic fibres in the CNS (Baraniuk, 1992; 
Canning, 2002; Tai and Baraniuk. 2002; Groneberg et al., 2004). Entry of 
impulses into the CNS is also bypassed by collateral fibres emanating from the 
maxillary and mandibular branch of the trigeminal nerve (Lundblad et al., 1983; 
Widdicombe, 1990; Groneberg et al., 2004). These peripheral sensory fibres 
form a varicosity with the vidian/caudal nasal nerve in the SPG (figure 1.3). 
Activation of the parasympathetic nerve fibres causes the signal to be passed 
antidromically towards the effector organs within the nasal airway (i.e. arterioles, 
venules, glands and venous sinusoids), where it causes glandular secretion, 
extravasation, vasodilation and possibly even nasal blockage (Baraniuk, 1992; 
Kaliner, 1992; Canning, 2002). Sneezing is a reflex caused by the activation of 
motor neurones (as opposed to parasympathetic fibres), which innervate various 
muscles in the lower airway.
The principle neurotransmitter thought to be responsible for mediating these 
parasympathetic effects is acetylcholine (ACh). It activates all five subtypes of 
G-protein coupled muscarinic receptor (m1-m5) and all five are present within 
the human nasal airway (atopic and non-atopic). However, they all differ in their 
subantaomical distribution and density (van Megen et al., 1991b; Nakaya et al., 
2002).
1.3.1.2.4 Inhibition of sympathetic activity
Under inflammatory conditions, the parasympathetic nervous system induces 
effects on the microvasculature which oppose the effects of noradrenaline. 
These opposing actions are mediated by a neural reflex, which is propagated by 
postganglionic parasympathetic nerve fibres that synapse with postganglionic 
sympathetic nerve terminals. Depolarisation of these parasympathetic nerve 
fibres induces the release of acetylcholine and the activation of presynaptic 
inhibitory muscarinic receptors (found on sympathetic nerve terminals) 
responsible for inhibiting the release of noradrenaline (Jackson and Steele, 
1985).
1.3.1.2.5 Neurogenic inflammation
By definition, the sensory nervous system is only composed of afferent nerve 
fibres. However, it is capable of propagating a neural reflex which generates an 
inflammatory response known as neurogenic inflammation. Activation of the
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sensory neurones generates an impulse which, as mentioned before, is 
projected orthodromically towards the CNS, but also passes antidromically 
through collateral sensory fibres found within the periphery of the nervous 
system (figure 1.3) (Foreman, 1987). The collateral sensory fibres innervate the 
parasympathetic nervous system or project antidromically into the nasal mucosa 
and release neuropeptides such as substance P (SP), calcitonin gene related 
peptide (CGRP) and neurokinin A (NKA).
1.3.1.2.6 Glandular exocytosis
Activation of glands within the nasal airway is mediated by the parasympathetic 
nervous system. Sufferers of allergic rhinitis produce excessive amounts of 
serosal fluid and this is thought to be a major cause of rhinorrhea (Druce et al., 
1985; Meltzer et al., 1992; White, 1993). Intranasal challenge with methacholine 
(a non-selective, longer acting analogue of acetylcholine) causes dose- 
dependent rhinorrhea (Druce et al., 1985; Raphael et al., 1988; Raphael et al., 
1989a; White, 1993). A major constituent of the fluid is serosal in origin, and a 
rise in the proportion of glandular proteins such as lysozyme and lactoferrin 
(with respect to total protein content) is indicative of glandular activation 
(Raphael et al., 1989a).
Allergen challenge of atopic individuals also causes a rise in the ratio of 
glandular to total protein content of nasal lavage fluid (Raphael et al., 1991). On 
the basis that glands within the airway are not thought to express receptors for 
IgE, it is thought that allergen-induced activation is mediated by a neural reflex 
within the nasal airway. Pre-treatment of allergen challenged atopic individuals 
with a non-selective muscarinic receptor antagonists significantly reduces the 
symptoms of rhinorrhea (Meltzer et al., 1992).
Immunohistochemical analysis of muscarinic receptors found on glands within 
the submucosa of inferior nasal turbinates has revealed that m l, m2, m3 and 
m5 subtypes are present (the most abundant being m l and m3) (Nakaya et al., 
2002). Unfortunately, determining which subtype is responsible for glandular 
activation has been hindered by a lack of selective agonists or antagonists for 
these receptors.
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During nasal allergy or infection, glandular secretions combine with exudate, 
goblet cell secretions, condensed inspired moisture and epithelial secretions to 
form the fluid produced during rhinorrhea.
1.3.1.2.7 Production of NANC transmitters
As mentioned above, the classical neurotransmitters found in the autonomic
nervous system are noradrenaline and acetylcholine. However, peptides also 
play a role in neurotransmission referred to as non-adrenergic non-cholinergic 
(NANC) transmission.
1.3.1.2.7.1 Vasoactive Intestinal Peptide
Vasoactive intestinal peptide (VIP) is a neuropeptide, which predominantly (but 
not exclusively) co-exists with ACh in cholinergic fibres (figure 1.4). These fibres 
primarily innervate blood vessels and seromucosal glands, and in allergic rhinitic 
airways their densities are significantly increased compared to non-allergic 
rhinitics (Uddman et al., 1981; Fang and Shen, 1998; Fang et al., 1998). 
Biopsies from nasal turbinates have shown that the levels of VIP in allergic
individuals are also significantly elevated compared to those of non-allergic
individuals (Fang and Shen, 1998; Fang et al., 1998). Expression of VIP 
receptors (VPAC1 and VPAC2) within the nasal airway strongly correlates with 
the distribution patterns of VIP-positive fibres (Baraniuk et al., 1990a). 
Unfortunately, the importance of each receptor subtypes in allergic rhinitis has 
not been determined.
His-Ala-Asp-Gly-Val-Phe-Thr-Ser-Asp-Phe-Ser-Lys-Leu-Leu-Gly-Gln-Leu-Ser-
Ala-Lys-Lys-Tyr-Leu-Glu-Ser-Leu-Met-NH2
Figure 1.4) The amino acid sequence of VIP.
Co-localisation of VIP with ACh-positive fibres has implicated it in cholinergic 
mediated transmission. Nasal challenge with histamine or allergen (in atopies) 
also causes the release of VIP via the sensory-parasympathetic reflex 
(Mosimann et al., 1993). Like ACh, intranasal application of VIP into the human 
nasal airway causes rhinorrhea (Chatelain et al., 1995). Unfortunately, no 
studies have been performed in vivo to determine whether glandular proteins 
are produced during this response. However, it is known that treatment of
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human nasal biopsies with VIP does cause a rise in the level of lactoferrin 
(Baraniuk et al., 1990a).
Another symptom which is thought to be mediated by cholinergic transmission is 
nasal blockage. This hypothesis is supported by the fact that (1) electrical 
stimulation of feline trigeminal nerves (with lesions in the sympathetic 
component of the vidian nerve) causes marked nasal vasodilation (Lundblad et 
al., 1983), (2) electrically-induced vasodilatory responses are partially sensitive 
to atropine and (3) a high density of muscarinic receptors are expressed on 
arterioles, veins and cavernous sinusoids within the human nasal airway (van 
Megen et al., 1991b; Nakaya et al., 2002).
Similarly, intranasal application of VIP to the human nasal airway causes 
atropine-resistant vasodilation and nasal blockage in non-atopic individuals 
(Barnes et al., 1991a; Barnes et al., 1991b; Chatelain et al., 1995).
1.3.1.2.7.2 Neuropeptide Y
Neuropeptide Y (NPY) is a 36 amino acid peptide, which predominantly (but not 
exclusively) co-exists with noradrenaline in noradrenergic fibres of the nasal 
airway (figure 1.5). NPY-positive fibres innervate arteries, arterioles, AVAs and 
capacitance vessels within the nasal airway. Binding sites for NPY exhibit an 
almost identical distribution pattern to NPY-positive nerve fibre distribution 
(Baraniuk, 1990; Fang and Shen, 1998; Fang et al., 1998).
Tyr-Pro-Ser-Lys-Pro-Asp-Asn-Pro-Gly-Glu-Asp-Ala-Pro-Ala-Glu-Asp-Leu
Ala
Tyr-Arg-Gln-Arg-Thr-lle-Leu-Asn-lle-Tyr-His-Arg-Leu-Ala-Ser-Tyr-Tyr-Arg
Figure 1.5) The amino acid sequence of NPY.
Co-localisation of NPY in noradrenergic fibres has implicated it in the regulation 
of vascular tone within the nasal airway. Intranasal application of NPY to human 
airways causes a long-lasting vasoconstriction and an increase in nasal patency 
(Baraniuk et al., 1992; Cervin et al., 1999). Its vasoconstrictive effects also 
synergise with those of noradrenaline in vitro (Fischer et al., 1993). However, no
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studies have been performed with NPY receptor antagonists in vivo to 
determine the role of NPY in the control of vascular tone and nasal patency.
NPY has 6 receptor subtypes, NPY Y1 - NPY Y6 (Balasubramaniam, 1997). 
However, only NPY Yi and NPY Y2have been located in human nasal airways.
NPY Yi is a post junctional receptor whose activation is thought to be 
responsible for the vasoconstrictive effects observed within the microvasculature 
(Baraniuk et al., 1990b). A selective antagonist for this receptor subtype has 
been developed, called BIP3226. Use of BIP3226 has shown that NPY Y1 
contributes to electrically-induced vasoconstriction of porcine nasal 
microvasculature (Lundberg and Modin, 1995). NPY Y2 is a pre-synaptic 
receptor believed to be present on parasympathetic nerve terminals. Activation 
of NPY Y2 attenuates the activity of field-stimulated cholinergic nerves in guinea- 
pig tracheal tissue and canine nasal airways (Stretton and Barnes, 1988; 
Lacroix et al., 1994). This suggests that NPY Y2 is a presynaptic inhibitory 
receptor present on cholinergic nerves. These findings concur with studies in 
human nasal airways in which topical pre-treatment with the selective NPY Y2 
agonist, TASP-V, attenuates histamine-induced nasal blockage (Malis et al.,
1999).
NPY does not have any significant effects on plasma exudation or glandular 
excitation (Baraniuk et al., 1992).
1.3.1.2.7.3 Tachy kinins
Substance P, neurokinin A (NKA) and neurokinin B (NKB) all belong to a family 
of neuropeptides called tachykinins. These peptides are 10/11 amino acids in 
length and all have similar C-terminal sequences recognised by one of three 
neurokinin receptors, NKi, NK2 and NK3. Binding is selective, but not specific, 
with SP preferentially binding to NK1t NKA to NK2 and NKB to NK3 (figure 1.6).
Substance P: Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met 
Neurokinin A: His-Lys-Thr-Asp-Ser-Phe-Val-Gly-Leu-Met
Neurokinin B: Asp-Met-His-Asp-Phe-Phe-Val-Gly-Leu-Met
Figure 1.6) The amino acid sequence of SP, NKA and NKB.
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Most of the effects of tachykinins in the human airways are mediated by NKi 
and NK2 receptors, as they are the most abundant neurokinin receptors found in 
the peripheral nervous system while, (Baraniuk, 1990) NK3 receptors are 
predominantly found in the central nervous system and autonomic ganglia 
(Canning, 1997). SP and NKA tend to be co-expressed in sensory fibres which 
innervate arterioles, venules, sinusoids, seromucosal glands and the epithelium 
(sparsely) (Uddman et al., 1981; Uddman et al., 1983; Barnes et al., 1991; 
Konno et al., 1996).
The levels of SP found in the airways of atopic individuals are greater than those 
in non-atopic individuals (Fang and Shen, 1998; Fang et al., 1998), and 
intranasal challenge with allergen causes these levels to rise further (Mosimann 
et al., 1993).
Exogenous application of SP to atopic airways causes dose-dependent nasal 
blockage (Devillier et al., 1988; Braunstein et al., 1991; Konno et al., 1996). This 
blockage is thought to be due to a combination of vasodilation (Konno et al., 
1996) and an accumulation of exudate within the submucosa (Braunstein et al., 
1991). In non-allergic individuals, higher doses of SP are required to induce 
nasal blockage (Devillier et al., 1988), but unlike in challenge of atopic 
individuals, nasal blockage is also associated with facial flushing.
SP is also thought to be able to induce rhinorrhea in vivo. Intranasal 
administration of SP to allergic rhinitics causes an increase in vascular 
permeability (Braunstein et al., 1991), and application to human nasal explants 
induces glandular activation (Mullol et al., 1992).
1.3.1.2.7.4 Calcitonin Gene Related Peptide
Calcitonin Gene Related Peptide (CGRP) is a neuropeptide which is 37 amino 
acids in length. There are two forms of CGRP: CGRP-a and CGRP-p, which 
differ in structure by 3 amino acids (Baraniuk and Kaliner, 1991). CGRP-p is 
predominantly found in the enteric nervous system, while CGRP-a is 
predominantly found in the sensory nervous system, where it co-exists with SP 
and NKA (figure 1.7) (Fang and Shen, 1998; Fang et al., 1998). CGRP-positive 
fibres innervate arterial and venous blood vessels but occasionally extend to the 
epithelium and serosal glands (Baraniuk et al., 1990c; Baraniuk and Kaliner, 
1991).
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A
Thr-Ala 
Asp Thr
Ala-Cys s s -  Cys-Val-Thr-His-Arg-Leu-Ala-Gly-Leu-Leu-Ser-Arg-Ser
Gly
Gly
Phe-Ala-Lys-Ser-Gly-Val-Asn-Thr-Pro-Val-Phe-Asn-Asn-Lys-Val-Val
B
Thr-Ala 
Asn Thr
Ala-Cys- s s -  Cys-Val-Thr-His-Arg-Leu-Ala-Gly-Leu-Leu-Ser-Arg-Ser
Gly
I
Gly
Phe-Ala-Lys-Ser-Gly-Val-Asn-Thr-Pro-Val-Phe-Asn-Ser-Lys-Val-Met
Figure 1.7) The amino acid sequence of a-human CGRP (A) and p-human CGRP (B)
CGRP is released in response to allergen challenge (Walker et al., 1988; 
Mosimann et al., 1993), and exogenous application causes vasodilation without 
nasal blockage, glandular secretion or an increase in vascular permeability 
(Baraniuk et al., 1990c; Rangi et al., 1990; Guarnaccia et al., 1994). This 
suggests that the vessels innervated are AVA as opposed to arterioles or 
venous sinusoids. However, autoradiographical studies have shown that binding 
sites for CGRP are mainly found on arterioles but they are also present on veins 
and epithelial cells (Baraniuk et al., 1990c).
1.3.1.2.8 Termination of NANC transmission
Termination of NANC signalling is carried out by a variety of different non­
specific proteases found within the nasal airway. A reduction in the expression 
of these proteases is thought to contribute to the pathophysiology of allergic 
rhinitis.
Neutral endopeptidase (NEP) [EC 3.4.24.11] is a zinc containing membrane- 
bound protein, with a molecular weight between 94 and 100 kD, depending on 
its degree of glycosylation (Baraniuk and Kaliner, 1991; Baraniuk et al., 1993).
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NEP is expressed on epithelial cells, submucosal glands, vascular smooth 
muscle and endothelial cells and is also found in nasal secretions (Baraniuk et 
al., 1993; Ohkubo et al., 1994). It is responsible for degrading SP, NKA, NKB, 
VIP, CGRP and NPY (Ohkubo et al., 1994; Chatelain et al., 1995; Koehne et al.,
1998). It is not known whether expression of NEP is altered in atopic airways 
(Nadel, 1990), but it is known that short-term pre-treatment with steroids 
reduces the symptoms of allergic rhinitis and this is associated with increased 
expression of NEP in asthmatic lower airways (Sont et al., 1997).
Angiotensin converting enzyme (ACE) [EC 3.4.15.1] is a membrane bound zinc- 
containing metalloprotease. It is found on vascular endothelial cells, between 
epithelial cells and in luminal secretions (Ohkubo et al., 1994). ACE is 
responsible for degrading SP and NKA (Ohkubo et al., 1994). However, 
functional studies in vivo suggest that its role in neuropeptide degradation is 
minor in comparison to NEP (Chatelain et al., 1995).
Non-membrane bound enzymes such as mast cell tryptase and mast cell 
chymase also contribute to the termination of NANC signalling (Caughey, 1989; 
Tam and Caughey, 1990; Sommerhoff et al., 2000).
1.3.1.2.9 Inflammatory mediator production
1.3.1.2.9.1 Prostanoids
Prostanoids are 20-carbon, fatty acid derivatives of arachidonic acid (5,8,11,14- 
eicosatetraenoic acid), synthesised by an inducible enzyme called cyclo- 
oxygenase-2 (COX-2). COX-2 converts arachidonic acid (liberated from cell 
membranes by the action of phospholipase C and/or A2) into prostaglandins and 
thromboxanes both of which are referred to as prostanoids.
Prostanoids are produced in atopic airways as a result of allergen challenge 
(Brown et al., 1987; Sugimoto et al., 1994; Naclerio et al., 1996). It is thought 
that their production may induce congestion, which occurs as part of the 
immediate response (Doyle et al., 1990; Nantel et al., 2004). However, high 
doses of COX inhibitors which are known to inhibit prostanoid production do not 
affect allergen-induced symptoms (Brooks et al., 1984; Brown et al., 1987; 
Proud et al., 1987).
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1.3.1.2.9.2 Leukotrienes
Leukotrienes are also derivatives of arachidonic acid. Synthesis of these 
mediators is initiated by the activation of an enzyme called 5-lipoxygenase 
(Haberal and Corey, 2003). The interaction of 5-lipoxgenase with a membrane 
bound protein called 5-lipoxygenase activating protein results in the production 
of leukotriene A4 (LTA4). LTA4 is a precursor of LTB4 and another group of 
cysteinyl-containing leukotrienes (LTC4, LTD4, LTE4 and LTF4) called 
sulphidopeptide leukotrienes.
Intranasal challenge of atopic individuals with the relevant airborne allergen 
dose-dependently elevates the levels of leukotrienes B4, C4, D4 and E4 found 
within their nasal lavages (Creticos et al., 1984; Shaw et al., 1985; Miadonna et 
al., 1987). Leukotrienes have also been implicated in nasal allergy due to the 
strong correlation between symptom severity in allergen- challenged individuals 
and the time course of their elevation in nasal lavage fluid (Miadonna et al., 
1987). Allergen challenge acts as a stimulus for basophils and mast cells to 
synthesise and release leukotrienes, but it must be noted that other cells (such 
as neutrophils, eosinophils and epithelial cells) require stimuli other than IgE to 
contribute to leukotriene production (Howath, 2000).
LTC4 and LTD4 have been introduced into human nasal airways and the only 
symptom experienced was nasal blockage, accompanied by vasodilation 
(Bisgaard et al., 1986; Miadonna et al., 1987). These findings coincide with 
autoradiographic analysis of inferior human nasal turbinates where it was found 
that binding sites for cysteinyl-leukotrienes are distributed sparsely on arterioles, 
veins and sinusoids (Tai and Baraniuk, 2002). However, in this study only one of 
two types of cysteinyl leukotriene receptor (CysLTI) was visualised. CysLT2 
receptors are not thought to play a role in the pathophysiology of allergic rhinitis.
Evidence supporting treatment of allergic rhinitis by targeting leukotrienes is 
equivocal. The CysLTI receptor antagonist, zafirlukast, and lipoxygenase 
inhibitors, A78773 and zileuton, significantly reduce allergen induced nasal 
blockage in allergic rhinitis (Knapp, 1990; Howarth et al., 1995; Jiang, 2006). 
However, when used in a clinical setting, zafirlukast’s (10, 20, 40 and 100 mg) 
effects did not appear to be dose-dependent. It was only found to be 
therapeutically useful at doses of 20 and 40 mg (Donnelly et al., 1995). Two 
weeks pre-treatment with another CysLTI receptor antagonist, montelukast (10
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and 20 mg), also failed to inhibit seasonal increases in rhinitic symptoms 
(Malmstrom et al., 1998) but has succeeded in other trials (Philip et al., 2002).
1.3.1.2.9.3 Histamine
Histamine is a decarboxylated derivative of the amino acid histidine. It is 
synthesised and stored in the cytoplasmic granules of mast cells and basophils, 
and degraded by the enzyme diamine oxidase. In allergic rhinitis, granular 
exocytosis is an IgE mediated response to allergen, but it may also be induced 
by an IgE-independent mechanism (Petersen et al., 1997; Foreman, 1987; 
Austin et al., 1996; Schierhorn et al., 1995).
Intranasal challenge with allergen causes a rise in the histamine content of 
nasal lavage fluid of allergic individuals (Naclerio et al., 1985; Togias et al., 
1988; Walden et al., 1988; Naclerio, 1990; Baroody et al., 1994; Naclerio et al.,
1996). Exogenous application of histamine to the nasal airway generates 
symptoms of allergic rhinitis (Pipkorn, 1982; Doyle et al., 1990; Taylor-Clark et 
al., 2005). Therefore, histamine has long been a major target for the treatment 
of allergic rhinitis.
There are four known histamine receptors, Hi, H2, H3 and H4, all of which have 
been identified in the human nasal airway (Okayama et al., 1992; Nakaya et al.,
2004). Histamine Hi receptors are densely expressed on arterioles, veins, 
venules, cavernous sinusoids and the nerves of inferior nasal turbinates, with 
sparse distribution on the epithelium and glands (Nakaya et al., 2004). 
Activation of histamine Hi receptors (vascular and sensory) is responsible for 
inducing symptoms of nasal blockage (vascular), rhinorrhea (sensory and 
vascular), pruitis (sensory) and sneezing (sensory). This has been confirmed by 
the use of the histamine Hi receptor agonist, betahistine, (Shelton and Eiser,
1994) and the reduction of histamine-induced symptoms in human nasal 
airways with a selective histamine Hi receptor antagonist, cetirizine (Braunstein 
et al., 1992; Austin and Foreman, 1994b). The role of histamine Hi receptors in 
allergic rhinitis has been established by the use of selective Hi receptor 
antagonists. Antagonism of these receptors eradicates allergen-induced 
sneezing and itching, with little effect on nasal blockage (Kirkegaard et al., 1983; 
Wagenmann et al., 1994; Wang et al., 1996).
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Histamine H2 receptors are thought to play a minor role in the effects of 
histamine on the human nasal airway. Immunohistochemical analysis has 
revealed that the highest density of histamine H2 receptors is found on glands, 
and the epithelium of inferior nasal turbinates, with sparse distribution on 
arterioles, veins, venules and cavernous sinusoids (Nakaya et al., 2004). 
Exogenous application of a selective H2 receptor agonist, dimaprit, to human 
nasal airways induces reversible nasal blockage without symptoms of 
rhinorrhea, sneezing or pruitis (Shelton and Eiser, 1994; Taylor-Clarke -  thesis, 
2005). However, use of histamine H2 receptor antagonists in conjunction with 
histamine Hi receptor antagonists, does not completely reverse allergen or 
histamine-induced nasal blockage (Holmberg et al., 1989; Taylor-Clark et al.,
2005).
Histamine H3 receptors have been identified on epithelial cells, arterioles, veins, 
venules and cavernous sinusoids. They are most abundant on the nerves of 
human nasal turbinates (Nakaya et al., 2004). Further analysis has revealed that 
H3 receptors are situated on presynaptic sympathetic nerve terminals (Varty et 
al., 2004). Activation of these receptors in vitro, by the H3-receptor agonist, R-a- 
methyl-histamine, reversibly inhibits the effects of electrical field stimulation 
(EFS) on human nasal turbinates. EFS induced an a r  and a2-adrenoceptor- 
dependent contraction of the human nasal tissue. It was therefore concluded 
that activation of the histamine H3 receptor inhibits EFS-induced contraction by 
attenuating the release of noradrenaline. These results were corroborated by 
studies in vivo. Introduction of R-a-methyl-histamine to human nasal airways 
causes dose-dependent nasal blockage, which is not significantly augmented by 
the use of the a!-adrenoceptor agonist, corynanthine (Taylor-Clark et al., 2005).
Histamine H4 receptors have only recently been discovered due to their genetic 
sequence homology with histamine H3 receptors. They are expressed on 
nerves, basophils, CD8+ T-cells, mast cell, eosinophils and neutrophils (Nakaya 
et al., 2004; de Esch et al., 2005). Their role in the pathophysiology of allergic 
rhinitis is not clearly understood but it is known that they regulate leukocytic 
chemotaxis and cytokine production (Kobayashi et al., 2001; de Esch et al.,
2005).
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1.3.1.2.9.4 Platelet activating factor (PAF)
Platelet activating factor (1-o-alkyl-2-acetyl-sn-glyceryl-3-phosphorycholine) is a 
biologically active phospholipid. It was originally discovered by Benveniste et al., 
in 1972, who found that rabbit IgE-dependent activation of rabbit basophils 
causes the release of a serum-soluble factor, which activates platelets. Its 
structure was determined 5 years later, and it was given the name platelet- 
activating factor.
Cellular sources of PAF are predominantly, but not exclusively, leukocytic in 
nature. These sources include eosinophils, neutrophils, platelets, macrophages, 
basophils, mast cells and endothelial cells (Barnes et al., 1988; Townley et al., 
1989; Atkinson and Kaliner, 1995). A variety of different stimuli are required to 
promote the synthesis of PAF in these cells, all of which trigger a rise in free 
intracellular [Ca2+],
Calcium is required for the activation of phospholipase A2. Phospholipase A2 
converts cell membrane phospholipids into arachidonic acid and lyso-PAF (1-o- 
alkyl-2-lyso-sn-glycero-3-phosphocholine). Lyso-PAF, is then converted into 
PAF by the cytoplasmic enzyme, acetyl transferase (figure 1.8) (Barnes et al., 
1988; Townley et al., 1989). A second pathway for the synthesis of PAF has 
been proposed, which involves the transfer of phosphorycholine groups to 1-o- 
alkyl-2-acetyl-sn-glycerols by the enzyme phosphocholine transferase (figure 
1.8). The extent to which these pathways play a role in the synthesis of PAF in 
vivo is not known.
Free fa tty
acids
PLA2 Acetylhydrolase
Acetyl-PAF
(1-o-alkyl-2-acetyl-
Lyso-PAF
(1 -o-alkyl-2-lyso-sn-
PAF
(l-o-alkyl-2-acetyl-sn-
glyceryl-3- glycero-3- glyceryl-3-
phosphocholine) phosphorycholine)phosphocholine)
Phosphocholine
transferase Acetyltransferase
Figure 1.8) The synthesis and metabolism of PAF adapted from 
Barnes et al., 1988 and Townley et al., 1989.
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Being a phospholipid, PAF is not stored by cells; it is synthesised and released 
on demand. Recovery of PAF, phospholipase A2 and acetylhydrolase from 
atopic airways in vivo has been demonstrated after allergen challenge (Touqui 
et al., 1994). However, in other studies, lyso-PAF (the inactive 
precursor/metabolite of PAF), and not PAF, have been detected in atopic nasal 
lavages. The inability to detect PAF in these samples is thought to be due to 
elevations in acetylhydrolase activity (Touqui et al., 1994).
Immunohistochemical examination of human nasal mucosa has revealed that 
receptors for PAF are situated on interstitial cells, vascular endothelial cells and 
epithelial cells: the highest level being expressed by submucosal serous glands 
(Shirasaki et al., 2005). This distribution pattern correlates with the most 
prominent effects of exogenous PAF on the nasal airway. Exogenous PAF 
causes nasal blockage (Leggieri et al., 1991; Maniscalco et al., 2000), an 
increase in vascular permeability (Maniscalco et al., 2002) and nasal 
discomfort/pain (Maniscalco et al., 2000; Maniscalco et al., 2002). Nasal 
discomfort is a sign of C-fibre activation, which would suggest that PAF either 
activates sensory neurones directly or by the production of other mediators 
which activate C-fibres.
Studies on PAF’s role in allergic rhinitis have been hampered by a lack of 
promising results with PAF receptor antagonists in the lower airways. Pre­
treatment of allergic asthmatics with PAF antagonists (WEB2086, UK74-505 
and SR27417A) does not offer protection against allergen-induced 
bronchoconstriction or airway hyperreactivity (Freitag et al., 1993; Kuitert et al., 
1993; Evans et al., 1997). This lack of effectiveness is not likely to be due to 
problems with the antagonists, as (1) a lower dose of WEB2086 inhibits PAF- 
induced bronchoconstriction in non-allergic airways (Adamus et al., 1990), and 
(2) platelets removed from the blood of allergic individuals, after oral receipt of 
UK74-505, exhibit a significantly diminished aggregatory response to treatment 
with PAF (Kuitert et al., 1993).
1.3.1.2.9.5 Protease Activated Receptors (PARs)
Protease activated receptors are a relatively new family of self-activating, seven 
transmembrane G-protein coupled receptor. The N-terminal sequences of these 
receptors undergo specific site-directed cleavage by extracellular proteases, to
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form a tethered ligand that binds to, and irreversibly activates the receptor (Lan 
et al., 2002; Reed and Kita, 2004).
Four subtypes of these receptors have been cloned and characterised using 
proteases which cause their activation: PAR1, PAR2, PAR3 and PAR4. PARs 
are also distinguishable pharmacologically by selective synthetic ligands that 
have been synthesised based on the N-terminal amino acid sequence of their 
tethered ligands (table 1.1). Receptor activity is terminated by other enzymes or 
internalisation and lysosomal degradation, as opposed to agonist dissociation 
(Trejo et al., 1998; Lan et al., 2002; Reed and Kita, 2004).
PARs are ubiquitously expressed throughout the body, but, of the four 
receptors, PAR2 receptors of the human airway have gained a lot of interest 
because of their potential to be activated by mast cell tryptase in vivo (table 1.1). 
Another potential pathophysiological activator of PAR2 receptors in vivo is 
house dust mite (Lan et al., 2002). As well as being an allergen, house dust mite 
also displays cysteine protease activity in vivo (Hewitt et al., 1997). This 
proteolytic activity enables house dust mite to disrupt epithelial intercellular 
adhesion and increase paracellular permeability, so it can infiltrate the nasal 
mucosa to encounter mast cells or antigen presenting cells (Winton et al., 1998).
PAR2 receptors have been identified on epithelial and endothelial cells 
throughout the human airway, and their expression is up-regulated in asthmatics 
and allergic rhinitics (Cocks and Moffatt, 2001; Knight et al., 2001; Dinh et al.,
2006). Unfortunately, to date no investigations looking at the role of PAR2 
receptors in the nasal airway have been published. Studies in other tissues 
using selective agonists for PAR2 have revealed that it induces vasodilation 
(Robin et al., 2003; Wang et al., 2005), which if extrapolated into the human 
nasal airway, could cause nasal blockage.
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PAR1 PAR2 PAR3 PAR4
Enzyme
activators
Thrombin 
Trypsin 
Granzyme A 
Factor Xa
Trypsin 
Tryptase 
Cathepsin G 
Elastase 
Derp3  
Derp9 
Factor Xa
Thrombin Thrombin 
Trypsin 
Cathepsin G
Amino acids of 
tethered ligand 
sequence
SFLLRN SLIGKV TFRGAP GYPGQV
Amino acids of 
selective 
synthetic 
peptide agonist
TFLLR SLIGRL - -
Cellular
distribution
Epithelium 
Airway smooth 
muscle 
Mast cells 
Endothelial cells 
Vascular 
smooth muscle 
Eosinophils 
Neutrophils 
Monocytes 
Dendritic cells 
Lymphocytes 
Alveolar 
macrophages 
Fibroblasts 
Neurons
Epithelium 
Airway smooth 
muscle 
Mast cells 
Endothelial cells 
Vascular smooth 
muscle 
Eosinophils 
Neutrophils 
Monocytes 
Dendritic cells 
Lymphocytes 
Alveolar 
macrophages 
Fibroblasts 
Neurons 
Bronchial glands
Epithelium
Eosinophils
Alveolar
macrophages
Dendritic
cells
Epithelium
Table 1.1) Distribution of PAR receptors, agonists and activating enzymes 
within the airway (Lan et al., 2002; Reed and Kita, 2004)
1.3.1.3 Leukocyte infiltration
Leukocytic infiltration into the nasal mucosa is a delayed response to 
inflammatory mediators produced as a result of the immediate response. The 
significance of the entry of leukocytes into allergic airways is not completely
56
Chapter 1 Introduction
understood, but it is thought to play a role in inducing the late phase response 
and airway hyper-reactivity (AHR).
Mast cells, TH2-lymphocytes, epithelial cells and endothelial cells activated 
during the immediate response produce an array of cytokines and inflammatory 
mediators which aid the entry of leukocytes into the nasal airway 
(Christodoulopoulos et al., 2000; Howarth et al., 2000; Skoner, 2001).
Leukocytic infiltration is initiated by inducing endothelial expression of the 
adhesion molecules, P-selectin and E-selectin. These selectins form brief bonds 
with the counterligand, L-selectin, present on the surface of inactive leukocytes. 
The brief interactions formed between these selectins allow the leukocytes to 
roll across the endothelium towards the site(s) of inflammation (Howarth, 1995). 
Rolling leukocytes are eventually activated by various cytokines, chemokines 
and proinflammatory mediators which induce the expression of adhesion 
molecules such as Very Late Antigen-4 (VLA-4) and Lymphocyte Function 
Antigen-1 (LFA-1) (Baraniuk, 1997; Bachert et al., 1998). The counterligands 
(Intracellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion 
molecule 1 (VCAM-1)), for the newly expressed leukocytic adhesion molecules 
are up-regulated on endothelial cells in response to cytokines such as IL-1, IL-4, 
IL-13 and TNFa (Howarth, 1995; Bachert et al., 1998; Howarth et al., 2000). 
ICAM-1 and VCAM-1 form firm bonds with VLA-4 and LFA-1 that ultimately 
terminate cellular rolling and allow the leukocytes to traverse the endothelium to 
enter the nasal submucosa.
The importance of ICAM-1 in eosinophilic migration has been shown in primate 
models of asthma that display eosinophilia sensitive to pre-treatment with mAb 
R6.5, a monoclonal antibody raised against ICAM-1 (Wegner et al., 1990). 
Allergen challenge of allergic individuals also induces eosinophilia associated 
with an up-regulation of VCAM-1, ICAM-1 and E-selectin (Lee et al., 1994; 
Braunstahl et al., 2001).
1.3.1.4 Leukocyte activation
Neutrophils are granulocytes which are usually resident in most sites of 
infection. They are activated by mediators such as PAF, LTB4, IL-4 and IL-8. In 
response, they produce a host of different mediators including LTB4, 
myeloperoxidase, reactive oxygen species and reactive nitrogen species.
57
Chapter 1 Introduction
Neutrophils are also a source of chemokines such as IL-8, MIP-1a and MIP-1(3. 
These chemokines promote additional neutrophil infiltration, and initiate the 
infiltration of other leukocytes into the nasal airway (Lukacs et al., 1995). Studies 
in vitro have revealed that neutrophils release cytotoxic proteins that cause the 
detachment of epithelial cells from their basement membranes (Venaille et al.,
1995). The ability of neutrophils to detach epithelial cells from basement 
membranes was thought to induce airway hyper-reactivity in vivo, but 
histological analysis of human atopic nasal biopsies has revealed that there is 
no increase in epithelial damage or loss (Lim et al., 1995). Moreover, 
glucocorticosteroids abolish AHR in vivo but have no effect on the survival of 
neutrophils within atopic human airways (Togias et al., 1988; Baroody et al., 
1992; Barnes, 1998). Nonetheless, neutrophil numbers are elevated in allergic 
airways in- and out of season, and in response to allergen challenge (Lim et al.,
1995).
Eosinophils are granulocytes commonly known to assist the combat of parasitic 
infections. However, in rhinitic nasal mucosa their numbers are elevated out of 
season and these numbers are increased further in response to challenge with 
allergen (4-6 hour later) out of season (Bentley et al., 1992; Lim et al., 1995). 
Activation of eosinophils within the nasal mucosa is thought to aid the 
inflammatory process by releasing pre-stored cytokines such as TNFa, and 
chemokines such as eotaxin and Regulated upon Activation Normal T-cell 
Expressed and Secreted (RANTES) (Baraniuk, 1997). Eosinophils are also a 
major source of LTC4, which is chemotactic for neutrophils and eosinophils 
(Howarth, 2000). Allergen challenge of allergic individuals is associated with an 
increase in eosinophil markers such as eosinophil derived neurotoxin (EDN), 
eosinophil peroxidase (EPO), major basic protein (MBP) and eosinophil cationic 
protein (ECP) (Turner et al., 2001). These proteins are thought to be responsible 
for inducing airway hyper-reactivity (Coyle et al., 1995; Turner and Foreman,
1999) and the development of late phase response symptoms (Howarth et al.,
2000).
Basophils are granulocytes, which form more than 1% of the white blood cells 
within the human body. Like mast cells, basophils are bone marrow-derived 
CD34+ cells (Howarth, 1995). They mature in the blood (as opposed to the 
nasal mucosa), with the aid of cytokines such as IL-3, IL-5 and IL-13 and enter 
the nasal mucosa in response to cytokines such as RANTES, IL-3, IL-5 and IL-8 
(Baraniuk, 1997). They also posses high affinity FceRI receptors which allow
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them to release histamine and leukotriene C4 in response to challenge with 
allergen. Unlike mast cells, they synthesise negligible amounts of PGD2 and 
tryptase (Howarth, 1995) and it is because of this fact that they are thought to 
play a role in the late phase response (Togias et al., 1988; Wagenmann et al.,
1997).
T lymphocytes are present within the nasal mucosa and two thirds are thought 
to be CD4+ bearing cells. In perennial allergic (but not seasonal allergic) rhinitic 
nasal airways, the number of active (CD25+ bearing) cells is increased and they 
are of the TH2 phenotype (Howarth et al., 2000). TH2 lymphocytes release a 
variety of cytokines and chemokines which promote additional T-lymphocyte 
chemotaxis and TH2 differentiation as well as neutrophilia, eosinophilia and B- 
cell differentiation.
1.3.1.5 Late Phase Response
Approximately 4-12 hours after development of the immediate response, 50% of 
allergic individuals experience a re-emergence of nasal symptoms, called the 
late phase response (Naclerio et al., 1985; Naclerio et al., 1996). The 
manifestation of these symptoms coincides with inflammatory mediator 
production and leukocyte infiltration (Naclerio et al., 1996), but the mechanism 
behind late phase development has not been elucidated. Mediators produced in 
the late phase include kinins, histamine and leukotrienes. Kinins may be 
synthesised by kallikrein or in response to a delayed influx of leukocytes into the 
nasal airway (as discussed in chapter 1.4.2.3) to cause symptoms of nasal 
blockage and rhinorrhea (Naclerio et al., 1985; Naclerio et al., 1996; Lauredo et 
al., 2004). Histamine is recovered in the absence of tryptase and PGD2, which 
supports the possibility that it is produced by basophils, and causes symptoms 
of nasal blockage, sneezing and pruitis (Naclerio et al., 1985; Naclerio et al.,
1996). Leukotrienes could be produced by a variety of cells and may also play a 
part in the congestive response (Togias et al., 1988).
1.3.1.6 Airway Hyper-reactivity
Airway hyperreactivity (AHR) is the exacerbation of nasal symptoms in response 
to intranasal challenge with allergen or mediators such as bradykinin and 
histamine. Symptoms affected by AHR may include nasal blockage (Turner et 
al., 2001), sneezing and even rhinorrhea (Klementsson et al., 1991). It is an
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extremely common symptom of allergic rhinitis and usually occurs as early as 4 
hours after the immediate response and can persist for a further 20 hours.
The mechanism behind the development of AHR in allergic rhinitis has not been 
completely elucidated but several theories have been proposed.
A dysfunctional epithelium
A variety of mediators detected in allergic rhinitic airways are cytotoxic or 
detrimental to epithelial cells in vitro and they include PAF (Ganbo et al., 1991), 
neutrophil derived products (Venaille et al., 1995), eosinophil derived proteins 
(Tagari et al., 1992) and bradykinin (Proud and Kaplan, 1988). Disruption of the 
epithelial barrier in vivo would directly expose mucosal receptors to invading 
pathogens and noxious or irritant particles found in the nasal lumen. 
Additionally, enzymes such as ACE and NEP, found within the epithelium, would 
be lost, and inflammatory peptides would accumulate in the airway lumen. 
Consequently, nasal responses to allergen may be enhanced. However, 
histological analysis of human atopic nasal biopsies has revealed no increase in 
epithelial damage or loss (Wilson and Yates, 1978; Lim et al., 1995).
Allergic rhinitics are reported to have an increase in mucosal permeability. An 
enhanced influx of irritants from the epithelial surface into the submucosa would 
be a feasible explanation for the development of AHR. However, the capacity of 
low molecular weight molecules, present within human upper airways, to 
infiltrate atopic nasal mucosa is significantly reduced during the allergy season. 
On the other hand, the histamine-induced exudative capacity is increased during 
the allergy season (Svensson et al., 1998).
Enhanced inflammatory mediator production
PAF is a mediator not found in the nasal airways of non-atopics, but challenge 
of atopic individuals with allergen causes the recovery of detectable levels of 
PAF from nasal lavages (Shin et al., 1994). Exogenous application of PAF to 
non-atopic airways induces AHR to bradykinin and histamine (Austin and 
Foreman, 1993), and in seasonal allergic individuals it induces AHR in response 
to challenge with pollen (Andersson and Pipkorn, 1988). While binding sites for 
PAF in human nasal airways have been established, the mechanism behind 
PAF’s ability to induce AHR has not been determined.
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Receptor modulation
Cholinergic hyperreactivity is a common feature of allergic rhinitis. Intranasal 
challenge with methacholine induces excessive rhinorrhea and nasal blockage 
in atopic, but not in non-atopic individuals (Druce et al., 1985; White, 1993; 
Marquez et al., 2000). One possible reason for this exaggerated response may 
be an increase in muscarinic receptor density within the nasal airway. 
Autoradiographic analysis of rhinitic nasal airways by Van Megen et al., (1991) 
revealed no change in muscarinic receptor density, but an increase in ligand 
binding affinity (van Megen et al., 1991b). Conversely, Ishibe et al., (1983) found 
an increased muscarinic receptor density with no change in binding affinity. 
Ultimately, both findings could be sufficient explanations for cholinergic 
hyperreactivity in vivo.
Altered neuromodulation
The sympathetic nervous system is not only responsible for maintaining nasal 
patency, it is also responsible for counteracting the effects of the 
parasympathetic nervous system. Toluene diisocynate-induced airway hyper­
reactivity in guinea-pigs has revealed that the noradrenaline content of the nasal 
mucosa is significantly reduced. Consequently, it is speculated that 
dysfunctional sympathetic activity may be responsible for causing AHR in 
allergic rhinitis (Kubo and Kumazawa, 1993).
Tachykinins have also been implicated in the development of AHR. In models of 
allergic asthma in which guinea-pigs are sensitised to olvalbumin, allergen 
produces an immediate response, a late phase response, eosinophilia and AHR 
to histamine (Schuiling et al., 1999). NICi and NK2 receptor antagonists abolish 
the AHR but have no effect on histamine-induced bronchoconstriction. Whether 
neurogenic inflammation plays a role in inflamed human nasal airways has not 
been established, but it is known that challenge with mediators such as 
bradykinin significantly elevates the levels of SP within the nasal airways in vivo 
(Baumgarten et al., 1997).
The eosinophil derived protein, MBP, is thought to modify parasympathetic 
activity in human airways. Radioligand binding studies have revealed that it 
displaces muscarinic ligands bound to muscarinic m2 receptors (Jacoby et al.,
2001). Within the lower and upper airways, parasympathetic nerve terminals 
possess presynaptic autoinhibitory m2 receptors. MBP is thought to antagonise
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these receptors and prevent feedback inhibition, resulting in the release of 
excessive amounts of acetylcholine and hence AHR (Jacoby et al., 2001).
Additionally, the density of VIP-positive fibres innervating human nasal airways 
is increased in atopic individuals (Fang et al., 1998). A concomitant enhanced 
release of VIP would be expected to contribute to symptoms of nasal blockage, 
rhinorrhea and AHR.
Reduced inflammatory mediator metabolism
The enzymes NEP and ACE are responsible for the degradation of inflammatory 
peptides within the nasal airway. The down-regulation of both of these enzymes 
in the lower airways of asthmatic individuals is thought to cause an 
accumulation of inflammatory peptides in human airways. This is likely to cause 
persistent activation of receptors for non-degraded inflammatory peptides and 
subsequently lead to AHR (Nadel, 1990; Sont et al., 1997; Roisman et al., 
1999).
Altered intracellular signalling
NO production is increased in the nasal airways of seasonal and perennial 
allergic rhinitis (Henriksen et al., 1999). This suggests that activity of one or 
more of the three isoforms of NOS is increased. It is speculated that increased 
NO production in the airway may induce AHR by reacting with superoxide to 
form free radicals which damage surrounding mucosal and epithelial tissue. 
Ironically, chronic non-selective inhibition of NOS induces AHR to histamine and 
bradykinin in the nasal airway (Turner et al., 2000a).
1.4 Kinins
Within human airways there are two subtypes of receptor activated by kinins, 
which are referred to as kinin B2 receptors and kinin receptors. The kinins, 
bradykinin and kallidin, are agonists of kinin B2 receptors formed by the 
degradation of kininogen by enzymes called kallikrein. Kinin Bi receptors are 
activated by des-arg9-bradykinin and des-arg10kallidin which are metabolites of 
bradykinin and kallidin respectively. For the duration of this thesis I shall use the 
term kinins to refer to agonists of kinin B2 receptors.
62
Chapter 1 Introduction
1.4.1 Discovery of the kallikrein-kinin system
The nonapeptide, bradykinin (BK), was discovered in 1949 by Rocha e Silva 
and his co-workers, as a result of investigations looking into the histamine 
releasing capability of Bothrops jararaca snake venom on animal tissue (Beraldo 
and Rosenfield, 1949). It was observed that canine blood, treated with Bothrops 
jararaca venom or trypsin, elicited an atropine- and antihistamine-resistant 
contraction of guinea-pig ileum. The substance was given the name bradykinin, 
due to the relatively slow (=brady in Greek), movement (=kinin in Greek), which 
it induces compared to acetylcholine and histamine. A decade later, bradykinin 
was purified and its structure determined from plasma treated with B. jararaca 
(figure 1.8) (Zuber and Jaques, 1960; Boissonnas et al., 1963).
Bradykinin: H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH 
Kallidin: H-Lys- Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH
Figure 1.9) The amino acid sequence of bradykinin and kallidin.
Kallidin (Lys-bradykinin) was discovered in 1937 by E. Werle and his co-workers 
who observed that human urine contained a substance which induced intestinal 
smooth muscle contraction in vitro and hypotension in vivo (Werle et al., 1937). 
It became apparent that vasodilation and smooth muscle contraction were only 
elicited if urine was mixed with serum proteins. The active substance 
responsible for these actions was kallidin (KD), nicknamed “substance DK” on 
the basis of its original name darmkontrahierender stoff, which is German for 
intestine-contracting substance (figure 1.9).
Tissue kallikrein was discovered in 1925 by E. K. Frey, who found that 
intravenous administration of canine urine into another dog induced hypotension 
and tachycardia (Frey, 1926). Frey went on to work with H. Kraut to isolate 
tissue kallikrein from human urine, which they called F-substance (Frey 
substance). F-substance was renamed kallikrein (Greek for pancreas), after the 
discovery of high concentrations of tissue kallikrein in human pancreas. 
Kallikrein was later discovered in human salivary glands (Werle and Von Roden, 
1936). It was also observed that it is activated by trypsin and inactivated by 
human serum.
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Plasma kallikrein was also discovered by Werle and his co-workers, during an 
attempt to prevent the binding and subsequent inhibition of urinary kallikrein by 
serum proteins present in urine (Kraut et al., 1928). Acidification of urine 
reactivated very small quantities of the inhibited urinary kallikrein. This was 
shown by its hypotensive inducing effects in vivo. However, acidification of 
serum produced profound hypotensive-inducing effects. It was subsequently 
discovered that there is another kallikrein-like enzyme present in plasma. The 
active enzyme was given the name plasma kallikrein, according to its source, 
purification requirements and trypsin sensitivity.
In 1961, Erdos isolated carboxypeptidase N (kininase I) from human plasma and 
discovered that it deactivated kinins (amongst other peptides) by the removal of 
the carboxyl terminal arginine (Erdos, 1961). Kininase II was isolated from 
human plasma in 1967 by Yang and Erdos (Yang and Erdos, 1967). It 
inactivates bradykinin by cleaving the Pro7-Phe8 bond. In 1979, kininase II was 
found to be the same as angiotensin converting enzyme.
The precursors to bradykinin and kallidin, kininogens I and II, were discovered in 
bovine plasma by Haberman et al., (1963). The human variants of these 
kininogens were isolated from human plasma soon after and given the names 
high molecular weight kininogen (HMWK) and low molecular weight kininogen 
(LMWK).
1.4.2 Synthesis of bradykinin and kallidin
Kinins are generated in seasonal allergic rhinitis (Geppetti et al., 1991; Turner et 
al., 2001), perennial allergic rhinitis (Dear et al., 1996) and non-atopic 
individuals challenged with PAF (Turner et al., 2000b). Synthesis of kinins in 
vivo occurs via one of three pathways: a tissue kallikrein-dependent pathway, a 
plasma kallikrein dependent pathway and a cellular protease dependent 
pathway.
1.4.2.1 Plasma kallikrein-dependent kinin synthesis
Intranasal allergen challenge of allergic individuals induces an increase in 
plasma kallikrein activity and an elevation in the level of kininogen (Baumgarten 
et al., 1986a) and kinins found in nasal lavages (Proud et al., 1983; Naclerio et
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al., 1985; Turner et al., 2001). The activation of plasma kallikrein in the presence 
of Hageman factor catalyses the excision of bradykinin from high molecular 
weight kininogen.
1.4.2.1.1 High molecular weight kininogen
High molecular weight kininogen is a 115 kD glycoprotein, predominantly, but 
not exclusively, synthesised in the liver (Neth et al., 2001) by alternative splicing 
of a single gene (Bhoola et al., 1992). When released into the circulation, it 
binds to either prekallikrein or coagulation factor XI (FXI) in a ratio of 1:1 
(Mandle et al., 1976; Thompson et al., 1977; Proud and Kaplan, 1988). In 
human plasma, its concentration is between 70 and 90 pg/ml and accounts for 
approximately 1/3 of the total kininogen present in plasma (Neth et al., 2001; 
Kaplan et al., 2002).
HMWK is a single glycosylated chain of 626 amino acids, with a single 
disulphide bond between its amino- and carboxy- terminal cysteine residues 
(figure 1.10). Excision of bradykinin (domain 4), from the chain, 
disproportionately splits it into two chains linked only by the disulphide bond. 
The chain closest to the original amino terminal is called the heavy chain and 
the chain closest the original carboxy terminal is called the light chain. The 
heavy chain consists of three separate domains, each with distinct functions. 
Domain 1 comprises residues 1 to 116, domain 2 comprises residues 117 to 
238 and domain 3 comprises residues 239-360. Domain 1 contains a low affinity 
binding site for Ca2+ (Farmer, 1997). Domains 2 and 3 are responsible for the 
inhibition of cysteine protease activity, namely cathepsins B, H and L, papain, 
ficin and platelet derived calpains I and II (Bhoola et al., 1992; Farmer, 1997). 
Domain 3 is also responsible for HMWK binding to cell surfaces (Reddigari et 
al., 1993a; Wachtfogel et al.1994). The light chain of HMWK, amino acids 371 to 
626, contains two domains, domain 5 and domain 6. Domain 5, amino acids 91 
to 121, is rich in histidine residues and is also responsible for the binding of 
HMWK to cell surfaces (Wachtfogel et al., 1994; Shariat-Madar and Schmaier, 
1999). Domain 6, amino acids 185 to 242, is responsible for binding to and 
activating FXI or prekallikrein (Thompson et al., 1979; Kaplan et al., 2002).
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Figure 1.10) The domains (D) within HMWK, adapted from Kaplan et al., 2002.
A combination of radioligand binding experiments and confocal microscopy have 
revealed that HMWK requires Zn2+ to bind with high affinity to the cell 
membranes of endothelial cells (Reddigari et al., 1993a), vascular smooth 
muscle cells (Fernando et al., 2005), unstimulated platelets (Meloni et al., 1992), 
astrocytes (Fernando et al., 2003) and neutrophils (Gustafson et al., 1989; 
Figueroa et al., 1992). HMWK is also suspected to bind unactivated tissue 
kallikrein (prokallikrein) (Raab and Kemme, 2000).
1.4.2.1.2 Hageman Factor [3.4.21.38]
Hageman Factor or coagulation factor XII (FXII) is an 80 kD glycosylated 
proenzyme, predominantly, but not exclusively, synthesised in the liver (Neth et 
al., 2001). It circulates in the plasma, unbound to other proteins, at 
concentrations between 30 and 35 pg/ml (Kaplan et al., 2002). Activation, by 
site-specific cleavage, of this protein catalyses the progression of the 
complement pathway, the fibrinolytic pathway, the extrinsic coagulation cascade 
and the kallikrein-kinin pathway (Bhoola et al., 1992).
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FXII is a single glycosylated chain of 596 amino acids, with a single disulphide 
bond between two cysteine residues (Proud and Kaplan, 1988; Kaplan et al.,
2002). The first 279 amino acids of the chain are referred to as the heavy chain 
region of FXII. Amino acids 331 to 596 are referred to as the light chain region, 
and amino acids 279 to 330 are referred to as the heavy and light chain 
connecting region of FXII.
Activation of FXII can be brought about by the binding of its heavy chain to 
negatively charged surfaces such as glass, kaolin, dextran sulfate and sulfatides 
(Pixley et al., 1987; Proud and Kaplan, 1988; Citarella et al., 2000). FXII 
activation is augmented and initiated by self-cleavage. It is believed that binding 
of FXII to artificial surfaces firstly induces a conformational change in the protein 
that allows it to become a better substrate for itself (autoactivation) and, 
secondly, generates a large localised concentration of FXII needed for 
autoactivation (figure 1.12).
The cleavage of the Arg353- Val354 bond by plasma kallikrein or FXI la (active 
Hageman factor) causes the activation of FXII (figure 1.1). Arg353 and Val354 are 
both enclosed within the disulphide bond and therefore, the single chain is 
converted into two disulphide-linked chains; a heavy chain (and connecting 
region) and a light chain (Kaplan et al., 2002). The light chain of FXIIa displays 
serine protease activity and is responsible for the activation of prekallikrein.
FXIIa may be subjected to further cleavage, which convert it into two smaller 
fragments, referred to as Xllf. Xllf retains its ability to activate prekallikrein, but 
lacks a heavy chain and the ability to activate FXI (Dunn and Kaplan, 1982). The 
first fragment is 30 kD in weight and is liberated from its membrane bound 
heavy chain by a cleavage at Arg334 in the connecting region. The second 
fragment is 28.5 kD in weight, and is formed by reducing the connecting region 
of the first X llf to 9 amino acids in length by a cleavage at Arg343 (Dunn and 
Kaplan, 1982; Kaplan et al., 2002) (figure 1.11).
Studies with purified enzyme preparations and human plasma have revealed 
that FXII activation by plasma kallikrein, and autoactivation are dependent on 
the presence of HMWK (Meier et al., 1977). Unfortunately, the mechanism 
behind how HMWK augments FXII activity has not been completely elucidated. 
However, it is now appreciated that HMWK is not only a substrate required by
67
Chapter 1 Introduction
plasma kallikrein for bradykinin-synthesis but it is also an essential cofactor in all 
reactions catalysed by the activation of FXII.
Radioligand binding and biotinylation studies have revealed that FXII, in the 
presence of Zn2+, binds to a similar population of cells as HMWK (Joseph et al., 
1996; Fernando et al., 2003; Johne et al., 2006). In fact, it has been observed 
that on artificial and endothelial cell surfaces that HMWK competes with FXII for 
the same binding sites, and FXII competes with HMWK for FXII (Shimada et al., 
1985; Reddigari et al., 1993a; Reddigari et al., 1993b).
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Figure 1.11) The structure of FXIIa and its cleavage sites (1), (2) and (3) adapted from
Kaplan et al., 2002.
1.4.2.1.3 Plasma prekallikrein [EC 3.4.21.34]
Prekallikrein is a proenzyme predominantly, but not exclusively, synthesised in 
the liver, the kidney and the pancreas (Neth et al., 2001). Prekallikrein is a 
single glycosylated chain of 619 amino acids with a single disulphide bond. It is 
synthesised in two forms, an 85 kD form and an 88 kD form (Hojima et al., 
1985). Both isoforms are the product of a single 56 kD heavy chain bound to 
either a 33 kD or 36 kD light chain. Like FXII, activation of prekallikrein is 
brought about by the cleavage of a bond (Arg371-lie372) encompassed by its 
disulphide bond (Page et al., 1994). The active form of prekallikrein (plasma 
kallikrein) is therefore a two-chain protein: a heavy chain (371 amino acids) 
linked to a light chain (248 amino acids) by a disulphide bond. The light chain of 
plasma kallikrein displays serine protease activity and is responsible for the
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excision of bradykinin from HMWK, the activation of FXII and the autoactivation 
of prekallikrein (Tans et al., 1987). The heavy chain of prekallikrein consists of 
four homologous 90-91 amino acid disulphide loops referred to as apple 
domains 1 -4 (A1-4). HMWK binds to prekallikrein via A1, A2 and A4 (Page and 
Colman, 1991; Page et al., 1994; Herwald et al., 1996; Renne et al., 1999).
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Figure 1.12) The activation of prekallikrein by FXI! and FXI If on artificial surfaces.
1.4.2.1.4 Activation of prekallikrein on cell surfaces
The high affinity binding of FXII and HMWK to human umbilical vein endothelial 
cells (HUVECs) (Reddigari et al., 1993a), platelets (Meloni et al., 1992) and 
neutrophils (Gustafson et al., 1989; Figueroa et al., 1992; Henderson et al., 
1994) in the presence of Zn2+, occurs in a reversible and saturable manner. This 
discovery prompted the isolation of the cell surface proteins responsible for the 
binding of FXII and HMWK. The passage of solublised-HUVEC cell membranes 
over a HMWK affinity column revealed that the globular heads of the cell surface 
receptor, gC1qR, bind with high affinity to the light chain of HMWK (Joseph et 
al., 1996). However, it was observed that the heavy chain of HMWK also bound 
with high affinity to the plasma membranes of HUVECs (Reddigari et al., 
1993a). The protein responsible for the binding of the heavy chain of HMWK to 
HUVECs was isolated and revealed to be cytokeratin 1 (CK1) (Joseph et al., 
1999).
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Antibodies raised against gC1qR and CK1 revealed that gC1qR and CK1 are 
responsible for 72% and 30% of HMWK binding to HUVECs respectively, while 
the combined antisera inhibited HMWK binding by 85% (Joseph et al., 1999). 
Consequently, it is believed that a third protein is responsible for the binding of 
HMWK to HUVECs. Immunostaining and biotinylation studies have revealed 
that this protein is urokinase plasminogen activator receptor (u-PAR) (Hasan et 
al., 1998; Mahdi et al., 2001).
Enzyme assays have revealed that activation of FXII is induced by its incubation 
with gC1qR and CK1, in the presence of HMWK and Zn2+ (Joseph et al., 2001). 
Hence, the activation of prekallikrein is potentiated by FXII in the presence of 
HMWK, Zn2+ and purified CK1 or gC1qR. However, CK1 and gC1qR do not 
appear to have any effect on the activation of prekallikrein in the absence of FXII 
or Zn2+. Studies with human plasma, incubated with HUVECs, have also 
revealed that the plasma becomes activated in the presence of Zn2+ and this 
activity is inhibited by antibodies raised against gC1qR and CK1 (Joseph et al., 
2001). This is consistent with the theory that FXII is activated on the surface of 
cells by binding to CK1 or gC1qR in the presence of Zn2+.
1.4.2.2 Tissue kallikrein-dependent kinin synthesis
1.4.2.2.1 Low molecular weight kininogen
Low molecular weight kininogen is a single chain of 409 amino acids. It also has
a single disulphide bond between its amino- and carboxy- terminal cysteine 
residues. Its heavy chain and the first 12 amino acids of the light chain are 
identical to that of HMWK, but, it lacks domain 6 and therefore does not posses 
any procoagulant activity or the capacity to bind prekallikrein.
1.4.2.2.2 Tissue prokallikrein [EC 3.4.21.35]
Tissue or glandular kallikrein is a 26-42 kD glycoprotein (depending on the 
degree of glycosylation) synthesised from one gene in a variety of organs, 
including the kidney, pancreas, liver, salivary glands and the brain (Lu et al., 
1989). In glands of the upper and lower airway, it is stored as an inactive 
precursor and released in response to allergen challenge in atopies 
(Baumgarten et al., 1986b; Christiansen et al., 1987; Christiansen et al., 1992;
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Nishiyama et al., 2001). Once in the nasal mucosa, it converts LMWK into 
kallidin and a two-chain glycoprotein. However, under conditions where there is 
little or no LMWK available, tissue kallikrein may also act on HMWK to produce 
kallidin (Maier et al., 1983a; Baumgarten et al., 1986b).
The definition of a true tissue kallikrein is an enzyme that exhibits kininogenase 
activity by the excision of a kallidin molecule from LMWK. However, a new 
family of 14 other enzymes with molecular homology to glandular kallikrein are 
also referred to as tissue kallikreins (Mahabeer and Bhoola, 2000; Clements et 
al., 2001; Yousef and Diamandis, 2001; David et al., 2002; Yousef and 
Diamandis, 2003). These enzymes are also serine proteases but lack 
kininogenase activity. They are used as markers for the diagnosis of various 
forms of human cancer. For clarity, during the remainder of this thesis, the term 
tissue kallikrein will only be used with reference to the enzyme which displays 
kininogenase activity in conjunction with LMWK.
Prokallikrein, the inactive precursor of tissue kallikrein, is a single chain of 238 
amino acids, with an additional 7 N-terminal amino acids (Ala-Pro-Pro-lle-GIn- 
Ser-Arg) (Takahashi et al., 1988; Lu et al., 1989). Removal of these 7 N-terminal 
amino acids results in the activation of prokallikrein. Enzymes capable of 
activating prokallikrein in vitro include thermolysin (a bacterial enzyme), and 
trypsin (Takada et al., 1985). However, their contribution to tissue kallikrein 
activation in the nose is thought to be limited, as thermolysin and trypsin are not 
thought to be present in the nasal airway. The only other enzyme capable of 
activating tissue prokallikrein in vitro is plasma kallikrein. However, it has not 
been determined whether plasma kallikrein is responsible or capable of 
activating tissue prokallikrein in vivo.
1.4.2.3 Alternative kininogenase pathways
Kinin production in individuals allergic to the house dust mite, 
Dermatophagoides farinae, is thought to occur via a kallikrein-dependent and 
kallikrein-independent pathway. D. farinae contains a biochemically active 
protease (Df protease), which also exhibits kininogenase activity (Maruo et al., 
1991). Studies in vivo have revealed that it is capable of kinin synthesis and 
activating FXII and prekallikrein in vitro.
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In addition to glands within the nasal airway, tissue kallikrein is also synthesised 
and released by vascular endothelial cells, monocytes, macrophages and 
neutrophils (Figueroa et al., 1989; Kemme et al., 1999; Lauredo et al., 2004; 
Yayama et al., 2003). The significance of non-glandular tissue kallikrein activity 
in the synthesis of kinins within the nasal airway is not known. However, it is 
possible that they may hamper as opposed to augment kinin synthesis within 
the nasal airway, as exposure of prokallikrein to the neutrophilic enzymes, 
neutrophil elastase and cathepsin G, impedes tissue kallikrein activity (Podlich 
et al., 1999). These results are corroborated by the findings of another group, 
who found that the ability of tissue kallikrein and plasma kallikrein to release 
kinins from their respective kininogens is impeded by pre-treatment with 
neutrophil elastase (Dulinski et al., 2003). Yet, in contrast, a mixture of human 
neutrophil elastase and mast cell tryptase is thought to produce comparable 
yields of kinins to plasma kallikrein and tissue kallikrein when acting on HMWK 
and LMWK (Kozik et al., 1998).
IgE-mediated release of an enzyme with kininogenase activity and the ability to 
activate prekallikrein has been detected in chopped human lung fragments 
(Meier et al., 1983; Proud and Kaplan, 1988). The enzyme(s) was originally 
thought to be mast cell tryptase, but this is unlikely as it was found that tryptase 
requires a non-physiological pH, pH 5.5, for optimum kinin synthesis in vitro 
(Proud et al., 1988). Moreover, contraction of guinea-pig ileum in response to 
exposure to HMWK which has been treated with plasma kallikrein is attenuated 
if the HMWK is also pre-treated with mast cell tryptase (Maier et al., 1983b).
Conversely, studies with guinea-pig skin have revealed that products from the 
degradation of physiological concentrations of HMWK by mast cell tryptase (at 
pH 7.4) cause a dose-dependent increase in vascular permeability. It was 
postulated that tryptase causes kinin production in vivo by the activating plasma 
kallikrein in addition to directly catalysing the synthesis of bradykinin by the 
degradation of HMWK. Unfortunately, kinin production was not measured and 
kinin B2 receptor antagonists were not used to confirm the findings of this study 
(Imamura et al., 1996).
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1.4.3 Termination of the kallikrein-kinin pathway
1.4.3.1 Kininases
Enzymes responsible for the termination of kin in-mediated activity are referred 
to as kininases. There are two classes of kininases’, kininase I and kininase II.
Type I Kininases
Carboxypeptidase N (CPN) [EC 3.4.17.3] comprises a 50 kD and 48 kD active 
subunit each bound to an 83 kD regulatory subunit (Erdos, 1992). It is 
synthesised in the liver, released into the circulation and resides on a variety of 
cells within the nasal airway (Ohkubo et al., 1994). CPN transforms the kinins 
bradykinin and kallidin into des-arg9-bradykinin and des-arg10-kallidin by 
removing their C-terminal arginne amino acids (figure 1.13).
Type II Kininases
Angiotensin converting enzyme (ACE) [EC 3.4.15.1] is a single chain 140-170 
kD glycoprotein found in most bodily fluids and anchored to the plasma 
membrane of cells all over the human body (Bhoola et al., 1992). In the nasal 
airway, it has been identified on vascular endothelial cells, between epithelial 
cells and in luminal secretions (Ohkubo et al., 1994). ACE has two Zn2+- 
containing active sites: one found in its N-terminal domain and the other in its C- 
terminal domain. Both domains contribute to kinin degradation, but the N- 
terminal domain is thought to be responsible for 76% of its activity (Jaspard et 
al., 1993). ACE terminates kinin activity by the lysis of the Pro7- Phe8 and Ser6- 
Pro7 bonds (figure 1.13)(Bhoola et al., 1992).
Neutral endopeptidase (NEP) [EC 3.4.24.11] is a membrane bound 
glycoprotein. It has one Zn2+-containing active site and is expressed in the 
human nasal airway (Baraniuk et al., 1993). It terminates kinin activity by the 
lysis of the Pro7- Phe8 bond (figure 1.13).
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Figure 1.13) A summary of the kallikrein-kinin pathway. 
1.4.3.2 Endogenous kallikrein inhibition
Termination of kallikrein-dependent kinin synthesis is mediated by a group of 
endogenous plasma proteins known as SERPINs (serine proteinase inhibitors). 
They inhibit serine protease activity by binding to enzyme active sites. The most 
notorious SEPRINs include the complement fragment 1 (C1) inhibitor, a2- 
macroglobulin, a r-antitrypsin, antithrombin III and a2-antiplasmin.
Hageman Factor enzyme activity is inhibited by a combination of C1 inhibitor, 
ot2-macroglobulin, antithrombin III and a2-antiplasmin. Approximately 91% of its 
inhibition in human plasma is mediated by C1 inhibitor (Pixley et al., 1985) and 
over 50% of this inhibition is achieved in 10 minutes (Schousboe, 2003). Plasma 
kallikrein activity in normal human plasma is inhibited by approximately 89% in 5 
minutes. 52% of its inhibition is mediated by C1 inhibitor, 35% by a2- 
macroglobulin and the remaining 13% by a combination of other plasma 
proteins (van der Graaf et al., 1983; Olson et al., 1993). Tissue kallikrein is 
inhibited by a-i-antitrypsin (o^-AT) and kallikrein binding protein (KBP) (Geiger et 
al., 1981; Chen et al., 1990). Half maximal binding of tissue kallikrein to KBP 
takes approximately 30 minutes and in excess of 6 hours with a^AT. The slow 
binding kinetics of tissue kallikrein to plasma proteins suggests that it is 
relatively resistant to inhibition in vivo.
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1.4.4 The role of kinins, kallikrein and kininases in the nasal airway
Kinin receptors are not constitutively expressed in human nasal airways. 
However, expression of kinin Bre ce pt o r  mRNA is significantly greater in 
allergic individuals and is increased further by allergen challenge (Christiansen 
et al., 2002). Unsurprisingly, intranasal challenge of both allergic and non- 
allergic individuals with the kinin B  ^ receptor agonist, des-arg10-kallidin, 
produces no observable symptoms (Rajakulasingam et al., 1990; Austin and 
Foreman, 1994a; Reynolds et al., 1999; Christiansen et al., 2002).
Kinin B2 receptors are constitutively expressed in both allergic and non-allergic 
airways. Autoradiographic analysis of human nasal mucosa has revealed that 
binding sites for bradykinin are present on nerves, arterioles, capillaries, small 
venules and venous sinusoids, with no specific binding to submucosal glands or 
goblet cells (Baraniuk, 1990). Intranasal challenge of atopic and non-atopic 
individuals with bradykinin causes dose-dependent nasal blockage, nasal 
discomfort and rhinorrhea (extravasation and glandular activation). However, 
nasal responses to bradykinin are altered in atopic individuals during the allergy 
season (Riccio and Proud, 1996). Unilateral application of bradykinin to 
seasonal and perennial allergic individuals causes contralateral glandular 
secretion, a response not seen in non-allergic individuals. This response was 
attenuated by pre-treatment of the contralateral nasal cavity with atropine, 
suggesting that the glandular activation was a cholinergic-mediated reflex 
response. Additionally, bradykinin also activates sensory neurones, shown by its 
capacity to produce a significant increase in substance P in atopic nasal lavages 
(Baumgarten et al., 1997).
Kinins are also thought to play a role in the development of airway 
hyperreactivity in the upper and lower airways. Allergic individuals challenged 
with allergen display an immediate and delayed increase in nasal lavage kinin 
content (Naclerio et al., 1985; Togias et al., 1988; Turner et al., 2001). 
Additionally, kinin B2 receptor antagonists inhibit allergen-induced airway hyper­
reactivity in seasonal allergic individuals (Turner et al., 2001). However, these 
findings are not supported by the fact that intranasal challenge with kinins does 
not induce airway hyper-reactivity to histamine in non-atopic individuals (Turner 
et al., 2000b).
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The kinin B2 receptor antagonist, icatibant, exhibits different efficacies in the 
immediate response of individuals with perennial allergic rhinitis and seasonal 
allergic rhinitis. In perennial allergic rhinitis, icatibant (previously known as HOE 
140) abolishes HDM-induced nasal blockage, but, in seasonal allergic rhinitis it 
has no significant effect on pollen induced nasal blockage (Turner et al., 2001). 
Coincidently, icatibant also reduces the allergen-induced increases in kinin 
content of nasal lavage fluid from individuals with perennial allergic rhinitis (Dear 
et al., 1996).
1.4.5 Kinin B2 Receptor Antagonists
The first kinin receptor antagonist was a D-Phe7 substitute of bradykinin 
(Stewart et al., 1999). Further substitution of bradykinin amino acids and the 
addition of an amino-terminal arginine residue lead to the synthesis of the first 
generation of kinin antagonists, such as NPC 567 ([D-Arg°, Hyp3, D-Phe7]- 
bradykinin). Unfortunately, the potency of these drugs in vivo was very limited 
(Pongracic et al., 1991; Austin and Foreman, 1994a). High doses of NPC 567 
do not antagonise bradykinin-induced effects in non-atopic nasal airways. This 
lack of potency was attributed to their relatively low affinity for kinin B2 receptors 
and their susceptibility to degradation by CPN (Stewart et al., 1999).
Second generation bradykinin antagonists were created by the introduction of 
two artificial amino acids, octahydroindole-2-carboxylic acid (Oic) and D- 
tetrahydroisoquinoline-3-carboxylic acid (Tic), into the structure of first 
generation antagonists. Icatibant was the first successful second generation 
compound to be recognised for its resistance to CPN degradation, increased 
affinity for kinin B2 receptors and increased potency in vivo (Hock et al., 1991; 
Wirth et al., 1991). This has been exemplified by its potency in human nasal 
airways where icatibant effectively antagonises bradykinin-induced effects at 
doses of 30 pg (Austin and Foreman, 1994; Proud et al., 1995; Dear et al.,
1996).
Substitution of amino acid residues in icatibant for other artificial amino acids 
has led to the synthesis of third and fourth generation receptor antagonists. 
These drugs are also resistant to NEP activity, retain their affinity for kinin B2 
receptors and have significantly improved affinities for kinin B-i receptors 
(Burkard et al., 1996; Stewart et al., 1996; Stewart et al., 1999).
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1.5 Aims of the project
a) To determine the effect of kinin receptor antagonists on kinin synthesis in the 
human nasal airway.
b) To determine the effect of kinin receptor antagonists on kallikrein enzyme 
activity.
c) To determine the effect of kinin receptor antagonists on enzyme activity from 
human nasal lavage fluid.
d) To determine the effect of kinin receptor antagonists on kallikrein activation.
e) To determine whether kinin Bi and kinin B2 receptors play a role in nasal 
airway hyper-reactivity.
f) To determine if nerves in the nasal airway play a role in PAF-induced airway 
hyper-reactivity.
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CHAPTER 2
M ATERIALS &  METHODS
2.1 Techniques which can be used to study the nasal airway
Gaining an understanding of the physiology and pathophysiology of diseases of 
the upper airway is enhanced by being able to manipulate its function in situ. 
This usually involves pharmacological intervention and/or provocation, in 
conjunction with a means of assessing the nasal airway. The most common 
route of pharmacological application is nasally, in the form of a spray or paper 
disc.
2.1.1 Estimation of nasal airflow
Rhinomanometry is a technique used to determine the level of resistance to 
airflow within the nasal airway while breathing. More than 80% of the resistance 
within the nasal airway is generated within the region of the inferior nasal 
turbinate (Malm, 1997). Resistance is therefore used as a direct measure of 
nasal congestion. Nasal airway resistance is calculated by the division of 
pressure within the posterior region of the nares, by the rate of airflow through 
the nasal airway. Airflow and pressure are determined with aid of an airtight 
mask, with a ‘flow head’ and a pressure sensing tube inserted into the mouth or 
the nostrils (Malm, 1997; Nathan et al., 2005). Calculation of pressure within the 
nasal airway by insertion of the tube into the mouth is called posterior 
rhinomanometry, while insertion of the tube into each nostril is called anterior 
rhinomanometry. Anterior rhinomanometry is favoured over posterior 
rhinomanometry because it calculates the resistance of each nostril individually 
and requires less subject compliance, but it is flawed if unilateral nasal 
obstruction occurs.
Nasal peak flow measures either the maximum inspiratory flow rate (NPIF) in 
litres per second or the maximum nasal expiratory flow rate (NPEF) in litres per 
second (Malm, 1997; Nathan et al., 2005). Readings are obtained with the aid of 
a flow meter attached to a mask. Both methods are quick, non-invasive and 
require very little subject compliance. As with rhinomanometry, nasal peak flow
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readings are influenced by resistance within the region of the inferior nasal 
turbinate, however, the level of reproducibility is limited by a number of factors 
including subject technique, vestibular collapse (with NPIF), poor inspiratory 
reserve, nasal obstruction and poor equipment sterility.
2.1.2 Estimation of nasal blood flow.
Xenon clearance and laser-Doppler velocimetry (LDV) are techniques used to 
measure changes in blood flow within the nose. Xenon is a radioactive marker, 
injected into the nasal mucosa using a small-gauge needle. Blood flow is 
determined by detection of xenon activity, taking into consideration its solubility 
within the blood and the nasal mucosa (partition coefficient) (Druce, 1993). 
Unfortunately, the accuracy of this technique is limited by its flaws. Firstly, it is 
invasive, therefore nasal trauma is likely to produce undesirable effects on the 
vasculature. Secondly, measurements can only be taken when the patient is 
supine, however, they must receive allergen while in a seated position, which 
means changes in posture may affect the results. Thirdly, xenon activates neural 
receptors and may also interfere with results.
LDV works on the principle of the Doppler effect. The Doppler effect is a change 
in frequency or wavelength of a wave (electromagnetic or sound) perceived by a 
moving object relative to its position to the source of the wave. In LDV the wave 
is light and the objects are red blood cells within the microvasculature. Light is 
scattered by red blood cells as they pass through the microvasculature. The 
wavelength and frequency of the scattered light is identical to the wavelength 
and frequency which is received by the red blood cells. However, this changes 
relative to their position to the laser. Scattered light is detected by a 
photomultiplier tube. A reference wave, which is not passed through 
microvasculature, is also detected by the photomultiplier tube. Both sets of 
waves, scattered and reference, are transformed into an electrical signal and 
used to detect a change or “shift” in the light’s wavelength. The faster the red 
blood cells move, the greater the degree of scatter and therefore the greater the 
change in the frequency (or wavelength) of the scattered light (Druce, 1993). 
LDV is non-invasive and can be used to measure dynamic changes in blood 
flow and volume. However, positioning of the probe, which emits and detects the 
light, is likely to be complicated by the inability to see the nasal turbinate and by 
subject non-compliance.
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2.1.3 Estimation of nasal patency
Magnetic resonance imaging and computed tomography are techniques that are 
used to visualise the nasal airway (Malm, 1997). They provide three-dimensional 
images of the nasal airway and can be used to measure changes in nasal 
congestion. However, the downfalls with these techniques are the large running 
costs and the high doses of radiation exposure.
Acoustic rhinometry measures the minimum nasal cross sectional area (Amin), 
within a certain depth of the nasal airway. Measurements are taken from the 
narrowest region of the nasal cavity, which tends to be around the inferior nasal 
turbinate, to give an objective measurement of nasal blockage.
Acoustic rhinometry uses sound waves to map out the internal anatomy of the 
nasal cavity. The rhinometer is a long hollow pipe with a pulse generator at the 
bottom end and a microphone just below the top end. A sterile plastic tube 
(approximately 6 cm long) is attached to the top of the rhinometer and is placed 
in the anterior aperture of the nostril. Subjects sit on a stable stool, with a 
straight back and face forwards. They are then required to take a deep breath 
through their mouths, then close their mouths and hold still whilst the 
measurement is taken. The pulse generator discharges a sound wave up the 
tube, this echoes within the nasal passage and reflected sound waves are 
recorded by a microphone, then amplified and sent to the computer where a 
graph of Amjn. against distance is generated, as shown in figure 2.3. Each 
recording takes approximately 0.5 seconds to obtain.
While acoustic rhinometry may not directly calculate the nasal airway resistance, 
changes in Amin correlate strongly with changes in airway resistance calculated 
by rhinomanometry (Austin and Foreman, 1994b). Acoustic rhinometry provides 
quick, reproducible and accurate results with very little subject compliance.
Assuming that the nasal airway is a tube in which air flows without turbulence, 
the minimal cross sectional area of the nasal cavity can be calculated as follows:
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Where:
r = the radius of the nasal airway 
Poiseuille’s law states that:
/  :
7rAP .r 4
8 rjl
where:
I = rate of airflow through nasal airway
AP = pressure difference across the nasal airway
r = Radius of airway
I = length of nasal airway
tp  viscosity of air
Ohms law can be used to describe the magnitude of resistance within the nasal 
airway as follows:
i
where:
AP = pressure difference across the nasal airway 
I = rate of airflow through nasal airway
Therefore Poiseuille’s law can be re-written as follows (after using ohms law for 
substitution of I):
* =  A lL
n  .r
R = AP/I
P = pressure diff across nasal cavity 
I = rate of airflow through the nasal cavity
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Therefore the resistance to airflow through the tube is inversely proportional to 
the fourth power of its radius, meaning that a reduction in the diameter of the 
nasal airway results in a large increase in the resistance to airflow.
The nose is clearly not a smooth tube, it has a number of internal protrusions, 
which prevent streamlined movement of air through the nasal cavities and 
increase its surface area. The most prominent protrusions are the nasal 
turbinates. Thus, Poiseuille’s law is an approximation for determining the 
resistance to airflow in the nasal airway.
2.1.4 Measurement of nasal inflammation and mediator production
Irrigation of the nasal airway is known as nasal lavage. Nasal lavage is a 
technique used to recover cells, mediators and enzymes from the nasal airway 
for biochemical and/or histological analysis (Baumgarten et al., 1986a; 
Svensson et al., 1989; Turner et al., 2001). It cannot be used to determine 
mediator concentrations on the surface of the nasal airway, it is simply used to 
monitor changes in mediator concentration. Basal mediator concentrations 
within the nasal airway may be high, therefore, pre-challenge lavages are 
usually performed and repeated to dilute mediator concentrations so a baseline 
mediator concentration, with little mediator accumulation, can be established. 
Nasal lavages may also be performed in conjunction with nasal biopsy. Tissue 
samples may be removed surgically, by scraping or by brushing and used for 
microscopy, cell staining, radioligand binding or a variety of other in vitro 
techniques (Mullol et al., 1992; Dear et al., 1996; Rajakulasingam et al., 1997b)
2.1.5 Symptoms scores
Subjective assessments of symptoms severity quantified on a numerical scale. 
Symptoms usually assessed include nasal blockage, pruitis, sneezing and 
rhinorrhea.
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2.2 Nasal challenge experiments
Materials &  Methods
2.2.1 Subjects
All studies were carried out on non-atopic individuals. Any subjects with ill health 
or taking medication less than 4 weeks prior to the study were excluded. All 
subjects gave informed consent and studies were approved by UCL Research 
Ethics Committee. Experiments were performed in a laboratory at controlled 
temperature and humidity.
2.2.2 Dilution of challenge agents
Stock solutions of the nasal challenge agents were made by dilution in sterile 
saline (154 mM NaCI). 1.5 ml aliquots were then placed into 7 ml bijouxs and 
stored at -20°C. The concentration of each stock aliquot was as follows: 
bradykinin, 1 and 2.5 mg/ml; histamine, 2 mg/ml; [D-Arg°, Hyp3, D-Phe7]- 
bradykinin, 2 mg/ml; des-arg10-kallidin, 2 and 4 mg/ml; des-arg10-leu9-kallidin, 2 
mg/ml; aprotinin, 1 mg/ml; icatibant, 0.1, 0.3, 1 and 2 mg/ml. Platelet activating 
factor (PAF) was initially dissolved in ethanol and then diluted in deoxygenated 
saline, to produce a 0.6 mg/ml or 0.8 mg/ml solution of PAF, in 1% ethanol. 1.5 
ml aliquots were placed into 7 ml bijouxs and filled with nitrogen gas before 
being frozen at -20°C. Aliquots of PAF were only stable for 3 to 4 days at -20°C.
2.2.3 Nasal challenge
All nasally administered drugs were delivered via a hand-held pump spray 
(Perfect-Valois UK Ltd), which delivers 100 pi of solution with 98% accuracy. 
Drugs were dissolved and diluted in sterile saline. All nasal sprays were warmed 
to 37°C before administration.
2.2.4 Nasal lavage
A nasal olive (made of medical grade silicone) was attached to the end of a 5 ml 
syringe, to ensure a watertight seal when applied to each nostril. A kwill tube 
was also attached to the end of the syringe and used to withdraw 2.5 mis of
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sterile saline from vessel heated to 37°C (figure 2.1). The kwill tube was then 
removed and the olive left attached to the syringe.
Syringe Kwill tube
Medical grade
Silicone
Figure 2.1) Diagram of a syringe, with a kwill tube and medical grade silicone attached, 
used for nasal lavage.
Subjects were then asked to lean over a sink, at an angle of approximately 50° 
from vertical, to prevent fluid entering the nasopharynx. The saline was slowly 
instilled into the nasal cavity and then mixed for 10 seconds. The contents of the 
nasal cavity were expelled into a sink. This procedure was repeated twice in 
each nasal cavity. The fluid from the third pre-challenge lavages, of each nostril, 
was collected into a 15 ml conical tube and kept in ice until the end of the 
experiment. Approximately five minutes later subjects were challenged (to 
induce a nasal response) or treated (to inhibit a nasal response) with the 
appropriate agent. After intranasal challenge, subjects underwent a final lavage 
without any pre-washes, and the contents were collected in a new 15 ml conical 
tube. All nasal lavage fluid was then centrifuged at 1000 x g for 10 minutes at 
4°C. The supernatant was then placed in polypropylene Eppendorf tubes and 
stored at -70°C until assay, unless otherwise stated. This protocol is 
summarised in figure 2.2.
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Pre-treatment: 
Saline/Antagonist Challenge:
1
Saline/Ac 
r  i
ive agent
r
- 2  mins 0  mins 2 0  mins
jk i k
3 x nasal 1 x nasal
lavage lavage
Figure 2.2) General protocol for studying the effect of intranasal challenge on mediator 
production on in the nasal airway
2.2.5 Acoustic Rhinometry
Nasal patency was determined with an acoustic rhinometer from GM 
Instruments, Kilwinning, UK. The minimum cross sectional area of both nasal 
cavities was measured (in triplicate) immediately prior to and then at, 2, 5, 10, 
and 15 minutes after all nasal challenges. The units of the minimum cross 
sectional area (Amin.) are cm2 (figure 2.3).
1 0 .0 i
Pre
Post
COI
CO
CO
Distance (cm)
Figure 2.3) A map of the cross-sectional area of a nasal cavity prior and post nasal 
blockage. The x-axis corresponds to the distance from the end of the rhinometer which 
the cross-sectional area is measured. The y-axis corresponds to the cross-sectional 
area. The deepest troughs found in both the pre and post challenge recordings 
corresponds to the minimum cross-sectional area and probably represent the distribution 
caused by the inferior nasal turbinate.
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2.2.6 Data analysis
The resting patency of each nasal cavity, was determined by calculating the 
mean, for each nostrils triplicate resting Amin. values (Amin. values obtained prior 
to nasal challenge). The overall resting nasal patency was the mean of the 
resting values for each nostril. These calculations were repeated with each set 
of triplicate values, for both nasal cavities, at each time point after nasal, 
challenge to determine the average nasal patency after intranasal challenge. 
Due to intra- and inter-subject variation in nasal patency, all post challenge 
values of Amjn. were normalised to the baseline Amin. Figure 2.4 is a graph 
showing the effect of saline and bradykinin on nasal patency after intranasal 
challenge.
1 1  -i
1.0 i  y
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Figure 2.4) The time course of bradykinin-induced nasal blockage. The effect of bilateral 
intranasal challenge with saline or bradykinin (100 pg) on nasal patency. Amin was 
measured in triplicate in each nasal cavity immediately prior, 2, 5, 10 and 15 min after 
each challenge. Values were normalised by expressing Amin as a percentage decrease 
in Amin from baseline for each subject. Data are means from 9 subjects, displayed as 
mean ± standard error of the mean.
To quantify the degree of nasal blockage caused by a particular drug, nasal Amin 
vs. time graphs (figure 2.4) were integrated (mathematically) to find the area 
under the curve (AUC). If measurements were taken over a 15-minute period a 
value of 15 units.min corresponds to no change in nasal patency (i.e. an 
average normalised value of 1 unit over the 15 minute recording period) and a
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value less than 15 units.min corresponds to a reduction in nasal patency or an 
increase in nasal congestion. In this way figure 2.4, can be transformed into 
figure 2.5.
16-.
Saline Bradykinin
Figure 2.5) The effect of bilateral intranasal challenge with saline or bradykinin (100 pg) 
on nasal patency. Amin was measured immediately prior, 2, 5, 10 and 15 min after each 
challenge. Values were normalised by expressing Amin as a percentage decrease in 
Amin from baseline for each subject, following which the AUC was determined. Data are 
means from 9 subjects, displayed as mean ± standard error of the mean.
2.2.7 Statistical analysis
All data was analysed statistically using a one-tailed non-parametric analysis, 
and when appropriate a post hoc Dunn’s test. Non-parametric analyses were 
used because the data did not follow a Gaussian distribution. The null- 
hypothesis for each test assumed there was no difference between the control 
and active treatments.
In every experiment, each subject was exposed to both the active and control 
treatments, and so repeated measure statistical tests were used. As only two 
treatments were being compared (i.e. the active and inactive group) a Wilcoxon 
signed-rank tests was used. Probability values (p) less than 0.05 were 
considered statistically significant.
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2.3 Endothelial Cells
EA.hy926 cells were kindly provided by Dr M. Peretti of the William Harvey 
Institute, London, UK. EA.hy926 are a hybrid of A459 epithelial cells and human 
umbilical vein endothelial cells (HUVECs). They retain their endothelial 
characteristics for up to 50 passages and are therefore frequently used as a 
substitute for HUVECs (Edgell et al., 1983).
EA.hy926 culture
EA.hy926 were grown in Dulbecco’s Modified Eagle’s Medium (DMEM) with 
nutrient mixture F12 HAM at 37°C, 5% C 02, 95% 0 2 and 100% humidity. DMEM 
was also supplemented with penicillin (100 units/ml), streptomycin (100 pg/ml), 
fetal calf serum (10%) and glutamine (2 mM). Once the cells reached 100% 
confluence, they were passaged, which occurred every 3-4 days.
EA.hy926 Passage
EA.hy926 were scraped from the surface of the T75 flasks and then centrifuged 
at 4°C and 500 x g for 5 minutes. They were then re-suspended in fresh nutrient 
medium at a ratio of 1:3 (old medium with EA.hy926: new medium) and placed 
in new T75 flasks to grow further in the conditions mentioned above. After 
achieving 100% confluence a total of three times, the EA.hy926 were 
homogenized.
EA.hy926 homogenization
The cells were scrapped off the surface of the T75 flasks and centrifuged at 4°C 
and 1000 x g for 10 minutes. The nutrient medium was aspirated and the cells 
were re-suspended in 1.5 mis of HEPES buffer (10 mM HEPES, 137 mM NaCI, 
4 mM KCI, 11 mM D-glucose, 0.5 mg/ml RIA grade BSA, pH 7.4). They were 
then lysed by sonication (Ultrasonic sonicator XL, Heat systems). 500 pi of the 
whole cell homogenate was aliquoted into Eppendorf tubes and stored at -70°C 
until use. The remaining millilitre of homogenate was centrifuged at 15 000 x g 
for 8 minutes. The supernatant was aliquoted and stored at -70°C until use. The 
pellet was re-suspended in 0.5 ml HEPES buffer aliquoted and stored at -70°C 
until use.
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2.4 Biochemical assays
2.4.1 Albumin enzyme-linked immunosorbent assay (ELISA)
The albumin content of nasal lavage fluid was measured by an indirect ELISA. 
This method is quick, reproducible, sensitive and economical with respect to 
other techniques, such as radioimmunoassay and radial immunodiffusion 
(Raphael et al., 1988).
Albumin lining the surface of 96-well microtiter plates competes with soluble 
albumin (from standards or samples), for a binding site on antihuman serum 
albumin conjugated to horseradish peroxidase (HRP). HRP cleaves the 
chromogenic substrate, o-phenylenediamine dihydrochloride, to produce a 
change in absorbance detectable by spectrophotometry.
Protocol:
(1) Human serum albumin (50 pg/ml) was dissolved in 0.1 M carbonate buffer at 
pH 9.6. The albumin-buffer was incubated overnight in a 96-well polypropylene 
microtiter plate at 4°C.
(2) The wells were washed 4 times with PT (PT; 0.05% Tween 80 in phosphate 
buffered saline at pH 7.4).
(3) The plate was incubated at 23°C for 30 minutes, with 200 pi of 0.1% goat 
serum diluted in PT.
(4) The wells were washed again, 4 times with PT.
(5) 50 pi of albumin standard (2-200 pg/ml) and diluted samples were added to 
separate microtiter wells in duplicate. 50 pi of goat antihuman serum albumin- 
HRP (diluted 1:1000 in PT) was added to all wells containing albumin standard 
and diluted nasal lavage samples. The plate was then incubated for 90 minutes 
at 23°C.
(6) The wells were washed again, 4 times with PT.
89
Chapter 2 Materials &  Methods
(7) The chromogenic reaction was initiated by the addition of 200 pi of o- 
phenylenediamine dihydrochloride (0.4 mg/ml, dissolved in distilled water).
(8) The plate was incubated at room temperature in the dark for 30 minutes 
before being read in a 96-well plate reader, at 450 nm.
The difference in absorbance of the albumin standards (ODx) and the blank 
(OD0) were plotted against the logarithmic value of the standard albumin 
concentration (figure 2.6). GraphPad (Prism 4) software was used to fit a curve 
to the graph and calculate the concentrations of albumin in the nasal lavage 
samples.
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Figure 2.6) A standard curve showing the change in optical density with soluble albumin 
content. The optical density is reduced with increasing soluble albumin content, due to 
an increasing reduction of antihuman serum albumin-HRP binding to albumin coating 
the wells.
2.4.2 slgA enzyme-linked immunosorbent assay (ELISA)
Secretory immunoglobulin A content of nasal lavages was determined using a 
commercially available sandwich ELISA (Oxford Biosystems). Specific binding of 
slgA (unknown and standards) to a rabbit anti-slgA polyclonal antibody, is 
determined by the simultaneous binding of a signal antibody (peroxidase 
labelled anti-slgA antibody) and a chromogenic substrate for peroxidase, 
tetramethylbenzidine (TMB). The change in optical density produced by the 
addition of TMB is directly proportional to the specific binding of slgA.
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Protocol:
(1) A 96-well microtiter plate, pre-coated with excess immobilised polyclonal 
rabbit slgA, was washed five times with ELISA buffer.
(2) Nasal lavage samples were diluted 1:1000 with the ELISA buffer.
(3) 100 jliI of diluted nasal lavage fluid, slgA standards (0, 22.2, 66.6, 200 and 
600 ng/ml) and calibrators were incubated and shaken, on a horizontal mixer, at 
room temperature for 1 hour in the 96-well microtiter plate.
(3) The wells were washed with the ELISA buffer.
(4) 100 pi of peroxidase-labelled slgA antibody was incubated and shaken, on a 
horizontal mixer, for 1 hour at room temperature in the 96-well microtiter plate.
(5) The wells were washed with the ELISA buffer.
(6) 100 jul of TMB (provided in assay kit, concentration not known) was added to 
the microtiter plate and incubated for 5-10 minutes at room temperature.
(7) 50 pi of stop solution (as provided in assay kit) was added to the microtiter 
plate and the absorption was determined immediately afterwards at 450 nm.
The slgA standards were used to generate a standard curve (figure 2.7) of slgA 
concentration against change in optical density. GraphPad (Prism 4) software 
was used to fit a curve to the graph and calculate the concentration of slgA in 
the nasal lavage samples.
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Figure 2.7) A standard curve showing the change in optical density with slgA content.
2.4.3 Bradykinin Radioimmunoassay (RIA)
The kinin content of nasal lavage fluid was determined by radioimmunoassay. 
This method is reproducible and more sensitive than an ELISA, but it is less 
economical and takes 3 days to complete.
The assay is based on a competition between a labelled 125l-bradykinin and 
unlabelled bradykinin (standard and unknown) binding to a limited amount of 
antibody. As the concentration of the standard or unknown peptide increases, 
the amount of [125l]-bradykinin bound to the antibody decreases. A standard 
curve displaying the amount of [125l]-bradykinin bound as a function of the 
concentration of unlabeled bradykinin is generated and used to calculate the 
amount of bradykinin in the lavage samples (figure 2.8).
In order to reduce kinin degradation in nasal lavage fluid, 0.5 ml samples were 
mixed with EDTA solution (1.5 mis of 53.3 mM) and kept on ice until the end of 
the experiment (Proud et al., 1983). These samples were then centrifuged at - 
4°C and 1000 x g, for 10 minutes. The supernatant was aliquoted into 
Eppendorf tubes and be frozen at -70°C until assay.
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Figure 2.8) A standard curve displaying the relationship between the concentration of 
non-labelled bradykinin and the binding of 125l-bradykinin to rabbit anti-bradykinin serum.
Protocol:
(1) 100 pi of nasal lavage samples and bradykinin standards were incubated 
overnight (16-24 hours) at 4°C with rabbit anti-bradykinin serum (100 pi) in 
polypropylene tubes. These tubes were also supplemented with 100 pi of RIA 
buffer. Rabbit anti-bradykinin serum was not added to the tubes in which the 
total count and non-specific binding of 125l-bradykinin were to be determined: 
these tubes only contain RIA buffer (200 pi).
(2) 100 pi of [125l]-bradykinin (10,000-15,000 cpm) was added to all the RIA 
tubes in the assay. They were then incubated overnight (16-24 hours) at 4°C.
(3) All bradykinin (labelled and non-labelled) bound to the rabbit anti-bradykinin 
antibodies was precipitated by centrifugation (1700 x g for 30 minutes at 4°C) 
after the addition of normal rabbit serum (100 pi) and goat anti-rabbit IgG serum 
(100 pi).
(4) The supernatant was then aspirated from all the tubes in the assay (apart 
from those used to determine the total activity) and the activity of the pellets 
determined.
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The specific binding of all the samples and the bradykinin standards was 
determined using the following equation:
Where:
X = the counts per minute of in the pellets of the standard or unknown samples.
NSB = the counts per a minute in the pellets of the non-specific binding tubes.
TB = the counts per a minute in the pellets of the total binding tubes.
A graph showing the effect of increasing non-labelled bradykinin concentrations 
on the binding of [125l]-bradykinin to rabbit anti-bradykinin serum was generated 
(figure 2.8). GraphPad (Prism 4) software was then used to fit a curve to the 
graph and calculate the concentrations bradykinin in the nasal lavage samples.
2.4.4 Bradford assay
The amount of protein found in the homogenized EA.hy926 cells was 
determined using a Bradford assay. This protein assay is fast and fairly 
accurate. It works on the principle that the degree of absorbance exhibited by a 
coloured dye found in Bradford reagent, increases proportionally with its binding 
to protein (figure 2.9).
(1) Human serum albumin standards (20 -100 jug/ml) were created in Tris buffer 
(50 mM Tris, 113 mM NaCI, pH 7.5).
(2) Protein samples were diluted 1:10 with Tris buffer.
(3) 10 pi triplicates of the standards and samples were placed in a polystyrene 
microtiter 96-well plate.
(4) The Bradford reagent was diluted 1:1 with distilled water.
X - N S B
max
Protocol:
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(5) 190 jllI of the diluted Bradford reagent was incubated for 30 minutes at room 
temperature, with all the wells that contained protein samples and standards.
(6) The absorbance was read at 570 nm.
(7) Samples with an absorbance that fell within the range of the standard curve 
were used to calculate the protein content of the undiluted samples.
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Figure 2.9) A standard curve displaying the linear relationship between protein content 
and absorbance at 470 nm.
2.4.5 Enzyme activity assay
Chromogenic substrates are short synthetic peptides with a chromophore 
attached to their terminus. When mixed with specific enzymes, chromogenic 
substrates produce a colour change by separation from their chromophores in 
solution due to the hydrolysis of the bond connecting the chromophore to the 
rest of the substrate. This hydrolytic reaction is catalysed by specific enzymes 
and its rate of cleavage is proportional to the rate of enzyme activity. The amino 
acids incorporated into the chromogenic substrate enhance enzyme selectivity 
and are usually similar or identical to those found adjacent to the site of 
cleavage in the natural substrate (figure 2.10) (Claeson et al., 1978).
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HMWK (Arg^-Ser571)
Afg-Pro-Prc>GV-Phe-Ser-Pro-Phe-/Vg Bradykinin
Pro-Phe-Arg-pNA S-2302
i i
PK
362Figure 2.10) The amino acid composition of high molecular weight kininogen (Arg -  
Ser371), bradykinin and the chromogenic substrate, S-2302. The arrows correspond to 
sites of HMWK cleavage by plasma kallikrein (PK) and tissue kallikrein (TK).
Chromogenic substrates selective for enzymes used throughout this thesis are 
stated in table 2.1.
One of the most commonly used chromophores is para-nitroaniline (pNA), when 
exposed to electromagnetic radiation, it selectively absorbs light at the 
wavelength 400 nm (violet). Atomically, absorption is the conversion of light 
energy (photons) into chemical energy, used by electrons of the chromophore to 
enter into a higher energy state. Simultaneously, certain wavelengths of light are 
not absorbed and these give rise to the yellow colour observed with pNA in 
solution. The intensity of this colour is directly proportional to the degree of violet 
light absorbed by the chromophore.
Enzyme Substrate Am ino acid sequence
Km
(m-M)
kcat
(s-1)
Plasma kallikrein, Human
(50 mM TRIS, pH 7.8, 16 mM NaCI)
(50 mM TRIS, pH 7.8, 16 mM NaCI)
S-2302
S-2266
D-Pro-Phe-Arg-pNA
D-Val-Leu-Arg-pNA
220
500
150
85
Tissue kallikrein, Human 
(50 mM TRIS, pH 9, 16 mM NaCI)
S-2266 D-Val-Leu-Arg-pNA 30 1
Trypsin, Bovine
(50 mM TRIS, pH 9, 245 mM NaCI) 
(50 mM TRIS, pH 9, 245 mM NaCI)
S-2765
S-2222
D-Arg-Gly-Arg-pNA
Bz-lle-Glu-Gly-Arg-pNA
10
20
170
240
Table 2.1) Kinetic constants and amino acid sequence of chromogemic substrates 
available for use with plasma kallikrein, tissue kallikrein and trypsin (Diapharma, 
Chromogenix Booklet).
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2.5 Enzyme assays
2.5.1 Crude nasal lavage fluid
Enzyme activity in nasal lavage fluid was determined by its ability to cleave the 
chromogenic substrate S-2266, a chromogenic substrate for kallikrein (table 
2.1). Nasal lavage fluid was centrifuged at 1000 x g and 4°C for 10 minutes.
37.5 | l l I  of the supernatant was incubated with 175 pi of Tris-HCI buffer (pH 7.8, 
50 mM Tris, 113 mM NaCI) at 37°C for 15 minutes in a polystyrene 96-well 
microtiter well plate. After the addition of S-2266 (37.5 pi of 2.66 mM), 
spectrophotometric readings were taken at 10-minute intervals for one hour. 
Figure 2.11 is an example of such an experiment.
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Figure 2.11) A graph showing the dose-dependent aprotinin-induced inhibition of S- 
2266, 400 pM, cleavage by crude nasal lavage fluid. Enzyme activity was measured by 
spectrophotometry. Readings were taken at 10-minute intervals for 1 hour at 37°C in 
Tris-HCI buffer.
Inhibition curves, in which various doses of enzyme inhibitor were added to 
crude nasal lavage fluid, were created by determining the initial rate of the 
reaction at various doses of inhibitor. The activity of each dose of inhibitor was 
normalised with respect to the negative control (which had no inhibitor present). 
This transforms figure 2.11 into figure 2.12.
Aprotinin (nM): 
■ 5000
A 2000 
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Figure 2.12) An inhibition curve showing the effect of aprotinin on the cleavage of S- 
2266 400 pM, by crude nasal lavage fluid. Readings were taken at 10-minute intervals 
for 1 hour at 37°C in Tris-HCI buffer. Where Vj is the initial velocity of the enzyme 
reaction and Vmax is the velocity of the reaction without inhibitor present.
2.5.2 Purified active enzyme
2.5.2.1 Porcine tissue kallikrein
(1) 100 pi of Tris-HCI buffer (pH 8.2, 200 mM Tris at 25°C) with or without 
various enzyme inhibitors and icatibant present, was added to a polystyrene 96- 
well plate.
(2) 80 pi of porcine tissue kallikrein dissolved in Tris-HCI buffer was added to the 
96-well microtiter plate and incubated at 37°C for 15 minutes.
(3) 20 pi of S-2266 were added to the microtiter plate and spectrophotmetric 
readings were taken at 9-second intervals with Soft Max Pro3 (plate reader 
software). Note: The chromogenic substrate S-2266 was chosen according to its 
kinetic constants displayed in table 2.1.
(4) The initial rate of each reaction was determined and normalised with respect 
to the negative control (with no enzyme inhibitors or icatibant present or the 
maximum dose of substrate).
Protocol:
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2.5.2.2 Human plasma kallikrein
Protocol:
(1) 100 pi of Tris-HCI buffer (pH 7.8, 50 mM Tris, 113 mM NaCI at 25°C) with or 
without various enzyme inhibitors and icatibant present, was added to a 
polystyrene 96-well plate.
(2) 80 pi of human plasma kallikrein dissolved in Tris-HCI buffer was added to 
the 96-well microtiter plate and incubated at 37°C for 15 minutes.
(3) 20 pi of S-2302 were added to the microtiter plate and spectrophotmetric 
readings were taken at 9-second intervals with Soft Max Pro3 (plate reader 
software). Note: The chromogenic substrate S-2302 was chosen according to its 
kinetic constants displayed in table 2.1.
(4) The initial rate of each reaction was determined and normalised with respect 
to the negative control (with no enzyme inhibitors or icatibant present or the 
maximum dose of substrate).
2.5.2.3 Human pancreatic trypsin
Protocol:
(1) 100 pi of Tris-HCI buffer (pH 7.8, 200 mM Tris, 20 mM CaCI2 at 25°C) with or 
without various enzyme inhibitors and icatibant present, was added to a 
polystyrene 96-well plate.
(2) 80 pi of human pancreatic trypsin dissolved in Tris-HCI buffer was added to 
the 96-well microtiter plate and incubated at 37°C for 15 minutes.
(3) 20 pi of S-2765 were added to the microtiter plate and spectrophotmetric 
readings were taken at 9-second intervals with Soft Max Pro3 (plate reader 
software). Note: The chromogenic substrate S-2765 was chosen according to its 
kinetic constants displayed in table 2.1.
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(4) The initial rate of each reaction was determined and normalised with respect 
to the negative control (with no enzyme inhibitors or icatibant present or the 
maximum dose of substrate).
2.5.3 Enzyme activation assays
2.5.3.1 Prekallikrein activation assays
Stock solutions of proteins used for prekallikrein activation assays were made by 
dilution in 4 mM sodium acetate buffer (pH 5.5 and 0.15 M NaCI) treated with 
0.1 mM (4-aminophenyl)-methanesulfonylfluoride (APMSF) and stored in
aliquots at -70°C. The concentration of each stock aliquot was as follows: FXII, 
400 pM; heat shock protein 90, 125.5 nM; HMWK, 400 pM; prekallikrein, 400
pM; and hyaluronic acid binding protein, 66.66 pg/ml.
Protocol:
(1) 96-well microtiter polystyrene plates were coated with 250 pi of 1%
polyethylene glycol diluted in HEPES buffer (10 mM HEPES, 137 mM NaCI, 4 
mM KCI, 11 mM D-glucose, 0.5 mg/ml RIA grade Bovine serum albumin, pH
7.4) for 2 hours at room temperature.
(2) Prior to assay all proteins were mixed with equal volumes of 8 mM sodium 
acetate buffer (pH 5.5 and 0.15 M NaCI) for 15 minutes.
(3) The proteins were then diluted to the appropriate concentration in HEPES 
buffer for 45 minutes at room temperature.
(4) 85 pi or 105 pi of HEPES buffer, with or without various enzyme inhibitors 
and icatibant, was then added to the 96-well microtiter plate.
(5) Assay proteins were then added to the 96-well microtiter plate. The volumes 
were as follows: prekallikrein, 35 pi; HMWK, 35 pi; FXII, 35 pi; heat shock 
protein; 20 pi; hyaluronic acid binding protein; 20 pi and endothelial cell lysate; 
20 pi.
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(6) 20 jlxI of S-2302 were added to the microtiter plate and incubated at 37°C for 
15 minutes. Note: The chromogenic substrate S-2302 was chosen according to 
its kinetic constants displayed in table 2.1.
(7) 20 jliI of freshly made ZnCI2 (diluted in HEPES buffer) were then added to the 
96-well microtiter plate and spectrophotmetric readings were taken with Soft 
Max Pro3 (plate reader software).
The final concentration of each protein and reagent used in these assays is 
stated in chapter 6.2.2. The protocol and doses used were based upon pilot 
studies and previous publications (Joseph et al., 2001: Joseph et al., 2002).
2.5.3.2 Human plasma activation assays
Collection of blood
Human blood (9 ml) was collected directly into a 15 ml polypropylene conical 
flask containing 0.1 mol/litre sodium citrate (1 ml) using a 10 ml syringe and 21 
gauge needle. The blood was centrifuged at 2000 x g and 25°C and for 15 
minutes. The plasma was aliquoted into 1.5 ml Eppendorffs and frozen at -70°C.
Protocol:
(1) 96-well microtiter polystyrene plates were coated with 250 jul of 1% 
polyethylene glycol diluted in HEPES buffer (10 mM HEPES, 137 mM NaCI, 4 
mM KCI, 11 mM D-glucose, 0.5 mg/ml RIA grade Bovine serum albumin, pH
7.4) for 2 hours at room temperature.
(2) 123.5 j lx I  of HEPES buffer, with or without various enzyme inhibitors and 
icatibant, was then added to the 96-well microtiter plate.
(3) 7.5 pi of human plasma was then added to the microtiter plate.
(4) 20 pi of endothelial cell lysate was then added to the microtiter plate.
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(5) 25 jiil of S-2302 (2.4 |jM) was added to the microtiter plate and incubated at 
37°C for 15 minutes. Note: The chromogenic substrate S-2302 was chosen 
according to its kinetic constants displayed in table 2.1.
(6) 25 jiil of freshly made ZnCI2, 8 mM, (diluted in HEPES buffer) was then 
added to the 96-well microtiter plate and spectrophotmetric readings were taken 
with Soft Max Pro3 (plate reader software).
The final concentration of each protein and reagent used in these assays is 
stated in chapter 6.2.2.
2.6 Statistical analysis of biochemical assays
All biochemical assay and enzyme assay data was analysed statistically using a 
one-tailed non-parametric analysis, and when appropriate a post hoc Dunn’s 
test. Non-parametric analyses were used because the data did not follow the 
Gaussian distribution. The null-hypothesis for each test assumed there was no 
difference between the control and active treatments. Probability values (p) less 
than 0.05 were considered statistically significant.
The suitability of one equation (or model) over another for data was chosen 
using an F test (global fitting analysis). A p value less than 0.05 was deemed 
statistically significant.
Statistical differences in Hill co-efficients from unity were determined using an F 
test. A p value less than 0.05 was deemed statistically significant.
2.7 Spectrophotometry
Spectrophotometry was performed with a 96-well plate reader (Molecular 
Devices, Thermomax microtiter plate reader) kindly provided by Pfizer, UK.
Spectrophotometry works on the principle that the absorption intensity is directly 
proportional to the concentration of the chromophore in solution. This is 
expressed by the Lambert-Beer law:
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Absorbance  =  Log
I
-  S .C .I
\  1 J
Where:
s = extinction coefficient (molar absorptivity), c = concentration of the solute (M)
I = length/thickness of the solution (cm), l0 = intensity of the light of incidence 
I = intensity of the light after passing through the solution 
Spectrophotometers quantify the intensity of monochromatic light which passes 
through a sample, and therefore can be used to determine the concentration of 
the chromophore in solution.
The spectrophotometer was used to measure the change in optical density of 
solutions associated with ELISAs, enzyme assays and Bradford assays.
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2.7 Materials
The materials used in this study are shown below along with their sources.
MATERIAL SOURCE
Pharmacological Agents
Acetyl-p-methylcholine chloride Sigma, Poole, UK.
[1-adamantaneacetyl-D-Arg°, Hyp3, beta- Bachem, St. Helens, UK. 
(2-thienyl)-Ala 5' 8' D-Phe7]-bradykinin
Aprotinin (5500 KlU/mg) Calbiochem, Nottingham, UK.
Bradykinin Bachem, St. Helens, UK.
Captopril, 12.5 mg (tablets) UCH Pharmacy, London, UK.
[D-Arg°, Hyp3, D-Phe7]-bradykinin 
(NPC 567)
Bachem, St. Helens, UK.
Des-arg10-kallidin Bachem, St. Helens, UK.
Des-arg10-leu9-kallikdin Bachem, St. Helens, UK.
Dimethyl Sulfoxide (DMSO) Sigma, Poole, UK.
Histamine Sigma, Poole, UK.
Icatibant Hoeschst, Frankfurt, Germany.
Platelet activating factor (Ci6) Calbiochem, Nottingham, UK.
Soybean trypsin inhibitor Calbiochem, Nottingham, UK.
WIN 64338 Torcris, Bristol, UK.
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Biochemical and Enzyme assays
96-well microtiter polystyrene plates
96-well microtiter polypropylene plates
Bovine serum albumin 
(RIA grade)
Bradykinin Radioimmunoassay Kit 
Calcium chloride 
D-glucose 
Goat serum
Hageman factor, human (FXII)
Heat sock protein-90, human 
HEPES
High molecular weight kininogen 
(human, single chain)
Human serum albumin, Fraction V
Hyaluronic acid binding protein 
(bovine nasal cartilage)
Kaolin
o-phenylenediamine dihydrochloride
p-Amidinophenyl-methanesulfonyl 
fluoride hydrochloride (p-APMSF)
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Griener, Gloucestershire, UK. 
Dynatech Labs., Virginia, USA. 
Calbiochem, Nottingham, UK.
Bachem, St. Helens, UK.
BDH, Poole, UK.
BDH, Poole, UK.
Sigma, Poole, UK.
Calbiochem, Nottingham, UK. 
Calbiochem, Nottingham, UK. 
Calbiochem, Nottingham, UK. 
Calbiochem, Nottingham, UK.
Miles Laboratories, Napervile, USA. 
Calbiochem, Nottingham, UK.
Sigma, Poole, UK.
Sigma, Poole, UK.
Calbiochem, Nottingham, UK.
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Calbiochem, Nottingham, UK.Plasma kallikrein, human 
Polyethylene glycol 
Potassium chloride 
Prekallikrein, human 
Protein standard solution 
S-2266 
S-2302 
S-2675
Secretory Immunoglobulin A ELISA kit
Sheep antihuman serum albumin 
conjugated to horseradish peroxidase
Sodium acetate
Sodium bicarbonate
Sodium carbonate
Sodium phosphate (monobasic)
Sodium phosphate (dibasic)
Tissue kallikrein, porcine
Tris
Trypsin, human pancreas 
Tween 80
Sigma, Poole, UK.
BDH, Poole, UK.
Calbiochem, Nottingham, UK. 
Sigma, Poole, UK.
Quadratech, Surrey, UK. 
Quadratech, Surrey, UK. 
Quadratech, Surrey, UK.
Oxford Biosystems. Oxford, UK. 
Europa Bioproducts, Cambridge, UK
Sigma, Poole, UK.
Sigma, Poole, UK.
BDH, Poole, UK.
Sigma, Poole, UK.
Sigma, Poole, UK.
Calbiochem, Nottingham, UK. 
Calbiochem, Nottingham, UK. 
Calbiochem, Nottingham, UK. 
Sigma, Poole, UK.
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ZnCI5 Sigma, Poole, UK.
Cell culture
DMEM + F12 nutrient 
Fetal calf serum 
L-Glutamine 
Penicillin 
Streptomycin 
EA.hy926 cells
Miscellaneous
Acetic acid 
EDTA
Hydrochloric acid 
Medical grade silicone seals
Sodium chloride 
Sodium citrate
Sigma, Poole, UK.
Invitrogen, Paisley, UK.
Sigma, Poole, UK.
Sigma, Poole, UK.
Sigma, Poole, UK.
William Harvey Institute, London, 
UK.
BDH, Poole, UK.
Calbiochem, Nottingham, UK.
BDH, Poole, UK.
Kapitex Healthcare, Wetherbery, 
UK
BDH, Poole, UK.
Calbiochem, Nottingham, UK.
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CHAPTER 3
THE EFFECT OF ICATIBANT ON PAF- 
INDUCED KININ PRODUCTION IN THE 
HUMAN NASAL AIRWAY
3.1 Introduction
Individuals who suffer from perennial allergic rhinitis, which is caused by house dust 
mite (HDM) allergen, also produce kinins in response to intranasal challenge with 
house dust mite (Dear et al., 1996). Kinins play a significant role in the nasal 
blockage of individuals who suffer from perennial allergic rhinitis as intranasal pre­
treatment with the kinin B2 receptor antagonist, icatibant, abolishes HDM-induced 
nasal blockage and attenuates the recovery of kinins from nasal lavage fluid (Dear 
et al., 1996). Kinin generation stimulated in non-atopic nasal airways, by intranasal 
challenge with PAF, is also inhibited by pre-treatment with icatibant (Turner et al., 
2000b).
Exogenous application of PAF to the upper airway induces kinin production and 
also mimics symptoms of allergic rhinitis (Miadonna et al., 1996; Turner et al., 
2000b; Maniscalco et al., 2000). Therefore, it is possible that PAF generates an 
increase in tissue or plasma kallikrein activity within the human nasal airway.
In this chapter non-atopic individuals will be challenged intranasally with PAF: (1) to 
determine whether it induces glandular activation (by measurement of secretory IgA 
in nasal lavage fluid using an ELISA); (2) to determine whether it induces an 
increase in vascular permeability (by measurement of the albumin content of nasal 
lavage fluid using an ELISA) and; (3) to determine the level of kinin production in 
nasal lavage fluid (measured by radioimmunoassay). The effect of PAF on kallikrein 
enzyme activity in crude nasal lavages fluid will also be determined by 
spectrophotometry using the chromogenic substrate S-2266. Non-atopic individuals 
will also be topically pre-treated with a kallikrein inhibitor, aprotinin, to determine 
whether it reduces PAF-induced kinin production within the nasal airway. Subjects 
will also be challenged intranasally with methacholine to determine if it increases
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kallikrein enzyme activity in nasal lavages fluid. Lastly, the effectiveness of the kinin 
B2 receptor antagonists, icatibant and NPC 567, and the kinin B•, receptor 
antagonist, des-arg10-leu9kallidin, at reducing PAF-induced kinin and albumin 
production in non-atopic airways will be investigated.
Bradykinin: Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg
NPC 567: Arg-Arg-Pro-Hyp-Gly-Phe-Ser-D-Phe-Phe-Arg
Icatibant: Arg-Arg-Pro-Hyp-Gly-Thi-Ser-D-Tic-Oic-Arg
Figure 3.1) The amino acid sequence of the kinin B2 receptor agonist, bradykinin, and the 
kinin B2 receptor antagonists, NPC 567 and icatibant.
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3.2 Experimental protocol
All experiments were performed on non-atopic individuals. Subjects were made 
blind to the treatments which they received during the course of the investigation.
3.2.1 The effect of PAF on kallikrein-like activity, albumin, slgA and kinin 
production
The aim of this study was to determine the effect of PAF on the kallikrein-like 
enzyme activity, kinin production, secretory IgA (slgA) levels and albumin content of 
crude nasal lavage fluid. Subjects underwent three pre-challenge nasal lavages (the 
third lavage was used as the baseline while the first two lavages were discarded) 
followed by a bilateral intranasal challenge with a 100 pi aerosol of saline or PAF, 
60 pg. Twenty minutes after intranasal challenge with PAF or saline, subjects 
underwent a final nasal lavage. All subjects received PAF or saline in a random 
order, on separate occasions, at least 3 days apart. The dose of PAF used in this 
study was chosen on the basis of previously published data (Turner et al., 2000b). 
The protocol of this investigation is summarised in figure 3.2:
Challenge: 
Saline/PAF
r
0 mins 20 mins
i i  i k
3 x nasal 1 x nasal
lavage lavage
Figure 3.2) Protocol for investigating effect of PAF on kallikrein enzyme activity, albumin 
production, slgA levels and kinin content of lavage fluid from the nasal airway.
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3.2.2 The effect of methacholine on kallikrein-like enzyme activity
The aim of this study was to determine whether challenge with the muscarinic 
receptor agonist, methacholine, induces the release of tissue kallikrein from serosal 
glands within the nasal airway. Subjects underwent three pre-challenge nasal 
lavages (the third lavage was used as the baseline while the first two lavages were 
discarded) followed by a 100 pi aerosol of saline or methacholine (1 mg, 3 mg or 10 
mg) in both nostrils. Ten minutes after intranasal challenge subjects underwent a 
final nasal lavage. All 6 subjects received all 4 treatments in a random order, on 
separate occasions, at least 2 days apart. The protocol of this investigation is 
summarised in figure 3.3:
Challenge:
Time:
Saline/Me hacholine
r
0 mins 10 mins
i k i k
3 x nasal 
lavage
1 x nasal 
lavage
Figure 3.3) Protocol for investigating effect of methacholine on kallikrein enzyme activity of 
lavage fluid from the nasal airway.
3.2.3 The effect of icatibant on PAF-induced albumin and kinin production
The aim of this study was to determine the effect of the high affinity kinin B2 
receptor antagonist, icatibant, on PAF-induced kinin and albumin production in 
nasal lavage fluid. Subjects underwent three pre-challenge nasal lavages (the third 
lavage was used as the baseline while the first two lavages were discarded) 
followed by bilateral pre-treatment with a 100 pi aerosol of saline or icatibant. Two 
minutes later they were challenged bilaterally with PAF, 60 pg, or saline. Twenty 
minutes after intranasal challenge with PAF or saline, subjects underwent a final 
nasal lavage. All 7 subjects received each of the following 7 treatments in a random 
order, on separate occasions, at least 3 days apart:
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• Saline / saline
• Saline / PAF, 60 |ug
• Icatibant, 10 p.g / PAF, 60 fig
• Icatibant, 30 fig / PAF, 60 |ig
• Icatibant, 100 fig / PAF, 60 fig
• Icatibant, 200 |ig / PAF, 60 fig
• Icatibant, 200 fig / saline
The doses of icatibant used in this study are based on previous published studies 
(Dear et al., 1996). The protocol of this investigation is summarised in figure 3.4:
Pre-treatment:
Saline/lcatibant Challenge:
Salin
r i
9/PAF
r
-2 mins 0 mins 20 mins
i k
3 x nasal 1 x nasal
lavage lavage
Figure 3.4) Protocol for investigating the effect of icatibant on PAF-induced albumin and 
kinin production within the nasal airway.
3.2.4 The effect of icatibant on the binding of bradykinin to rabbit anti- 
bradykinin serum
The aim of this study was to determine whether icatibant interferes with the 
detection of bradykinin by radioimmunoassay (RIA). RIA rabbit anti-bradykinin 
serum was diluted in radioimmunoassay buffer then incubated with 11.5 pg/fil 
bradykinin and icatibant (10 nM, 100 nM, 1 fiM and 10 (iM). The kinin content of 
these samples were determined by radioimmunoassay. The concentration of 
bradykinin used in this investigation was chosen on the basis that it reduces the 
binding of [3H]-bradykinin to rabbit anti-bradykinin serum by 50%.
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3.2.5 The effect of NPC-567 on albumin and kinin production
The aim of this study was to determine the effect of the low affinity kinin B2 receptor 
antagonist, NPC-567, on PAF-induced kinin and albumin production in nasal lavage 
fluid. Subjects underwent three pre-challenge nasal lavages (the third lavage was 
used as the baseline while the first two lavages were discarded) followed by 
bilateral pre-treatment with a 100 pi aerosol of saline or NPC-567, 200 pg. Two 
minutes later they were challenged bilaterally with PAF, 60 pg or saline. Twenty 
minutes after intranasal challenge with PAF or saline, subjects underwent a final 
nasal lavage. All 8 subjects received each of the following 4 treatments in a random 
order, on separate occasions, at least 3 days apart:
• Saline / saline
• Saline / PAF, 60 pg
• NPC-567, 200 pg / PAF, 60 pg
• NPC-567, 200 pg / saline
The protocol of this investigation is summarised in figure 3.5:
Pre-treatment: 
Saline/NPC 567 Challenge:
Time:
1
Salin
t i
9/PAF
r
-2 mins 0 mins 20 mins
i v t
3 x nasal 
lavage
1 x nasal 
lavage
Figure 3.5) Protocol for investigating the effect of NPC-567 on PAF-induced albumin and 
kinin production within the nasal airway.
3.2.5 The effect of aprotinin on albumin and kinin production
The aim of this study was to determine the effect of the kallikrein inhibitor, aprotinin, 
on PAF-induced kinin and albumin production in nasal lavage fluid. Subjects 
underwent three pre-challenge nasal lavages (the third lavage was used as the
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baseline while the first two lavages were discarded) followed by bilateral pre­
treatment with a 100 pi aerosol of saline or aprotinin, 100 pg. Two minutes later 
they were challenged bilaterally with PAF, 60 pg or saline. Twenty minutes after 
intranasal challenge with PAF or saline, subjects underwent a final nasal lavage. All 
8 subjects, received each of the following 4 treatments in a random order, on 
separate occasions, at least 3 days apart:
• Saline / saline
• Saline / PAF, 60 pg
• Aprotinin, 100 pg / PAF, 60 pg
• Aprotinin, 100 pg / saline
The protocol of this investigation is summarised in figure 3.6:
Pre-treatment:
Saline/Aprotinin Challenge:
1
Salin
r i
9/PAF
r
-2 mins 0 mins 20 mins
>l i
Time:
3 x nasal 
lavage
1 x nasal 
lavage
Figure 3.6) Protocol for investigating the effect of aprotinin on PAF-induced mediator 
production in the nasal cavity.
3.2.6 The effect of des-arg10-Ieuy-kallidin on albumin and kinin production
The aim of this study was to determine the effect of the kinin B, receptor antagonist, 
des-arg10-leu9-kallidin, on PAF-induced kinin and albumin production in nasal 
lavage fluid. Subjects underwent three pre-challenge nasal lavages followed by 
bilateral pre-treatment with a 100 pi aerosol of saline or des-arg10-leu9-kallidin, 200 
pg. Two minutes later they were challenged bilaterally with PAF, 60 pg or saline. 
Twenty minutes after intranasal challenge with PAF or saline, subjects underwent a
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final nasal lavage. All 6 subjects received each of the following 4 treatments in a 
random order, on separate occasions, at least 3 days apart:
• Saline / saline
• Saline / PAF, 60 pg
• Des-arg10-leu9-kallidin, 200 pg / PAF, 60 pg
• Des-arg10-leu9-kallidin, 200 pg / saline
The protocol is of this investigation is summarised figure 3.7: 
Pre-treatment:
Saline/DAKD Challenge:
Time:
3 x nasal 
lavage
1
Salin<
r i
9/PAF
f
-2 mins 0 mins 20 mins
t i - k
1 x nasal 
lavage
Figure 3.7) Protocol for investigating the effect of des-arg10-leua-kallidin on PAF-induced 
albumin and kinin production within the nasal airway. DAKD is des-arg10-leu9-kallidin.
3.2.7 Data analysis
Three nasal lavages were performed prior to intranasal challenge or pre-treatment 
with the appropriate agent, the first two lavages were discarded and the third lavage 
was kept on ice until the end of the experiment. A single lavage was performed after 
challenge with the appropriate agent and collected for analysis. Nasal lavage fluid 
was then centrifuged at 1000 x g for 10 minutes and 4°C. Aliquots of the 
supernatant were stored at -70°C until assay. The albumin and slgA content of 
nasal lavage fluid were determined by ELISA and the kinin content by 
radioimmunoassay.
The supernatant of the nasal lavage fluid was incubated with Tris-HCI buffer (200 
mM Tris, pH 7.8 at 37°C) for 15 minutes at 37°C. Kallikrein enzyme activity of the 
lavage fluid was determined by spectrophotometry. The change in absorbance
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associated with the cleavage of S-2266, 400 |iM, at 405 nm, was measured at 10- 
minute intervals for a duration of one hour, as mentioned in chapter 2.5.1. Results 
were displayed as the rate of increase in optical density/minute.
A Wilcoxon sign-rank test (non-parametric, paired test), Friedman test (non- 
parametric, one-way analysis of variance test) and Dunn’s test (non-parametric, 
post hoc test) were used to determine statistical differences in albumin, slgA, kinin 
production and kallikrein activity. A p value less than 0.05 (p<0.05) was taken as 
statistically significant.
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3.3 Results
3.3.1 The effect of PAF on kallikrein-like activity, albumin, slgA and kinin 
production
Intranasal application of PAF, 60 pg, compared to saline, caused a significant rise in 
the kinin content of nasal lavage fluid recovered 20 minutes after challenge (p<0.05, 
Wilcoxon sign-rank test), as shown in figure 3.8.
Intranasal application of PAF, 60 pg, compared to saline, did not elevate kallikrein- 
like enzyme activity in nasal lavage fluid recovered 20 minutes after challenge, as 
shown in figure 3.9. Incubation of nasal lavage fluid with aprotinin, 1 pM, and 
soybean trypsin inhibitor (SBTI), 1 pM, significantly reduced kallikrein-like activity in 
samples of nasal lavage fluid collected before and after challenge with saline or 
PAF (p<0.05, Friedman test).
Intranasal application of PAF, 60 pg, compared to saline, did not cause a significant 
rise in the slgA content of nasal lavage fluid recovered 20 minutes after challenge, 
as shown in figure 3.10.
Intranasal application of PAF, 60 pg, compared to saline, caused a significant rise in 
the albumin content of nasal lavage fluid recovered 20 minutes after challenge 
(p<0.05, Wilcoxon sign-rank test), as shown in figure 3.11.
3.3.2 The effect of methacholine on kallikrein enzyme activity
Intranasal challenge with the muscarinic receptor agonist, methacholine (1, 3 and 
10 mg), did not increase kallikrein enzyme activity in nasal lavage fluid recovered 
10 minutes after challenge compared to saline, as shown in figure 3.12. Incubation 
of nasal lavage fluid with aprotinin, 1 pM, and SBTI, 1 pM, significantly reduced 
kallikrein-like activity in samples collected before and after challenge with saline and 
methacholine (p<0.05, Wilcoxon sign-rank test).
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Figure 3.8) The effect of intranasal challenge with PAF, 60 pg, or saline on the kinin content 
of nasal lavage fluid recovered prior to and 20 minutes after challenge. The difference (A) in 
kinin content of the pre-challenge and post-challenge lavages was determined. Data are the 
means and s.e.m. from 6 subjects. The mean and standard errors of the levels of kinin 
found in nasal lavage fluid collected prior to challenge with saline and PAF were 29.7 ±
12.23 pg/ml and 11.65 ± 3.02 pg/ml respectively. *Significant increase in the kinin content of 
nasal lavage fluid after challenge with PAF, compared to nasal lavage fluid collected after 
challenge with saline (p<0.05, Wilcoxon sign-rank test).
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Figure 3.9) Enzyme activity in nasal lavage fluid recovered 20 minutes after intranasal 
challenge with PAF, 60 pg, or saline. Samples were incubated with aprotinin, 1 pM, or 
soybean trypsin inhibitor (SBTI), 1 pM. Data are the means and s.e.m. from 6 subjects. 
Basal levels of enzyme activity in nasal lavage fluid were 0.70 ± 0.25 x10~3OD/min prior to 
challenge with saline and 0.72 ± 0.18 x10'3 OD/min prior to challenge with PAF. ^Significant 
reduction in the enzyme activity of the nasal lavage fluid compared to the activity of nasal 
lavages fluid collected after challenge with saline or PAF with no inhibitors present in the 
assay (p<0.05, Friedman test).
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Figure 3.10) The effect of intranasal challenge with PAF, 60 pg, or saline on the secretory 
IgA content of nasal lavage fluid recovered prior to and 20 minutes after challenge. The 
difference ( A )  in slgA content of the pre-challenge and post-challenge lavages was 
determined. Data are the means and s.e.m. from 8 subjects. The mean and standard errors 
of the basal levels of slgA found in nasal lavage fluid collected prior to challenge with saline 
and PAF were 19.95 ± 2.56 pg/ml and 22.04 ± 3.26 pg/ml respectively.
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Figure 3.11) The effect of intranasal challenge with PAF, 60 pg, or saline on the albumin 
content of nasal lavage fluid recovered prior to and 20 minutes after challenge. The 
difference ( A )  in albumin content of the pre-challenge and post-challenge lavages was 
determined. Data are the means and s.e.m. from 9 subjects. The mean and standard errors 
of the basal levels of albumin found in nasal lavage fluid collected prior to challenge with 
saline and PAF were 4.02 ± 0.69 pg/ml and 3.15 ± 0.5 pg/ml respectively. ^Significant 
increase in the albumin content of nasal lavage fluid after challenge with PAF, compared to 
nasal lavage fluid collected after challenge with saline (p<0.05, Wilcoxon sign-rank test).
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Figure 3.12) The effect of intranasal challenge with saline or methacholine (1, 3 and 10 mg) 
on the kallikrein enzyme activity of nasal lavage fluid recovered 10 minutes after intranasal 
challenge. Samples were incubated with aprotinin, 10 pM, and soybean trypsin inhibitor 
(SBTI), 10 pM. The mean levels of enzyme activity found in nasal lavage fluid collected prior 
to challenge ranged from 0.67 OD x10"3/min to 0.78 OD x10'3/min. Data are means and 
standard errors from 6 subjects.
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3.3.3 The effect of icatibant on PAF-induced albumin and kinin production
Intranasal pre-treatment with the kinin B2 receptor antagonist icatibant (10, 30, 100 
and 200 pg) failed to dose-dependently reduced the rise in the kinin content of 
nasal lavage fluid recovered 20 minutes after challenge with PAF, 60 pg, as shown 
in figure 3.13 (p>0.05, Friedman’s test). The increase in kinin production caused by 
challenge with PAF, 60 pg, was significantly reduced after pre-treatment with 
icatibant, 200 pg (p<0.05, Dunn’s test). Intranasal pre-treatment with saline did not 
reduce the elevation in the kinin content of nasal lavage fluid recovered 20 minutes 
after challenge with PAF, 60 pg. Icatibant, 200 pg, did not affect the kinin content of 
nasal lavage fluid recovered after challenge with saline.
Intranasal pre-treatment with icatibant (10, 30, 100 and 200 pg) failed to reduce the 
significant increase in albumin content of nasal lavage fluid recovered 20 minutes 
after challenge with PAF, 60 pg, as shown in figure 3.14 (p>0.05, Friedman’s test). 
Intranasal pre-treatment with saline did not reduce the elevation in albumin content 
of nasal lavage fluid recovered 20 minutes after challenge with PAF, 60 pg. 
Icatibant, 200 pg, did not affect the albumin content of nasal lavage fluid recovered 
after challenge with saline.
3.3.4 The effect of icatibant on the binding of bradykinin to rabbit anti- 
bradykinin serum
The aim of this study was to determine whether icatibant interferes with the 
detection of bradykinin by the radioimmunoassay rabbit anti-bradykinin serum. 
Icatibant, 10 nM to 10 pM, did not reduce the binding of rabbit anti-bradykinin serum 
to bradykinin, 11.5 pg/pl, as shown in figure 3.15.
3.3.5 The effect of NPC-567 on albumin and kinin production
Intranasal pre-treatment with the kinin B2 receptor antagonist NPC-567, 200 pg, did 
not reduce the rise in the kinin content of nasal lavage fluid recovered 20 minutes 
after challenge with PAF, 60 pg, as shown in figure 3.16. NPC-567,
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Figure 3.13) The effect of intranasal challenge with PAF, 60 pg, or saline on the kinin 
content of nasal lavage fluid after treatment with saline or icatibant. Nasal lavage fluid was 
recovered prior to intranasal pre-treatment and 20 minutes after intranasal challenge. The 
difference (A) in kinin content of the pre-challenge and post-challenge lavages was 
determined. The mean levels of kinin found in nasal lavage fluid collected prior to challenge 
ranged from 10 to 19.1 pg/ml. Data are the means and standard errors from 7 subjects. 
^Significant reduction in the kinin content of nasal lavage fluid compared to nasal lavage 
fluid collected after challenge with PAF and pre-treatment with saline (p<0.05, Dunn’s test).
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Figure 3.14) The effect of intranasal challenge with PAF, 60 pg, or saline challenge on the 
albumin content of nasal lavage fluid after pre-treatment with saline or icatibant. Nasal 
lavage fluid was recovered prior to intranasal pre-treatment and 20 minutes after intranasal 
challenge. The difference (A) in albumin content of the pre-challenge and post-challenge 
lavages was determined. The mean levels of albumin found in nasal lavage fluid collected 
prior to challenge ranged from 3.3 to 4.9 pg/ml. Data are the means and standard errors 
from 7 subjects. *Significant increase in the albumin content of nasal lavage fluid compared 
to nasal lavage fluid collected after challenge and pre-treatment with saline (p<0.05, Dunn’s 
test).
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Figure 3.15) The effect of icatibant on the binding of rabbit anti-bradykinin serum to 
bradykinin, 11 pg/100 pi. Data are the means and standard errors from 3 experiments.
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Figure 3.16) The effect of intranasal challenge with PAF, 60 |jg, or saline on the kinin 
content of nasal lavage fluid after pre-treatment with saline or NPC-567, 200 pg. Nasal 
lavage fluid was recovered prior to intranasal pre-treatment and 20 minutes after intranasal 
challenge. The difference (A) in kinin content of the pre-challenge and post-challenge 
lavages was determined. The mean levels of kinin found in nasal lavage fluid collected prior 
to challenge ranged from 11.6 to 12.1 pg/ml. Data are the mean and standard errors from 8 
subjects. NS, insignificant difference in the kinin content of nasal lavage fluid compared to 
nasal lavage fluid collected after challenge with saline and pre-treatment with NPC 567 
(p>0.05, Wilcoxon sign-rank test).
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200 fig, did not affect the kinin content of nasal lavage fluid recovered after 
challenge with saline.
Intranasal pre-treatment with NPC-567, 200 pg, did not reduce the rise in the 
albumin content of nasal lavage fluid recovered 20 minutes after challenge with 
PAF, 60 pg, as shown in figure 3.17. Intranasal pre-treatment with saline did not 
affect the elevation in albumin content of nasal lavage fluid recovered 20 minutes 
after challenge with PAF, 60 pg. NPC-567, 200 pg, did not affect the albumin 
content of nasal lavage fluid recovered after challenge with saline.
3.3.6 The effect of aprotinin on albumin and kinin production
Intranasal pre-treatment with the kallikrein inhibitor aprotinin, 100 pg, significantly 
reduced the rise in the kinin content of nasal lavage fluid recovered 20 minutes after 
challenge with PAF, 60 pg (p<0.05, Wilcoxon sign-rank test), but did not abolish it, 
as shown in figure 3.18. Aprotinin, 100 pg, did not affect the kinin content of nasal 
lavage fluid recovered after challenge with saline.
Aprotinin, 100 pg, failed to reduce the rise in the albumin content of nasal lavage 
fluid recovered 20 minutes after challenge with PAF, 60 pg, as shown in figure 3.19. 
Aprotinin, 100 pg, did not affect the albumin content of nasal lavage fluid recovered 
after challenge with saline.
3.3.7 The effect of des-arg10-leu9-kallidin on albumin and kinin production
Intranasal pre-treatment with the kinin receptor antagonist, des-arg10-leu9- 
kallidin, 200 pg, did not reduce the rise in the kinin content of nasal lavage fluid 
recovered 20 minutes after challenge with PAF, 60 pg, as shown in figure 3.20. 
Des-arg10-leu9-kallidin, 200 pg, did not affect the kinin content of nasal lavage fluid 
recovered after challenge with saline.
Intranasal pre-treatment with des-arg10-leu9-kallidin, 200 pg, did not reduce the rise 
in the albumin content of nasal lavage fluid recovered 20 minutes after challenge 
with PAF, 60 pg, as shown in figure 3.21. Intranasal pre-treatment with saline did
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not affect the elevation in albumin content of nasal lavage fluid recovered 20 
minutes after challenge with PAF, 60 (ig. Des-arg10-leu9-kallidin, 200 jug, did not 
affect the albumin content of nasal lavage fluid recovered after challenge with 
saline.
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Figure 3.17) The effect of intranasal challenge with PAF, 60 |jg, or saline on the albumin 
content in nasal lavage fluid after treatment with saline or NPC-567, 200 pg. Nasal lavage 
fluid was recovered prior to intranasal pre-treatment and 20 minutes after intranasal 
challenge. The difference ( A )  in albumin content of the pre-challenge and post-challenge 
lavages was determined. The mean levels of albumin found in nasal lavage fluid collected 
prior to challenge ranged from 2.9 to 3.9 pg/ml. Data are means and standard errors from 8 
subjects. NS, insignificant difference in the albumin content of nasal lavage fluid compared 
to nasal lavage fluid collected after challenge with saline and pre-treatment with NPC 567 
(p>0.05, Wilcoxon sign-rank test).
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Figure 3.18) The effect of intranasal challenge with PAF, 60 pg, or saline on the kinin 
content of nasal lavage fluid after pre-treatment with saline or aprotinin, 100 pg. Nasal 
lavage fluid was recovered prior to intranasal pre-treatment and 20 minutes after intranasal 
challenge. The difference ( A )  in kinin content of the pre-challenge and post-challenge 
lavages was determined. The mean levels of kinin found in nasal lavage fluid collected prior 
to challenge ranged from 11.1 to 39.4 pg/ml. Data are the mean and standard errors from 8
subjects. * Significant reduction in the kinin content of nasal lavage fluid compared to nasal 
lavages fluid collected after pre-treatment with saline and challenge with PAF (p<0.05, 
Wilcoxon sign-rank test).
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Figure 3.19) The effect of intranasal challenge with PAF, 60 jug, or treatment on the albumin 
content of nasal lavage fluid after treatment with saline or aprotinin, 100 pig. Nasal lavage 
fluid was recovered prior to intranasal pre-treatment and 20 minutes after intranasal 
challenge. The difference (A) in albumin content of the pre-challenge and post-challenge 
lavages was determined. The mean levels of albumin found in nasal lavage fluid collected 
prior to challenge ranged from 3.6 to 3.9 pg/ml. Data are means and standard errors from 8 
subjects. NS, insignificant difference in the albumin content of nasal lavage fluid compared 
to nasal lavage fluid collected after challenge with saline and pre-treatment with aprotinin 
(p>0.05, Wilcoxon sign-rank test).
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Figure 3.20) The effect of intranasal challenge with PAF, 60 |jg, or saline on the kinin 
content of nasal lavage fluid after pre-treatment with saline or des-arg10-leu9-kallidin, 200 pg. 
Nasal lavage fluid was recovered prior to intranasal pre-treatment and 20 minutes after 
intranasal challenge. The difference ( A )  in kinin content of the pre-challenge and post­
challenge lavages was determined. The mean levels of kinin found in nasal lavage fluid 
collected prior to challenge ranged from 10.6 to 29.7 pg/ml. Data are means and standard 
errors from 6 subjects. NS, insignificant difference in the kinin content of nasal lavage fluid 
compared to nasal lavage fluid collected after challenge with saline and pre-treatment with 
des-arg10-leu9-kallidin (p>0.05, Wilcoxon sign-rank test).
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Figure 3.21) The effect of intranasal challenge with PAF, 60 |jg, or saline on the albumin 
content of nasal lavage fluid after pre-treatment with saline or des-arg10-leu9-kallidin, 200 pg. 
Nasal lavage fluid was recovered prior to intranasal pre-treatment and 20 minutes after 
intranasal challenge. The difference (A) in albumin content of the pre-challenge and post­
challenge lavages was determined. The mean levels of albumin found in nasal lavage fluid
collected prior to challenge ranged from 2.5 to 3.9 pg/ml. Data are means and standard
errors from 6 subjects. NS, insignificant difference in the albumin content of nasal lavage 
fluid compared to nasal lavage fluid collected after challenge with saline and pre-treatment 
with des-arg10-leu9-kallidin (p>0.05, Wilcoxon sign-rank test).
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3.4 Discussion
Intranasal challenge with PAF, 60 p.g, caused a significant rise in the kinin content 
of nasal lavage fluid (figure 3.8). However, there was not a concomitant increase in 
kallikrein enzyme activity of the nasal lavage fluid (figure 3.9). The inability to detect 
an increase in enzyme activity after challenge with PAF implies one of four things:
(1) that the enzyme recovered by nasal lavage is not responsible for kinin synthesis,
(2) the enzyme responsible for PAF-induced kinin synthesis is not recoverable by 
nasal lavage, (3) the enzyme responsible for PAF-induced kinin synthesis is 
recoverable by nasal lavage but not detectable by spectrophotometry with S-2266 
or (4) there is no increase in activity of the enzyme responsible for kinin synthesis.
The latter theory could be explained by a lack of sensitivity of the assay. The 
kallikrein-kinin pathway is a cascade reaction that works in concert with various 
other proteolytic pathways in vivo (Heimark et al., 1980), consequently, only a small 
amount of prekallikrein (or prokallikrein) is required to produce an immense amount 
of kinin. Therefore, it is possible that the active form of the PAF-activated 
kininogenase is present in solution, but not detectable by spectrophotometry. 
However, it has been reported that the cleavage of S-2266 by crude bronchial 
lavage fluid of atopic asthmatics correlates well with kinin production induced by 
challenge with allergen (Christiansen et al., 1992). Kallikrein-like activity in crude 
nasal lavage fluid has also been detected by measuring the degradation of [3H]- 
TAME ([3H]-N-a-tosyl-L-arginine methyl ester) (Baumgarten et al., 1986b; 
Baumgarten et al., 1986c). Unfortunately, TAME is a non-specific substrate which is 
degraded by tissue kallikrein, plasma kallikrein (bound and unbound to a2- 
macroglobulin), mast cell tryptase, trypsin, plasmin and thrombin. Therefore, to 
conclusively identify tissue and plasma kallikrein in nasal lavage fluid, samples had 
to be concentrated, purified, probed by antibody affinity techniques and 
kininogenase activity measured by radioimmunoassay.
If PAF-induced kinin synthesis is not catalysed by tissue or plasma kallikrein, it 
could be mediated by mast cell tryptase (Imamura et al., 1996). However, there is 
very little evidence to show that PAF induces mast cell degranulation in vivo 
(Petersen et al., 1997) and up to 50% of kinin synthesis induced by PAF, 60 pig, 
within the nasal airway is inhibited by intranasal pre-treatment with the serine
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protease inhibitor, aprotinin, 100 pg, which does not inhibit mast cell tryptase (figure 
3.18) (Tanaka et al., 1983).
An inability to recover the enzyme responsible for PAF-induced kinin synthesis by 
nasal lavage could also be explained by the fact that enzyme precursors, such as 
prekallikrein, are not very stable in solution. They are also extremely dependant on 
the presence of cofactors and cell membrane receptors for their activation, 
interactions with both of these are disrupted by nasal lavage.
PAF, 60 pg, generated a significant increase in the albumin content of nasal lavage 
fluid recovered 20 minutes after intranasal challenge (figure 3.11). This is likely to 
have been caused by the activation of PAF receptors found on postcapillary vessels 
(Shirasaki et al., 2005).
Albumin leakage into the nasal cavity may be indicative of an increase in vascular 
permeability (Baumgarten et al., 1986) which is also associated with the exudation 
of prekallikrein and prekallikrein activating proteins, such as HMWK and FXII. This 
could explain the rise in kinin content of nasal recovered from subjects challenged 
with PAF.
Intranasal challenge with PAF, 60 pg, did not cause a rise in the slgA content of 
nasal lavage fluid recovered 20 minutes after challenge (figure 3.10). Secretory IgA, 
as well as tissue kallikrein, is stored within serosal glands of the nasal airway and is 
used as a marker of glandular activation (Poblete et al., 1993; Proud and Vio, 
1993). Therefore, the inability to detect glandular activation suggests that tissue 
kallikrein is not released into the nasal cavity in response to challenge with PAF, 60 
pg. However, receptors for PAF have been identified on submucosal glands within 
the human nasal airway (Shirasaki et al., 2005).
A second approach to investigate whether activation of glands within the nasal 
airway causes an increase in kallikrein activity of nasal lavage fluid, measurable by 
spectrophotometry with the chromogenic substrate S-2266, was to challenge 
subjects with the muscarinic receptor agonist methacholine. Intranasal challenge 
with methacholine ( 1 - 1 0  mg) failed to cause a detectable increase in kallikrein 
activity of the nasal lavage fluid (figure 3.12). However, methacholine, 10 mg, did
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cause facial flushing and symptoms of rhinorrhea, both of which suggest that 
challenge with methacholine did cause glandular activation. However, this may 
have been mucosal, as opposed to serosal, in origin. It must be noted that previous 
studies have found that methacholine induces an increase in slgA, but only with an 
intranasal dose of 25 mg (Raphael et al., 1988).
Considering that icatibant is a structural analogue of bradykinin which binds to kinin 
B2 receptors with high affinity, it is not unlikely that it may also bind to antibodies 
specific for bradykinin or kallidin. Topical administration of icatibant to non-atopic 
nasal airways is capable of inhibiting bradykinin-induced symptoms if administered 
up to 2 hours prior to intranasal challenge (Proud et al., 1994). Therefore residual 
icatibant is expected to be present in nasal lavage fluid collected 22 minutes after 
its introduction into the nasal airway. The aim of experiment 3.3.4 was to determine 
whether icatibant interferes with the binding of bradykinin to the rabbit anti- 
bradykinin serum of the radioimmunoassay which was used to detect kinin content 
of nasal lavage fluid. Unfortunately, the effective dose of icatibant required to inhibit 
kinin synthesis within the human nasal airway is not known, however, figure 3.15 
clearly shows that icatibant does not effect the binding of bradykinin to rabbit anti- 
bradykinin serum at doses likely to exceed those used in experiment 3.3.3 (figure 
3.13 and figure 3.14).
Pre-treatment with increasing doses of icatibant, 10 to 200 pg, failed to significantly 
increase the reduction in kinin content of nasal lavage fluid recovered after 
intranasal challenge with PAF, 60 pg (figure 3.13) (p>0.05, Friedman’s test). 
However, pre-treatment with 200 pg of icatibant significantly reduced PAF-induced 
kinin production (p<0.05, Dunn’s test) and generates an IC50 between 100 and 200 
pg. It must be noted that the dose at which kinin production was significantly 
attenuated by icatibant (200 pg) is also equal to the dose required to completely 
reverse bradykinin-induced nasal blockage and albumin production in human nasal 
airways, 200 pg (Austin et al., 1994c). A similar finding was also observed by 
Turner et al., (2000b), with the high affinity kinin B2 receptor antagonist, [Ad]-Bk ([1- 
adamantaneacetyl-D-Arg0, Hyp3-(2-thienyl)-Ala5,8, D-Phe7]-bradykinin). However, 
the low affinity kinin B2 receptor antagonist, NPC-567, failed to inhibit the recovery 
of kinins from PAF-challenged subjects (figure 3.16). This suggests that the ability 
of kinin B2 receptor antagonists to inhibit the recovery of kinins from nasal lavage
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fluid may be related to their ability to antagonise kinin B2 receptors activated by 
bradykinin or kallidin. Antagonism of postcapillary kinin B2 receptors in vivo by 
icatibant could reduce the recovery of kinins from PAF-challenged non-atopic 
individuals by impeding the influx of kininogen or prekallikrein into the nasal airway. 
However, the results of experiments 3.3.3 (figure 3.14) and 3.3.6 (figure 3.19) are 
contradictory to this theory. Aprotinin, 100 pg (p>0.05, Wilcoxon sign-rank test) and 
icatibant, 10 to 200 pg (p>0.05, Friedman’s test), failed to inhibit PAF-induced 
albumin production. This suggests that: (1) it is unlikely that the influx of 
prekallikrein (or its co-factors) into the nasal airway is induced by bradykinin or 
kallidin when challenged with PAF and (2) the influx of prekallikrein (or its co­
factors) into the nasal airway is not impeded by pre-treatment with icatibant after 
challenge with PAF. This result concurs with the conclusions of Dear et al., (1996) 
who deduced that icatibant’s ability to abolish HDM-induced kinin production is 
independent of the influx of prekallikrein into the nasal airway as an earlier study, 
Austin and Foreman (1994), found that intranasal challenge of atopic individuals 
with HDM does not cause an increase in albumin leakage into nasal lavage fluid. If 
true, this would also imply that there is no leakage of kininogen into the airway, as 
plasma exudate is the only local source of HMWK (120 kD), LMWK (64 kD) and 
albumin (66 kD). However, other investigations on individuals with perennial rhinitis 
airways have revealed that intranasal challenge with house dust mite does cause 
an increase in vascular permeability (de Graaf-in't Veld et al., 1997).
Although icatibant is principally a kinin B2 receptor antagonist, it also possesses a 
low affinity for kinin receptors in vitro (Stewart et al., 1996). Functional kinin B, 
receptors are not present within non-inflamed non-atopic nasal airways 
(Christiansen et al., 2002) but the possibility that they modulate the recovery of 
kinins from nasal lavage fluid cannot be ruled out as kinin B-i receptors are inducible 
and usually expressed under inflammatory conditions (Fernandes et al., 2003; 
Sugahara et al., 2003). In figure 3.20 and figure 3.21, subjects were pre-treated with 
200 pg of the high affinity kinin B  ^ receptor antagonist, des-arg10-leu9-kallidin, and 
challenged with PAF, 60 pg. Des-arg10-leu9-kallidin failed to modulate the PAF- 
induced kinin or albumin production. This implies that kinin B■, receptors do not play 
a role in modulating the recovery of kinins from nasal lavage fluid.
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The ability of icatibant to antagonise kinin B2 receptors with high affinity is 
unquestionable. Dear et al., (1996), showed that unlabelled bradykinin and icatibant 
abrogate the binding of [125l]-icatibant to a single high affinity site on human nasal 
turbinates, Kj = 0.99 and 0.48 nM, respectively. Therefore, if kinin B2 receptors do 
not play a role in controlling the recovery of kinins from nasal lavage fluid it is 
assumed that there is another high affinity binding site for icatibant that is 
overlooked by the surgical removal of turbinates from the human nasal airways.
An alternative binding site for icatibant in vivo is tissue or plasma kallikrein. 
Structural analogues of kinin B2 receptor antagonists inhibit tissue kallikrein activity 
in vitro. KKI-8 (Adamantaneacetyl-Phe-Arg-Ser-Val-Gln-NH2), an analogue of [Ad]- 
Bk, inhibits human tissue kallikrein with a K| of 4.2 pM (Okunishi et al., 1987; 
Okunishi et al., 1989). Inhibition of kallikrein activity in vivo would explain icatibant’s 
ability to impede the recovery of kinins from nasal lavage fluid following intranasal 
challenge. This theory relies on the possibility that PAF-induced kinin production is 
mediated by tissue or plasma kallikrein, however, as mentioned in chapter 1.4.2.3, 
this may not necessarily be true. Intranasal challenge with PAF is also associated 
with a delayed influx of neutrophils and eosinophils, both of which have the capacity 
to induce kinin synthesis within sites of inflammation. Neutrophils synthesise and 
release active tissue kallikrein in response to zymosan and phorbol ester (Lauredo 
et al., 2004) and activated eosinophils release ECP, which enhances the formation 
of plasma kallikrein in glass-activated human plasma (Venge et al., 1979). 
However, the PAF-induced influx of these leukocytes into non-atopic airways does 
occur until at least after 1 hour challenge and therefore does not coincide with kinin 
synthesis seen in any of the experiments performed in this chapter (Tedeschi et al., 
1994; Miadonna et al., 1996; Turner et al., 2000b).
In conclusion, icatibant reduces the recovery of kinins from PAF challenged non- 
atopic individuals. The mechanism by which it does this is not known but it is likely 
to be of significance on the basis that the IC50 for inhibition of bradykinin-induced 
nasal blockage (Dear et al., 1996) and IC50 for the inhibition of PAF-induced kinin 
production in vivo are similar.
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3.5 Summary
1. Intranasal challenge with PAF, 60 p.g, causes a significant rise in the kinin 
content of nasal lavage fluid recovered 20 minutes after challenge.
2. Nasal lavage fluid recovered 20 minutes after intranasal challenge with PAF, 60 
pg, does not exhibit an increase in kallikrein-like enzyme activity. The enzyme 
responsible for the cleavage of S-2266 is sensitive to the serine protease inhibitors, 
aprotinin and soybean trypsin inhibitor.
3. Intranasal challenge with PAF, 60 pg, causes a significant rise in the albumin 
content of nasal lavage fluid recovered 20 minutes after challenge.
4. Intranasal challenge with PAF, 60 pg, failed to cause a significant rise in the 
secretory IgA content of nasal lavage fluid recovered 20 minutes after challenge.
5. Intranasal challenge with methacholine, 1 to 10 mg, failed to cause an increase in 
kallikrein-like activity of nasal lavage fluid recovered 10 minutes after challenge.
6. Intranasal pre-treatment with icatibant, 10 to 200 pg, failed to dose-dependently 
inhibits the increase in kinin content of nasal lavage fluid from individuals 
challenged with PAF, 60 pg. Icatibant, 200 pg, significantly attenuates kinin 
production caused by PAF, 60 pg.
7. Intranasal pre-treatment with icatibant, 10 to 200 pg, does not affect the leakage 
of albumin into the nasal lavage fluid caused by challenge with PAF, 60 pg.
8. Icatibant, 10 nM to 10 pM, does not interfere with the binding of rabbit anti- 
bradykinin serum to bradykinin, 11.5 pg/pl.
9. Neither NPC-567, 200 pg or des-arg10-leu9-kallidin, 200pg, inhibit the recovery of 
kinins from nasal lavage fluid of individuals challenged with PAF, 60 pg.
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10. Neither NPC-567, 200 pg or des-arg10-leu9-kallidin, 200pg, inhibit the recovery 
of albumin from nasal lavage fluid of individuals challenged with PAF, 60 pg.
11. Intranasal pre-treatment with aprotinin, 100 pg, attenuates the recovery of kinins 
from the nasal lavage fluid of individuals challenged with PAF, 60 pg.
12. Intranasal pre-treatment with aprotinin, 100 pg, does not inhibit the recovery of 
albumin from the nasal lavage fluid of individuals challenged PAF, 60 pg.
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CHAPTER 4
THE EFFECT OF KININ RECEPTOR 
ANTAGONISTS ON KALLIKREIN ACTIVITY  
IN VITRO
4.1 Introduction
Tissue and plasma kallikrein are found in the upper and lower human airway 
(Poblete et al., 1993; Proud and Vio, 1993). Their enzyme activity, in vitro, is 
attenuated by the serine protease inhibitor, aprotinin. Coincidently, the enzyme 
responsible for PAF-induced kinin synthesis in non-atopic nasal airways is also 
susceptible to inhibition by aprotinin, as shown in chapter 3. Thus, it is possible that 
kininogenase activated by intranasal challenge with PAF may be tissue or plasma 
kallikrein.
Pre-treatment of non-atopic individuals with the kinin B2 receptor antagonist, 
icatibant, reduces PAF-induced elevations in the kinin content of nasal lavage fluid, 
as shown in chapter 3. The underlying mechanism behind this effect has not been 
determined, but it is thought to be independent of PAF-induced increases in 
vascular permeability.
An alternative binding site for icatibant may be tissue or plasma kallikrein. 
Analogues of kinin B2 receptor antagonists have been reported to inhibit tissue 
kallikrein activity with nanamolar affinity in vitro (Okunishi et al., 1987; Okunishi et 
al., 1989). Consequently, it is possible that icatibant inhibits PAF-induced kinin 
production in vivo by inhibiting tissue or plasma kallikrein enzyme activity.
In this chapter the ability of kinin receptor ligands to modulate kallikrein activity in 
vitro will be determined. The inhibition constants (Kj) obtained from the inhibition of 
tissue and plasma kallikrein activity will be compared to their inhibition constants 
obtained for the displacement of [125l]-lcatibant from human nasal kinin B2 receptors 
(Dear et al., 1996) to clarify whether the ability of icatibant to inhibit symptoms of
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nasal allergy might result from the inhibition of kallikrein as well as the antagonism 
of vascular kinin B2 receptors.
4.2 Molecular theory
Enzyme reactions were carried out at equilibrium and assumed to obey equation
4.1 in the presence of substrate concentrations which exceeded the concentration 
of the enzyme.
Where:
[E] is the concentration of free enzyme. [S] is the concentration of free substrate. [ES] is the 
enzyme-substrate complex concentration. [P] is the concentration of product formed.
However, if it is assumed that there is negligible degradation of the product, this 
assumption reduces equation 4.1 to equation 4.2.
Assuming that the law of mass action applies, equation 4.2 can be re-arranged to 
form the Michaelis-Menten equation (equation 4.3):
Vmax is the maximum initial velocity of the enzyme at saturating substrate concentrations, v 
is the initial velocity of the enzyme. kcat (= k+2) is the turnover number of the enzyme. [E0] is 
the total enzyme concentration. KM is the Michaelis-Menten constant.
Equation 4.1: [E ] +  [ s ] o [ £ S ] o [ £ ]  +  [/»]
k - \  - 2
Equation 4.2: [*] + [ s ] o ^ [ * ] + M
k - \
V: = VrEquation 4.3: max
Where:
^max =  k cat l E 0  }
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4.3 Experimental protocol
4.3.1 Enzyme assay
Kallikrein was incubated in a 96-well plate with the appropriate Tris-HCI buffer (see 
chapter 2.5.2), with or without an antagonist or inhibitor present, for 15 minutes at 
37°C. Reactions were initiated by the addition of the appropriate chromogenic 
substrate (S-2266 for tissue kallikrein and S-2302 for plasma kallikrein, chosen 
according to kinetics constants shown in table 2.1) and the change in optical density 
was measured with a spectrophotometer at 9-second intervals and at a wavelength 
of 405 nm. All reactions were performed in duplicate and were repeated at least 
three times.
4.3.2 Data Analysis
The rate of each reaction was calculated by determining the gradient of the change 
in optical density versus time graphs. SoftMax Pro3 (96-well plate reader software) 
was used to calculate the initial velocity of each assay by linear regression. 
Log10[dose]-response curves were created from these values and then fitted to the 
appropriate equation using GraphPad- Prism 4 software.
The suitability of one equation (or model) over another for data was chosen using 
an F test (global fitting analysis) found in Graphpad- Prism 4. A p value less than 
0.05 was deemed statistically significant.
Statistical differences in Hill co-efficients from unity were determined using an F test 
found in Graphpad- Prism 4. A p value less than 0.05 was deemed statistically 
significant.
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4.3 Results
4.3.1 The effect of human plasma kallikrein concentration on the cleavage 
of S-2302
Plasma kallikrein cleaved the chromogenic substrate S-2302, 100 pM, to cause a 
change in optical density. A concentration of 100 pM S-2302 was chosen on the 
basis of the predicted KM for S-2302 with human plasma kallikrein, 220 pM 
(diaPharma, Chromogenix booklet). The change in optical density caused by the 
release of the chromophore para-nitroaniline (pNA) was directly proportional to the 
concentration of plasma kallikrein present in each well (figure 4.1).
4.3.2 The effect of porcine tissue kallikrein concentration on the cleavage 
of S-2266
Porcine tissue kallikrein cleaved the chromogenic substrate S-2266, 10 pM, to 
cause a change in optical density. A concentration of 10 pM S-2266 was chosen on 
the basis of the predicted KM for S-2266 with tissue kallikrein, 30 pM (diaPharma, 
Chromogenix booklet). The change in optical density caused by the release of pNA 
was directly proportional to the concentration of porcine tissue kallikrein present in 
each well (figure 4.2).
4.3.3 The effect of S-2302 concentration on human plasma kallikrein enzyme 
activity
Plasma kallikrein, 6.78 nM, displayed Michaelis-Menten kinetics in the presence of 
increasing concentrations of S-2302 (figure 4.3A). The concentration of plasma 
kallikrein used in this assay was chosen on the basis that it was the lowest 
concentration of plasma kallikrein which produced a clear increase in enzyme 
activity with a substrate concentration close to its KM (figure 4.1). Enzyme activity 
was saturable, with a single value for Vmax and KM.
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Figure 4.1) A graph showing the effect of human plasma kallikrein concentration on the 
cleavage of S-2302, 100 pM. The data are results from a single experiment with duplicate 
samples.
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Figure 4.2) A graph showing the effect of porcine tissue kallikrein concentration on the 
cleavage of S-2266, 10 pM. The data are results from a single experiment with duplicate 
samples.
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Data was fitted to the Michaelis-Menten equation:
[^ ]V = V . r  , max
M
Vmax, Km and kcat were calculated to be 55.68 AOD x10'3/min, 171.3 pM and 20.25 
s'1 respectively (table 4.1).
Equation 4.3 was rearranged to produce equation 4.4.
Equation 4.4: Log 10
V.
V - vmax i
= nH.Logl0[ s ] - L o g l0K M
Linearisation of figure 4.3A using equation 4.4 generated a Hill-coefficient of 1.43 ± 
0.14 and KM of 76.74 pM (figure 4.3B). The Hill co-efficient was significantly greater 
than unity (p<0.05, F test).
Equation 4.3 was also re-arranged to form the Lineweaver-Burk equation (equation 
4.5).
1 _  1 +  K m  1
Equation 4.5: v  V  V  fal
i m a x  m a x  L J
Linearisation of figure 4.3A using equation 4.5 generated a Vmax, KM and kcat of 
55.59 AOD x10'3/min, 203 pM and 20.23 s'1 respectively (figure 4.4; table 4.1)
4.3.4 The effect of S-2266 concentration on porcine tissue kallikrein enzyme 
activity
Tissue kallikrein, 276 nM, displayed Michaelis-Menten kinetics in the presence of 
increasing concentrations of S-2266 (Figure 4.5A). The concentration of porcine 
tissue kallikrein used in this assay was chosen on the basis that it was the lowest 
concentration of tissue kallikrein which produced a clear
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Curve-fitting Linweaver-Burk Plot
Km
(m-M)
kcat
( s 1)
Vmax
(AOD
x10'3/min)
Km
(mM)
kcat
( s 1)
Vmax
(AOD
x10'3/min)
Kininogenase
Plasma
Kallikrein
(S-2302)
171.3±  
4.79
20.25 55.68 ± 0.49 203.0 20.23 55.59
Tissue
Kallikrein
(S-2266)
17.35 ± 
0.78
0.35 37.72 ± 0.72 23.5 0.48 52.91
Table 4.1) A summary of Vmax, kcat and KM generated by the cleavage of S-2302 and S-2266 
by plasma kallikrein and tissue kallikrein, respectively. Kallikrein activity was measured by 
spectrophotometry at 405 nm and 37° C. The data points are arithmetic averages and 
standard errors of 3 different experiments with duplicate samples.
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Figure 4.3) A Michaelis-Menten plot (A) and Hill plot (B) showing the effect of S-2302 
concentration on human plasma kallikrein (6.78 nM) enzyme activity. The data points are 
arithmetic averages and standard errors of 3 different experiments with duplicate samples.
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Figure 4.4) A Lineweaver-Burk plot showing the effect of S-2302 concentration on human 
plasma kallikrein (6.78 nM) enzyme activity. The data points are arithmetic averages from 3 
different experiments with duplicate samples.
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Figure 4.5) A Michaelis-Menten plot (A) and Hill plot (B) showing the effect of S-2266 
concentration on porcine tissue kallikrein (276 nM) enzyme activity. The data points are 
arithmetic averages and standard errors of 4 different experiments with duplicate samples.
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Figure 4.6) A Lineweaver-Burk plot showing the effect of S-2266 concentration on porcine 
tissue kallikrein enzyme activity. The data points are arithmetic averages from 4 different 
experiments with duplicate samples.
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increase in enzyme activity with a substrate concentration close to its KM (figure 
4.2). Enzyme activity was saturable, with a single value for Vmax and KM. Data was 
fitted to the Michaelis-Menten equation and Vmax, KM and kcat were calculated to be 
37.72 AOD x10'3/min, 17.35 pM and 0.35 s'1 respectively (table 4.1).
According to the Hill Plot, the Hill co-efficient and KM are 1.07 ± 0.03 and 14.13 jj.M , 
respectively (figure 4.5B). The Hill co-efficient was not significantly greater than 
unity (p>0.05, F test)
Linearisation of figure 4.5A using equation 4.5 generated a Vmax KM and kcat of 
52.91 AOD x10'3/min, 23.5 pM and 0.48 s'1 respectively (figure 4.6; table 4.1).
4.3.5 The effect of kinin receptor ligands on human plasma kallikrein enzyme
The cleavage of S-2302, 100 piM, by human plasma kallikrein was determined in 
the presence of the following kinin receptor ligands: icatibant, [Ad]-Bk, NPC 567 and 
WIN 64338 (which are kinin B2 receptor antagonists); bradykinin (which is a kinin B2 
receptor agonist); des-arg10kallidin (which is a kinin B receptor agonist) and; des- 
arg10-leu9kallidin (which is a kinin B1 receptor antagonist). Inhibition curves (figure 
4.7) were fitted to equation 4.6.
[I] is the concentration of the kinin receptor ligand. Vmax is the initial velocity in the absence 
of any kinin receptor ligands, y  is the initial velocity of the enzyme. [IC50] is the concentration 
of the kinin receptor ligand needed to reduce the initial velocity by 50%. nH is the hill co­
efficient.
The inhibition constants (K|) of each ligand were determined using the Cheng- 
Prusoff equation (equation 4.7):
activity
Equation 4.6: max ' [ I C J "  + [ / f
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K  =  £/ C “ - -
Equation 4.7: 1
1 + ^ 7
Inhibition constants and Hill coefficients for each ligand are summarised in table 
4.2.
Equation 4.6 was re-arranged to generate equation 4.8.
V,
Equation 4.8: Log10 V - v .m a x  i
= Log]0[lC S0\ -  Logt0[ l ]
[I] is the concentration of the kinin receptor ligand. Vmax is the initial velocity in the absence 
of any kinin receptor ligands. Vj is the initial velocity of the enzyme. [IC50] is the concentration 
of the kinin receptor ligand needed to reduce the initial velocity by 50%. nH is the hill co­
efficient.
Linearisation of figure 4.7 using equation 4.8 (figure 4.9) produced Hill-coefficients 
and values for IC50, which were converted into inhibition constants using equation 
4.7. These values are summarized in table 4.2.
4.3.6 The effect of kinin receptor ligands on porcine tissue kallikrein enzyme 
activity
The cleavage of S-2266, 10 pM, by porcine tissue kallikrein in the presence of the 
following kinin receptor ligands (figure 4.8): icatibant, [Ad]-Bk, NPC 567 and WIN 
64338 (which are kinin B2 receptor antagonists); bradykinin (which is a kinin B2 
receptor agonist); des-arg10kallidin (which is a kinin receptor agonist) and; des- 
arg10-leu9kallidin (which is a kinin B-\ receptor antagonist). Ligands which produced 
inhibition curves that could not be fitted to equation 4.6 were fitted to equation 4.9 
which assumes there are two non-interacting binding sites on the enzyme.
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V = v  f a r  , v  f c r
v i  • r t .. / n r i . . / n  T  r ^
Equation 4.9 1 m a x I m a x 2 * [ / C j w//2
Vj is the initial velocity of the enzyme. [I] is the concentration of the kinin receptor ligand. 
Vmaxi is the maximum initial velocity at the first binding site of the enzyme. Vmax2 is the 
maximum initial velocity at the second binding site of the enzyme. [IC50] is the concentration 
of the kinin receptor ligand needed to reduce the initial velocity by 50%. nH1 is the hill co­
efficient of binding site 1. nH2 is the hill co-efficient of binding site 2.
Data from figure 4.8 was also fitted to equation 4.9 (figure 4.10).
The inhibition constants (Ki) of each ligand were calculated using the Cheng-Prusoff 
equation (equation 4.7). Inhibition constants and Hill coefficients for each ligand are 
summarised in table 4.3. WIN 64338 and [Ad]-Bk were fitted with equation 4.9 
(which assumes porcine tissue kallikrein bares two binding sites for [Ad]-bk and 
WIN 64338) as equation 4.9 is a better fit than equation 4.6 to the data points 
(p<0.05, F test).
156
Chapter 4 The effect o f kinin receptor antagonists on kallikrein activity
o _
-- q
! >
tn
JS
Cl
3?
-7 -6 -5
Log ^[Inhibitor], (M)
120
100
80
60
♦ WIN 64338 
■ Icatibant
-  [Ad]-Bk
♦ Bradykinin
40
20
1
-3
120
100
80o
o
60
5 >
NPC-567
Des-arg10-leu9-kallidin
Des-arg10-kallidin
2 > 40
20
0 7 6 5 4 3
Log 10[lnhibitor], (M)
Figure 4.7) The cleavage of S-2302, 100 pM, by human plasma kallikrein, 6.78 nM, in the 
presence of kinin receptor ligands. Percentage changes were normalised to the control 
(mean of 60.6 OD x10'3/min, standard error of the mean 10.2 OD x10'3/min. Data represent 
the means from 3 experiments with duplicate samples.
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Figure 4.8) Cleavage of S-2266, 10 pM, by porcine tissue kallikrein, 276 nM, in the 
presence of kinin receptor ligands. Percentage changes were normalised to the control 
(mean of 11.7 OD x10'3/min, standard error of the mean 1.6 OD x10'3/min. Data represent 
the means and standard errors of the mean from 3 experiments with duplicate samples.
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Figure 4.9) A Hill plot showing the effect of kinin receptor ligands on the cleavage of S- 
2302, 100 pM, by human plasma kallikrein, 6.78 nM. Data represent the means from 3 
experiments with duplicate samples.
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Figure 4.10) A Hill plot showing the effect of kinin receptor ligands on the cleavage of S- 
2266, 10 pM, by porcine tissue kallikrein, 276 nM. Data represent the means from 3 
experiments with duplicate samples.
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Curve-fitting Hill Plot
Compound Ki (pM) nH Ki (pM) nH
Kinin B2 receptor 
antagonists
WIN 64338 33.00 ± 5.70 0.92 ± 0.09 45.29 0.91 ±0.04
[Ad]-Bk 223.14 ±27.1 1.33 ± 0.16 210.53 1.47 ±0.11
NPC 567 >500 - > 500 -
Icatibant >500 - >500 -
KininB2 receptor 
Agonist
Bradykinin 128.49 ±7.00 1.00 ±0.04 208.90 0.98 ± 0.04
Kinin Bi receptor 
Agonist
Des-arg10-kallidin >500 - >500 -
Kinin Bi receptor 
antagonist
Des-arg10-leu9-kallidin >500 - >500 -
Table 4.2) Inhibition constants (Kj) and Hill coefficients (nH) for kinin receptor ligands 
inhibiting human plasma kallikrein cleavage of S-2302, 100 pM. Data represent the means 
from 3 experiments with duplicate samples. [Ad]-BK is [1-adamantaneacetyl-D-Arg°, Hyp3- 
(2-thienyl)-Ala5,8, D-Phe7]-bradykinin.
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Curve fitting Hill Plot
Com pound Ki (pM) nH Ki (pM) nH
Kinin B2 receptor 
antagonists
WIN 64338*
0.70 ±0.01 4.33 ±0.25
6.56 1.14 ±0.15
6.62 ± 27.92 1.17 ± 0.03
[Ad]-Bk*
0.74 ±0.16 1.96 ±0.42
31.19 0.39 ±0.05
90.71 ±38.0 1.30 ±0.35
NPC 567 23.38 ±4.7 0.60 ± 0.04 28.84 0.63 ± 0.04
Icatibant 82.00 ±12.97 0.86 ±0.08 98.17 0.64 ± 0.05
Kinin B2 receptor 
Agonist
Bradykinin 108.00 ± 19.44 0.86 ± 0.09 131.83 0.61 ± 0.06
Kinin Bi receptor 
Agonist
Des-arg10-kallidin >500 - > 500 -
Kinin Bi receptor 
Antagonist
Des-arg10-leu9-kallidin > 500 - > 500 -
Table 4.3) Inhibition constants (Kj) and Hill coefficients (nH) for kinin receptor ligands 
inhibiting porcine tissue kallikrein cleavage of S-2266, 10 pM. Data represent the means 
from 3 experiments with duplicate samples. [Ad]-BK is [1-adamantaneacetyl-d-Arg°,Hyp3,- 
(2-thienyl)-Ala58,d-Phe7]-bradykinin. * WIN 64338 and [Ad]-Bk have two inhibition constants 
and two corresponding Hill-coefficients with porcine tissue kallikrein as their inhibition curves 
were fitted with equation 4.9.
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pKj,
[125l]-icatibant
displacement
pKj,
Tissue kallikrein 
inhibition
pKi,
Plasma kallikrein 
inhibition
Icatibant 9.319 4.087 <3.3
[Ad]-Bk* 8.921 6.128 4.042 <3.3
WIN 64338* 7.385 6.156 5.179 4.479
NPC 567 7.043 4.631 <3.3
Table 4.4) A table showing the correlation between the pKjS for the displacement of [125l]- 
icatibant from soluble human nasal turbinates and pK|S for the inhibition of tissue and 
plasma kallikrein by the kinin B2 receptor antagonists, icatibant, [Ad]-Bk, WIN 64338 and 
NPC 567. The pKj [125l]-icatibant displacement values were obtained from Dear et al., 
(1996). * WIN 64338 and [Ad]-Bk have two inhibition constants with porcine tissue kallikrein 
as their inhibition curves were fitted with equation 4.9.
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4.4 Discussion
Plasma kallikrein enzyme activity measured by the cleavage of S-2302, 100 pM, 
was detectable at concentrations of plasma kallikrein as low as 1.7 nM (figure 4.1). 
The rate of S-2302 cleavage was directly proportional to the concentration of 
plasma kallikrein. This implies that the reaction was first order with respect to 
plasma kallikrein and that there is only one active site per enzyme molecule. 
Plasma kallikrein also displayed a saturable increase in enzyme activity with 
increasing concentrations of S-2302 (figure 4.3A). A single value for the Michaelis- 
Menten constant (KM) was obtained by curve fitting (171.3 pM) and Linweaver-Burk 
transformation (203 pM). However, analysis of the data using a Hill plot produced 
an outlying value compared with the Michaelis-Menten constant, KM = 76.74 pM 
(figure 4.3B). This could be explained by the fact that the Hill plot is curved and has 
a Hill coefficient significantly greater than unity, 1.43 ± 0.14 (p<0.05, F test). This 
implies that human plasma kallikrein may exhibit positive cooperativity with the 
plasma kallikrein specific chromogenic substrate S-2302 and therefore may have 
multiple binding sites. Nonetheless, the former two values for KM are of similar 
magnitude to previous studies, 300 pM, in which KM was also determined by 
Lineweaver-Burk analysis (Friberger et al., 1986). Conversely, kcat, also known as 
the turnover number (20.25 s'1: curve fitting) is approximately 7-fold less than other 
literature values, 275 s'1 (van deer Graaf et al., 1982) and 180 s'1 (Friberger et al., 
1986). This discrepancy in catalytic activity may be accounted for by the difference 
in assay conditions as kallikrein is extremely sensitive to changes in pH and ionic 
strength (Friberger et al., 1978; Chao et al., 1983).
Porcine tissue kallikrein enzyme activity measured by the cleavage of S-2266, 10 
pM, was detectable at concentrations of enzyme as low as 12 nM (figure 4.2). The 
rate of S-2266 cleavage was also directly proportional to the concentration of tissue 
kallikrein, implying that it only has one active site per enzyme molecule. Its kcat, 0.35 
s'1 (curve fitting), is consistent with literature values of tissue kallikrein’s kcat with S- 
2266, 1 s'1 (diaPharma, Chromogenix booklet). Porcine tissue kallikrein also 
exhibited a saturable increase in enzyme activity with increasing concentrations of 
S-2266 (figure 4.5A). A single value for KM was obtained by curve fitting (17.35 pM), 
Linweaver-Burk transformation (23.5 pM) and Hill plot analysis (14.13 pM). This is 
in agreement with literature values of the Michaelis-Menten constant, 30 pM
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(diaPharma, Chromogenix booklet) and implies that tissue kallikrein only has one 
active site per enzyme molecule.
Initial studies on the kininogenase activity (the excision of kallidin from LMWK) of 
tissue kallikrein concluded that tissue kallikrein has two active sites per enzyme 
molecule. This was suggested because cleavage of the Met361-Lys362 bond of 
LMWK by was deemed a kinetically unfavourable reaction in comparison to the 
cleavage of the Arg371-Ser372 bond (Fiedler and Hinz, 1992). It was postulated that 
one active site cleaved the Arg371-Ser372 bond and the other active site cleaved the 
Met361-Lys362. However, X-ray analysis of crystal structures of porcine tissue 
kallikrein suggests that there is only one active site per molecule of porcine tissue 
kallikrein (Bode et al., 1983). It is now believed that tissue kallikrein cleaves both 
bonds simultaneously in a single enzyme-substrate complex (Fiedler and Hinz, 
1992).
High (millimolar) doses of the kinin receptor antagonist, des-arg10-leu9-kallidin, 
failed to inhibit porcine tissue kallikrein activity (figure 4.8). This result concurs with 
its inability to produce any discernable inhibition of PAF-induced kinin production 
within non-atopic airways, as shown in chapter 3. However, the kinin Bi receptor 
agonist, des-arg10-kallidin, weakly inhibited porcine tissue kallikrein. This may be 
due to pseudo product-inhibition, as kallidin is different in structure to des-arg10- 
kallidin by one amino acid. Similar results were obtained with assays of des-arg10- 
kallidin and des-arg10-leu9-kallidin against human plasma kallikrein (figure 4.7).
Human plasma kallikrein enzyme activity was weakly inhibited by kinin B2 receptor 
antagonists in vitro. The inhibition constants for icatibant and NPC-567 are in 
excess of 500 pM, while [Ad]-Bk has an inhibition constant of 223.14 pM (figure 4.7 
and table 4.2). [Ad]-Bk’s inhibition constant is in accordance with the Kj obtained for 
KKI-8 (a drug of similar structure to [Ad]-Bk) obtained with human plasma kallikrein, 
358 pM (Okunishi et al., 1989). WIN 64338 was the only antagonist with inhibitory 
activity within the low micromolar range (Kj = 33 pM: curve fitting). However, its 
inhibition constant is not dissimilar to that of bradykinin (Kj = 128.49 pM: curve 
fitting). This means it is very unlikely that icatibant inhibits the recovery of kinins 
from PAF-challenged individuals in vivo by inhibiting human plasma kallikrein as the
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doses required to inhibit plasma kallikrein activity are equivalent to those required 
for bradykinin to cause product inhibition of plasma kallikrein.
The inhibition of porcine tissue kallikrein by the kinin B2 receptor antagonists, WIN 
64338 and [Ad]-Bk, produced non-sigmoidal log10[dose]-inhibition curves which 
could not be fitted to a single binding site model for enzyme inhibition, equation 4.6 
(figure 4.8). Consequently, it was considered that porcine tissue kallikrein may 
possess multiple binding sites for these antagonists and their inhibition curves were 
re-fitted to a two-binding site model for tissue kallikrein inhibition (equation 4.9). A 
two-binding site model was considered a better fit for both antagonists (p<0.05, F 
test). The high and low affinity binding site inhibition constants of [Ad]-Bk were 0.74 
pM and 90.71 pM respectively. The high-affinity binding site has a Hill-coefficient of 
1.96 (p<0.05, F test), implying that positive cooperativity is occurring at this site and 
it is responsible for the inhibition of approximately 40% porcine tissue kallikreins 
activity. The low-affinity binding site has an inhibition constant of 90.71 pM (curve 
fitting) which concurs with the ability of KKI-8 (a drug of similar structure to [Ad]-Bk) 
to inhibit porcine tissue kallikrein (Kj = 72.7 pM). In addition, the Hill-coefficient of 
[Ad]-Bk at this site is not significantly different from unity (nH= 1.3 ± 0.35: curve 
fitting) implying that it binds to the low affinity binding site of tissue kallikrein in a 1:1 
ratio to produce approximately 60% inhibition of tissue kallikreins enzyme activity. 
WIN 64338 binds, with similar affinity, to the high-affinity binding site of porcine 
tissue kallikrein, 0.74 pM (curve fitting) and also has a Hill-coefficient significantly 
greater unity (nH= 4.33 ± 0.25: curve fitting) implying that positive cooperativity is 
occurring at this site. However, the low-affinity binding site of WIN 64338 has a Hill- 
coefficient of 1.17 ± 0.03 (curve fitting), which is close to unity. This may imply that 
WIN 64338 binds to the low affinity site of tissue kallikrein in a 1:1 ratio to produce 
approximately 50% inhibition of tissue kallikreins enzyme activity. As only one 
active site has been identified in tissue kallikrein, as mentioned earlier, it is possible 
that there are multiple subsites, within its active site, in which multiple molecules of 
WIN 64338 and [Ad]-Bk can bind (Katz et al., 1998; Power et al., 1984), while only 
one molecule of S-2266 can bind to the entire active site at once, as suggested by 
its Hill-coefficient of 1.07 ± 0.03 (figure 4.5B).
The inhibition of porcine tissue kallikrein by the kinin B2 receptor antagonist NPC- 
567 also produced a non-sigmoidal log10[dose]-inhibition curve. However, this could
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not be accurately fitted to a one- or two-binding site model for the inhibition of tissue 
kallikrein (figure 4.8). This suggests that tissue kallikrein possesses several binding 
sites for NPC-567 with inhibition constants of approximately 1 pM and above. For 
simplicity, the inhibition curve of tissue kallikrein with NPC-567 was fitted to a one- 
binding site model. In addition, statistically, a one-binding site model (equation 4.6) 
was deemed a better fit than a two-binding site model (equation 4.9) for the NPC 
567 data of figure 4.8 (p>0.05, F test).
The kinin B2 receptor antagonist, icatibant, dose-dependently inhibited the enzyme 
activity of porcine tissue kallikrein (figure 4.8). Its Hill-coefficient obtained by curve 
fitting, 0.86 ± 0.08, is significantly less than unity and suggests that icatibant binds 
to porcine tissue kallikrein with negative cooperativity. However, these interactions 
were of very low affinity, its inhibition constant was 82 pM (curve fitting). This result 
contradicts the theory that icatibant-induced inhibition of kinin recovery from the 
nasal airway of PAF-challenged individuals is mediated by the inhibition of tissue 
kallikrein. First, because NPC-567 is more potent than icatibant at inhibiting porcine 
tissue kallikrein in vitro, whereas icatibant is more potent than NPC-567 at inhibiting 
the recovery of kinins from PAF-challenged non-atopic individuals in vivo, as shown 
in chapter 3. Secondly, icatibant has a Kj for the inhibition of tissue kallikrein which 
is of similar magnitude to that of bradykinin, a potential product of its kininogenase 
activity in vivo (table 4.3 and 4.4; Dear et al., 1996).
Strong steric interactions between the active site of tissue (and plasma) kallikrein 
with peptide inhibitors and substrates are usually dependent on the presence of a 
charged arginine amino acid being adjacent to and at the N-terminal end of the 
bond to be cleaved. Tissue kallikrein inhibitor selectivity is also aided by the 
presence of bulky hydrophobic amino acids being an amino acid away and at the N- 
terminus of the bond to be cleaved. Inhibitors with hydrophobic amino acids in this 
position tend to have a high affinity for the active sites of tissue and plasma 
kallikrein (Power et al., 1984; Katz et al., 1998). This could explain the relatively 
small inhibition constants obtained with NPC 567, WIN 64338 and [Ad]-Bk, as they 
contain a mixture of hydrophobic and hydrophilic sites, unlike icatibant which is 
primarily composed of charged amino acids.
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Tissue and plasma kallikrein enzyme activity were inhibited by the kinin B2 receptor 
antagonists icatibant, [Ad]-Bk, NPC 567 and WIN 64338 between concentrations of 
100 nM and 500 pM. This suggests that if high enough concentrations of these 
antagonists were introduced into the nasal airway it is possible that they could 
inhibit the recovery of kinins from PAF-challenged individuals by inhibiting the 
enzyme activity of tissue kallikrein or plasma kallikrein. However, when their pKi’s 
for the inhibition of tissue and plasma kallikrein enzyme activity are compared to 
their pKj’s for the displacement of [125l]-icatibant from human nasal kinin B2 
receptors the kallikrein inhibition values are at least an order of magnitude smaller 
(table 4.4). This implies that the kinin B2 receptor antagonists used in this study are 
significantly better at antagonising kinin B2 receptors than they are at inhibiting 
tissue kallikrein or plasma kallikrein enzyme activity. In particular, icatibant has a pKj 
for the displacement of [125l]-icatibant from human nasal kinin B2 receptors which is 
5 orders of magnitude greater than its pKj for the inhibition of tissue kallikrein and 
plasma kallikrein. This suggests icatibant’s ability to inhibit HDM-induced nasal 
blockage in unchallenged sufferers of perennial allergic rhinitis is probably not as a 
result of the inhibition of kinin synthesis but due to the antagonism of kinin B2 
receptors in vivo.
Unfortunately, without knowledge of the effective concentration of icatibant needed 
to significantly inhibit PAF-induced kinin synthesis within the human nasal airway it 
is not possible to determine whether the concentrations of icatibant used in chapter
3.3.3 correlates well with the concentrations of icatibant needed to inhibit kallikrein 
activity, as shown in figure 4.7 and figure 4.8.
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4.5 Summary
(1) Human plasma kallikrein amidolytic activity (measured by the cleavage of 100 
pM S-2302 at pH 7.8, 37°C and 405 nm) is directly proportional to enzyme 
concentration.
(2) Porcine tissue kallikrein amidolytic activity (measured by the cleavage of 10 pM 
S-2266 at pH 8.2, 37°C and 405 nm) is directly proportional to enzyme 
concentration.
(3) Human plasma kallikrein displayed a saturable increase in amidolytic activity 
with increasing concentrations of S-2302. The Michaelis-Menten constant 
(determined by curve fitting) at pH 7.8, 37°C and 405 nm was 171.3 ± 4.79 pM.
(4) Porcine tissue kallikrein displayed a saturable increase in amidolytic activity with 
increasing concentrations of S-2266. The Michaelis-Menten constant (determined 
by curve fitting) at pH 8.2, 37°C and 405 nm was 17.35 ± 0.78 pM.
(5) The kinin B2 receptor antagonist, WIN 64338, and the kinin B2 receptor agonist, 
bradykinin, inhibited human plasma kallikrein with Kj values in the micromolar 
range. The kinin B2 receptor antagonists, NPC-567, icatibant and [1- 
adamantaneacetyl-D-Arg0, Hyp3-(2-thienyl)-Ala5,8, D-Phe7]-bradykinin produced 
inhibition constants in excess of 500 pM with human plasma kallikrein.
(6) The kinin B2 receptor antagonists, WIN 64338, NPC-567, icatibant and [1- 
adamantaneacetyl-D-Arg°, Hyp3-(2-thienyl)-Ala5 8, D-Phe7]-bradykinin inhibited 
porcine tissue kallikrein with Kj values in the micromolar range. Des-arg10-leu9- 
kallidin and des-arg10-kallidin produced inhibition constants in excess of 500 pM 
with porcine tissue kallikrein.
(7) The ability of icatibant ability to inhibit tissue and plasma kallikrein activity in
vitro, does not correlate with its ability to inhibit the recovery of PAF-induced kinin
production in non-atopic nasal airways as the concentration of kinin B2 receptor
antagonist needed to inhibit agonist binding in vitro are much smaller than the 
concentration of antagonist required for enzyme inhibition.
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CHAPTER 5
CHARACTERISATION OF THE KININ- 
FORMING ENZYME IN CRUDE NASAL 
LAVAGE FLUID I N  V IT R O
5.1 Introduction
Pre-treatment of non-atopic individuals with the kinin B2 receptor antagonist, 
icatibant, reduces PAF-induced elevations in the kinin content of nasal lavage fluid, 
as shown in chapter 3. The underlying mechanism behind this effect has not been 
determined, but it is not thought to be dependant on kinin-induced increases in 
vascular permeability.
Reports have shown that low affinity kinin B2 receptor antagonists are capable of 
inhibiting tissue and plasma kallikrein enzyme activity in vitro (Okunishi et al., 1987; 
Okunishi et al., 1989). Therefore, it is suspected that icatibant may reduce the 
recovery of kinins from the nasal lavage fluid by inhibiting the kininogenase 
responsible for PAF-induced kinin synthesis. This enzyme has not been identified.
Intranasal challenge of non-atopic individuals with PAF does not induce any signs 
of glandular activation, which could result in the release of tissue kallikrein, but it 
does generate an increase in vascular permeability (as shown in chapter 3), which 
is associated with the exudation of plasma proteins such as albumin and 
prekallikrein (Baumgarten et al., 1986a). Therefore it is possible that plasma 
kallikrein could be the kininogenase responsible for PAF-induced kinin production in 
non-atopic individuals.
In this chapter, the ability of crude nasal lavage fluid, from un-challenged non-atopic 
individuals, to cleave the chromogenic substrates S-2302 and S-2266 will be 
characterised to determine whether it displays any similarity to that of tissue or 
plasma kallikrein.
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5.2 Molecular theory
As mentioned in chapter 4.2.
5.3 Experimental protocol
5.3.1 Collection of nasal lavage fluid
Nasal lavage fluid was collected without any pre-washes and centrifuged at 4°C and 
1000 x g for 10 minutes. The supernatant was aspirated and used for enzyme 
assay.
5.3.2 Enzyme assay
Tissue kallikrein, plasma kallikrein and the supernatant of crude lavage fluid were 
incubated in 96-well plates with the appropriate Tris-HCI buffer (as mentioned in 
chapter 2.5.2), with or without an antagonist or inhibitor present, for 15 minutes at 
37°C. Reactions were initiated by the addition of a chromogenic substrate (S-2266 
with tissue kallikrein and crude nasal lavage fluid, S-2302 with plasma kallikrein and 
crude nasal lavage fluid) and read by spectrophotometry at a wavelength of 405 
nm. Chromogenic substrates were chosen according to the kinetic constants and 
substrate selectivity of tissue and plasma kallikrein shown in table 2.1. 
Spectrophotmetric readings with crude nasal lavage fluid were taken at 10-minute 
intervals, and 9-second intervals were used with plasma and tissue kallikrein.
5.3.3 Data Analysis
The rate of each reaction was calculated by determining the gradient of the optical 
density versus time graph. SoftMax Pro3 (96-well plate reader software) was used 
to calculate the initial velocity of each kallikrein assay by linear regression. The 
gradient of reactions performed with crude nasal lavage fluid were calculated using 
GraphPad-Prism 4 software, as mentioned in chapter 2.5.1. Log10[dose]-response 
curves were created from these values and then fitted to the appropriate equation 
using GraphPad- Prism 4.
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Statistical differences in Hill coefficients from unity were determined using an F test 
found in GraphPad- Prism 4. A p value less than 0.05 was deemed statistically 
significant.
Statistical differences in Michealis-Menten constants were determined using a 
Mann Whitney (non-parametric, unpaired) test. A p value less than 0.05 (p<0.05) 
was taken as statistically significant.
Statistical differences in dose-response curve kinetics were determined using an F 
test (global fitting analysis) found in GraphPad- Prism 4. A p value less than 0.05 
(p<0.05) was taken as statistically significant.
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5.4 Results
5.4.1 The cleavage of S-2266 by crude nasal lavage fluid and human plasma 
kallikrein
The cleavage of S-2266 by crude nasal lavage fluid and human plasma kallikrein, 
displayed Michaelis-Menten kinetics (figure 5.1 A). Enzyme activity was saturable, 
with a single value for Vmax and KM. Data was fit to the Michaelis-Menten equation:
V . = v  . - r - l-----------
' ■“ [s]+*„
The Km of crude nasal lavage fluid and human plasma kallikrein were calculated to 
be 525.9 ± 35.62 |iM and 694.5 ± 76.19 fiM respectively (figure 5.1 A). Note: the 
difference in KM for human plasma kallikrein (observed in this chapter) to the KM for 
human plasma kallikrein obtained in the previous chapter is accounted for by the 
use of a different chromogenic substrate.
Equation 5.3 was rearranged to produce equation 5.4.
Equation 5.4: Log 10 V - vmax i
= nH.Logl0[ s ] - L o g l0K u
Linearisation of figure 5.1 A using equation 5.4 generated a Hill-coefficient of 1.25 ± 
0.05 and 1.17 ± 0.16 for crude nasal lavage fluid and human plasma kallikrein 
respectively (figure 5.1B). Equation 5.3 was also re-arranged to form the 
Lineweaver-Burk equation (equation 5.5). Using this linearisation plot, the 
Michaelis-Menten constant of crude nasal lavage fluid and human plasma kallikrein 
were calculated as 496.78 pM and 727.27 |iM respectively (figure 5.2).
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Figure 5.1) A Michaelis-Menten plot (A) and Hill plot (B) showing the effect of S-2266 
concentration on nasal lavage fluid and human plasma kallikrein (6.78 nM) enzyme activity. 
Percentage changes were normalised to the control (mean of 1.72 x10'3 OD/min, standard 
error of the mean 0.49 x10'3 OD/min with crude nasal lavage fluid and mean of 357.9 x10'3 
OD /min, standard error of the mean 24.7 x103 OD/min with human plasma kallikrein). The 
data points are arithmetic averages and standard errors of 3 different experiments with
duplicate samples. ^Significant difference in the KM’s (p<0.05, Mann Whitney test).
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Figure 5.2) A Lineweaver-Burk plot showing the effect of S-2266 concentration on nasal 
lavage fluid and human plasma kallikrein (6.78 nM) enzyme activity. Kallikrein activity was 
measured by spectrophotometry at 405 nm and 37° C. The data points are arithmetic 
averages from 3 different experiments with duplicate samples.
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J. 1 __________
Equation 5.5: v  . y  i rv ,  V V ’ \s]1 m a x  m a x  L J
5.4.2 The cleavage of S-2302 by crude nasal lavage fluid and human plasma 
kallikrein
The cleavage of S-2302 by crude nasal lavage fluid and human plasma kallikrein, 
displayed Michaelis-Menten kinetics (figure 5.3A). Enzyme activity was saturable, 
with a single value for Vmax and KM. Data was fitted to the Michaelis-Menten 
equation. The KM of crude nasal lavage fluid and human plasma kallikrein were 
calculated to be 693.7 ± 38.6 pM and 171.3 ± 4.49 pM respectively.
Linearization of figure 5.3A using equation 5.4 generated Hill-coefficients of 1.44 ± 
0.09 and 1.42 ± 0.07 for crude nasal lavage fluid and human plasma kallikrein 
respectively (figure 5.3B). Equation 5.3 was also re-arranged to form the 
Lineweaver-Burk equation (equation 5.5). Using this linearization plot, the 
Michaelis-Menten constant of crude nasal lavage fluid and human plasma kallikrein 
were calculated as 509.68 pM and 203.00 pM respectively (figure 5.4).
5.4.3 The effect of soybean trypsin inhibitor and aprotinin on crude nasal 
lavage fluid enzyme activity
The cleavage of S-2302, 400 pM, by crude nasal lavage fluid was dose- 
dependently inhibited by aprotinin and SBTI (figure 5.5A). The inhibition curves 
were fit to equation 5.6.
Equation 5.6: max ' [ I C J "  + [ ! ] " '
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Figure 5.3) A Michaelis-Menten plot (A) and Hill plot (B) showing the effect of S-2302 
concentration on nasal lavage fluid and human plasma kallikrein (6.78 nM) enzyme activity. 
Percentage changes were normalised to the control (mean of 1.69 x10‘3 OD/min, standard 
error of the mean 0.66 x10 3 OD/min with crude nasal lavage fluid and mean of 44.1 x10'3 
OD/min, standard error of the mean 4.4 x103 OD/min with human plasma kallikrein). The 
data points are arithmetic averages and standard errors of 3 different experiments with 
duplicate samples where the standard errors are contained within the data point.
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Figure 5.4) A Lineweaver-Burk plot showing the effect of S-2302 concentration on nasal 
lavage fluid and human plasma kallikrein (6.78 nM) enzyme activity. The data points are 
arithmetic averages from 3 different experiments with duplicate samples.
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Figure 5.5) Inhibition curves (A) and Hill plots (B) showing the affect of aprotinin and 
soybean trypsin inhibitor (SBTI) on the cleavage of S-2302, 400 pM, by crude nasal lavage 
fluid. Percentage changes were normalised to the control (mean of 0.633 x10'3 OD/min, 
standard error of the mean 0.21 x10'3 OD/min). The data points are arithmetic averages and 
standard errors of 4 different experiments with duplicate samples.
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Inhibition constants were calculated using each inhibitors IC50 and the Cheng- 
Prusoff equation (equation 5.7). SBTI produced an inhibition constant of 423.3 ± 
65.73 nM with a Hill-coefficient of 0.75 ± 0.05. Aprotinin produced an inhibition 
constant of 45.06 ± 14.41 nM with a Hill-coefficient of 0.74 ± 0.07.
Figure 5.5A was linearised using equation 5.8 to produce figure 5.5B. The Hill- 
coefficient and inhibition constant of aprotinin with nasal lavage fluid were 
determined to be 0.69 ± 0.03 and 49.34 nM respectively. The Hill-coefficient and 
inhibition constant of SBTI with nasal lavage fluid were determined as 0.60 ± 0.05 
and 431.94 nM respectively.
kallikrein enzyme activity
The cleavage of S-2302, 100 pM, by human plasma kallikrein was dose- 
dependently inhibited by aprotinin and SBTI (figure 5.6A). The inhibition curves 
were fitted to equation 5.8. SBTI produced an inhibition constant of 68.4 ± 5.19 nM 
with a Hill-coefficient of 2.32 ± 0.23. Aprotinin produced an inhibition constant of
104.6 ± 6.32 nM with a Hill-coefficient of 1.78 ± 0.1.
According to the Hill plot, figure 5.6B, the Hill-coefficient and inhibition constant of
aprotinin with human plasma kallikrein were 1.34 ± 0.05 and 98.31 nM respectively.
According to the Hill plot, figure 5.6B, the Hill-coefficient and inhibition constant of
SBTI with human plasma kallikrein were 1.64 ± 0.11 and 92.6 nM respectively.
Equation 5.7:
K : = [ 'C»
l  +
Equation 5.8: L °g xo — Logl0[lC 50\ Log10[/]
5.4.4 The effect of soybean trypsin inhibitor and aprotinin on human plasma
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Figure 5.6) Inhibition curves (A) and Hill plots (B) showing the affect of aprotinin and 
soybean trypsin inhibitor (SBTI) on the cleavage of S-2302, 100 pM, by human plasma 
kallikrein, 6.78 nM. Percentage changes were normalised to the control (mean of 64.6 x103 
OD/min, standard error of the mean 2.57 x10~3 OD/min). The data points are arithmetic 
averages and standard errors of 4 different experiments with duplicate samples.
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Figure 5.7) Inhibition curves showing the affect of aprotinin and soybean trypsin inhibitor 
(SBTI) on the cleavage of S-2266, 10 piM, by porcine tissue kallikrein, 276 nM. Percentage 
changes were normalised to the control (mean of 13.7 x10"3 OD/min, standard error of the 
mean 0.15 x10'3 OD/min). The data points are arithmetic averages and standard errors of 3 
different experiments with duplicate samples.
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Kj (nM)
Curve-fitting Hill Plot
Aprotinin SBTI Aprotinin SBTI
Enzyme
Ki
(nM)
nH
Ki
(nM)
nH
Ki
(nM)
nH Kj (nM) nH
Crude
lavage
fluid
45.06 
± 14.41
0.74
±0.07
423.3
±65.73
0.75 
± 0.05
49.34
0.69
±0.03
431.94
0.60
±0.05
Plasma
kallikrein
104.60
±6.00
1.78
±0.1
68.4
±6.00
2.32
±0.23
110.27
1.41
±0.06
92.57
1.64
±0.11
Tissue
kallikrein
46.6 
± 14.57
2.62 
± 1.08
>10000 nd Poor fit >10000 nd
Table 5.1) Inhibition constants (K j) and Hill coefficients (nH) for the enzyme activity of crude 
nasal lavage fluid, human plasma kallikrein and porcine tissue kallikrein in the presence of 
aprotinin and soybean trypsin inhibitor (SBTI). nd means not determined. Values represent 
the mean and standard errors.
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5.4.5 The effect of soybean trypsin inhibitor and aprotinin on porcine tissue 
kallikrein enzyme activity
The cleavage of S-2266, 10 pM, by porcine tissue kallikrein was dose-dependently 
inhibited by aprotinin, and not SBTI (figure 5.7). However, inhibition of porcine 
tissue kallikrein by aprotinin does not appear to fit equation 5.6. Nonetheless, its 
inhibition constant and Hill-coefficient were estimated to be 46.6 nM and 2.62 
respectively.
5.4.6 The effect of kinin receptor ligands on the cleavage of S-2266 by crude 
nasal lavage fluid
Incubation of the kinin B2 receptor antagonists WIN 64338, NPC 567, [Ad]-Bk and 
icatibant with crude nasal lavage fluid failed to produce any discernable inhibition of 
the amidolytic activity with doses up to and including 10 pM. Above 10 pM S-2266 
cleavage was inhibited dose-dependently. Icatibant, 0.5 mM; WIN 64338, 0.5 mM; 
[Ad]-Bk, 0.5 mM and NPC 567, 0.5 mM, inhibited the amidolytic activity by 13.74%, 
16.88 %, 21.49% and 30.47% respectively.
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Figure 5.8) The cleavage of S-2266, 400 pM, by nasal lavage fluid in the presence of kinin 
receptor ligands. Percentage changes were normalised to the control (mean of 1.00 x10'3 
OD/min, standard error of the mean 0.36 x10 3 OD/min). Data represent the means and 
standard errors of the mean from 4 experiments with duplicate samples.
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5.4 Discussion
Human plasma kallikrein and crude nasal lavage fluid both display Michaelis- 
Menten kinetics with the kallikrein selective chromogenic substrate S-2266 (figure
5.1 A). The Hill-coefficient of the S-2266 [substrate]-response curve with human 
plasma kallikrein was not significantly different from unity, 1.17 ± 0.16 (p>0.05, F 
test), implying that it binds to each enzyme molecule in a ratio of 1:1 (figure 5.1B). 
However, the Hill-coefficient of the S-2266 [substrate]-response curve with crude 
nasal lavage fluid was significantly greater than unity, 1.25 ± 0.05 (p<0.05, F test), 
implying that positive cooperativity may be occurring (figure 5.1B).
The Michaelis-Menten constant of S-2266 with human plasma kallikrein is 694.5 pM 
(curve fitting). This value is of similar magnitude to the KM’s of human plasma 
kallikrein with S-2266 obtained in previous reports, 500 pM (Diapharma, 
Chromogenix Booklet). The Michalelis-Menten constant of crude nasal lavage fluid 
with S-2266, 525.9 pM (curve fitting), is significantly smaller (p<0.05, Mann Whitney 
test) than that of human plasma kallikrein’s, 694.5 pM (curve fitting), however, 
global fitting analysis of both data sets suggests the data from both curves are likely 
to have come from the same population (p>0.05, F test)(figure 5.1A). This implies 
that the kinetics of crude nasal lavage fluid with S-2266 are similar to those of 
human plasma kallikrein with S-2266. It must be noted that the only other 
kininogenase capable of cleaving S-2266 with Michalelis-Menten kinetics is tissue 
kallikrein, however, it has a Michaelis-Menten constant more than 40-times smaller 
than that of human plasma kallikrein with S-2266, as shown in chapter 4.3.4. This 
suggests that the enzyme present in crude nasal lavage fluid which is responsible 
for the cleavage of S-2266 is similar to human plasma kallikrein.
Characterisation of the kinin-forming enzyme in crude nasal lavage fluid with the 
substrate S-2302 produced intriguingly different results from those obtained with S- 
2266, even though the enzyme present in crude nasal lavage fluid responsible for 
the cleavage of S-2266 is likely to be the same enzyme responsible for the 
cleavage of S-2302. Human plasma kallikrein and crude nasal lavage fluid also both 
display Michaelis-Menten kinetics with the kallikrein selective chromogenic 
substrate S-2302 (figure 5.3A). The Michaelis-Menten constant of crude nasal 
lavage fluid, 693.7 pM, with S-2302, is approximately 4-times greater than that of
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human plasma kallikreins, 171.3 pM (figure 5.3A). The Michaelis-Menten constant 
of human plasma kallikrein is corroborated by previous reports with S-2302 
(Diapharma Chromogenix Booklet, 220 pM). However, the Hill plot of crude nasal 
lavage fluid amidolytic activity with S-2302 is parallel but displaced to the right of 
that of human plasma kallikrein with S-2302 (figure 5.3B). This parallel shift in its 
Hill plot could be explained by one of two possibilities, firstly, that the enzyme 
present in crude nasal lavage fluid which is responsible for the cleavage of S-2302 
is not human plasma kallikrein and has a distinctly different affinity for S-2302, or 
secondly, the enzyme present in crude nasal lavage fluid is human plasma kallikrein 
but is subject to inhibition by a physiological inhibitor also recovered by nasal 
lavage. The former theory is unlikely to be true because the only other enzyme, 
apart from plasma kallikrein, capable of cleaving S-2302 with Michaelis-Menten 
kinetics is FXIIa. However, FXIIa has a KM of 12 pM with S-2302 (Friberger et al., 
1986), it does not cleave S-2266 with a KM of 525.9 pM and it is weakly inhibited by 
SBTI (Kj > 18 pM) (Ratnoff and Saito, 1982), unlike crude nasal lavage fluid and 
human plasma kallikrein.
The possibility that the enzyme present within crude nasal lavage fluid is: (1), 
human plasma kallikrein and (2) inhibited by a physiological inhibitor, is a more 
plausible explanation for the rightward shift of crude nasal lavages Hill-plot (figure 
5.3B). The Hill-coefficients of crude nasal lavage fluid and human plasma kallikrein 
with S-2302, 1.42 ± 0.07 and 1.44 ± 0.09 respectively, imply that there may be 
multiple binding sites for S-2302 (exhibiting positive cooperatively) within the active 
sites of both enzymes. The reason for the larger difference in KM of human plasma 
kallikrein and crude nasal lavage fluid (in comparison to difference in KMs with S- 
2266) may be explained by the possibility that the physiological inhibitor partially 
interacts with a subsite which S-2302 also binds to, while S-2266 only interacts with 
a subsite which the physiological inhibitor does not interact with.
The possibility that the enzyme present within crude nasal lavage fluid is human 
plasma kallikrein is also supported by its susceptibility to inhibition by aprotinin and 
SBTI (figure 5.5; figure 5.6). However, unlike human plasma kallikrein, crude nasal 
lavage’s Hill-coefficients (obtained by curve fitting and Hill plot) were significantly 
less than unity, as opposed to being closer to a value of 2 (p<0.05, F test) (figure 
5.5; table 5.1). This suggests that human plasma kallikrein exhibits positive
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cooperativity with SBTI and aprotinin, while crude nasal lavage fluid exhibits 
negative cooperativity with SBTI and aprotinin. In addition, the inhibition constant of 
SBTI with crude nasal lavage fluid, 423.4 nM (curve fitting), is approximately 6- 
times greater than the Kj of SBTI with human plasma kallikrein, 68.4 nM (curve 
fitting) (figure 5.6A; table 5.1). This difference in magnitude of Hill coefficients and 
inhibition constants could also be explained by the presence of a physiological 
inhibitor which is bound to a subsite within the active site of human plasma 
kallikrein. It is possible that the inhibitor: (1) physically obstructs the binding of SBTI 
to an enzyme subsite to reduce the affinity of SBTI for the enzyme and (2) prevents 
a conformational change in the enzyme which gives rise to the positive cooperativity 
and therefore gives rise to negative cooperativity. Conversely, the affinity of 
aprotinin for the active site of the enzyme in crude nasal lavage fluid is smaller than 
that of aprotinin with human plasma kallikrein (figure 5.5A; figure 5.6A; table 5.1). 
This could be explained by the fact that in comparison to SBTI (Mr=22000), 
aprotinin (Mr=6514) is a low molecular weight inhibitor of kallikrein which may not 
necessarily interact with the same subsites as SBTI and the physiological inhibitor.
Porcine tissue kallikrein enzyme activity with S-2266, 10 pM, was dose-dependently 
inhibited by the serine protease inhibitor aprotinin but not SBTI (figure 5.7). This 
concurs with other reports on the inhibition of tissue kallikrein by aprotinin and SBTI 
(Baumgarten et al., 1986b). However, the inhibition curve did not appear to fit 
equation 5.6. This suggests that tissue kallikrein is not inhibited by aprotinin in a 
simple competitive manor. Reports of tissue kallikrein inhibition by aprotinin suggest 
that two inhibitor molecules competitively bind to the enzyme active site in a positive 
cooperative manner and cause a parabolic, as opposed to a sigmoidal, inhibition of 
its enzyme activity (Miranda et al., 1995). Tissue kallikrein’s lack of susceptibility to 
inhibition by SBTI make it very unlikely that it is responsible for the enzyme activity 
present in crude nasal lavage fluid.
The inhibition constants of kinin B2 receptor antagonists with purified human plasma 
kallikrein are in the micromolar range, as shown in chapter 4. However, millimolar 
concentrations of kinin B2 receptor antagonist failed to significantly inhibit the 
amidolytic activity of crude nasal lavage fluid. Assuming that the enzyme 
responsible for the cleavage of S-2266 in nasal lavage fluid is also the enzyme 
responsible for PAF-induced kinin synthesis in non-atopic airways, it is very unlikely
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that icatibant impedes the recovery of kinins from nasal lavage fluid by directly 
inhibiting this enzyme in vivo. Additionally, the inability of the icatibant to inhibit the 
enzyme activity of crude nasal lavage fluid, while being able to inhibit the recovery 
of kinins from crude nasal lavage fluid of individuals challenged with PAF may 
suggest that enzyme responsible for PAF-induced kinin synthesis is different from 
the enzyme recovered by nasal lavage (from unchallenged individuals).
Intranasal challenge with PAF causes a significant rise in the kinin content of nasal 
lavage fluid recovered from non-atopic individuals, however, there is no 
concomitant increase in the kallikrein-like amidolytic activity in nasal lavage fluid, as 
shown in chapter 3. An increase in amidolytic activity would be expected if the 
limiting factor in PAF-induced kinin synthesis were the availability of active 
kininogenase. However, if the basal kininogenase activity of unchallenged non- 
atopic individuals is sufficient enough to cause a significant rise in the kinin content 
of the nasal airway after 20 minutes, the limiting factor would be kininogen 
availability as opposed to kininogenase activity (Scuri et al., 2002). Assuming that 
the enzyme present in crude nasal lavage is the same as that responsible for PAF- 
induced kinin synthesis, the enzyme responsible for PAF-induced kinin synthesis 
could be human plasma kallikrein, according to the enzyme kinetics and inhibition 
profile of its amidolytic activity in crude nasal lavage fluid (figure 5.1 and figure 5.5).
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5.5 Summary
(1) Human plasma kallikrein and crude nasal lavage fluid displayed a saturable 
increase in amidolytic activity with increasing concentrations of S-2266. The
Michaelis-Menten constants (determined by curve fitting) at pH 7.8, 37°C and 405 
nm were 694.5 ±76.19 pM and 525.9 ± 35.62 pM respectively.
(2) Human plasma kallikrein and crude nasal lavage fluid displayed a saturable 
increase in amidolytic activity with increasing concentrations of S-2302. The
Michaelis-Menten constants (determined by curve fitting) at pH 7.8, 37°C and 405 
nm were 171.3 ± 4.49 pM and 693.7 ± 38.6 pM respectively.
(3) The cleavage of S-2302, 100 pM, by crude nasal lavage fluid was inhibited by 
the serine protease inhibitors, aprotinin and SBTI, with inhibition constants of 45.06 
± 14.41 nM and 423.3 ± 65.74 nM respectively.
(4) The cleavage of S-2302, 400 pM, by human plasma kallikrein was inhibited by 
the serine protease inhibitors, aprotinin and SBTI, with inhibition constants of 104.6 
± 6 nM and 68.4 ± 6 nM respectively.
(5) The cleavage of S-2266, 10 pM, by porcine tissue kallikrein was only inhibited 
by the serine protease inhibitors, aprotinin and not SBTI, with an inhibition constant 
of approximately 46.6 ± 14.57 nM respectively.
(6) The cleavage of S-2266, 400 pM, by crude nasal lavage fluid was not inhibited 
by kinin B2 receptor antagonists WIN 64338, NPC 567, [Ad]-Bk and icatibant. Their 
inhibition constants were in excess of 500 pM.
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CHAPTER 6
THE EFFECT OF ICATIBANT ON THE 
ACTIVATION OF PREKALLIKREIN
6.1 Introduction
Intranasal challenge with PAF causes a rise in the kinin content of nasal lavage fluid 
recovered from non-atopic individuals, without a concomitant increase in kallikrein 
enzyme activity, as shown in chapter 3. This may be due to limited kininogen 
availability, rather than insufficient kininogenase activity, being a limiting factor of 
PAF-induced kinin synthesis in vivo. The enzyme kinetics and inhibition profile of 
the enzyme present within crude nasal lavage fluid of unchallenged individuals is 
very similar to that of human plasma kallikrein, as shown in chapter 5. Therefore, 
assuming that: (1) the enzyme responsible for the cleavage of the chromogenic 
substrates S-2266 and S-2302 in crude nasal lavage fluid of unchallenged 
individuals is same the enzyme responsible for PAF-induced kinin synthesis in vivo; 
and (2) that limited kininogen availability is a limiting factor of kinin synthesis in vivo, 
the kininogenase responsible for PAF-induced kinin synthesis in non-atopic nasal 
airways could be human plasma kallikrein.
Icatibant’s ability to inhibit the recovery of kinins from PAF-challenged non-atopic 
individuals in vivo is not dependent on the influx of prekallikrein or HMWK into the 
nasal airway, as shown in chapter 3. Therefore, it is likely that icatibant either 
inhibits the synthesis of kinins in vivo or potentiates their degradation. The inhibition 
constant of icatibant with human plasma kallikrein in vitro is in excess of 500 fiM, as 
shown in chapter 4. This does not correspond with its potency to inhibit the recovery 
of kinins in vivo, however, amidolytic investigations do not take into consideration 
the possibility that kinin B2 receptor antagonists may interfere with activation of 
plasma prekallikrein in vivo.
The enzyme or cofactors responsible for the activation of tissue prokallikrein within 
the human nasal airway have not been conclusively identified. However, the
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enzymes, trypsin and human plasma kallikrein, are capable of activating tissue 
prokallikrein in vitro (Takada et al., 1985).
In this chapter the ability of icatibant, 10 pM, to inhibit the activation of purified 
prekallikrein and human plasma will be determined by spectrophotometry with the 
plasma kallikrein-selective chromogenic substrate S-2302 (table 2.1). In addition, 
the ability of various kinin receptors ligands to inhibit the enzyme activity of human 
pancreatic trypsin will be determined using the trypsin-selective chromogenic 
substrate S-2765 (table 2.1).
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6.2 Experimental protocol
6.2.1 Collection of human plasma
Human blood (9 ml) was collected directly into a 15 ml polypropylene conical flask 
containing 0.1 mol/litre sodium citrate (1 ml) using a 10 ml syringe and 21 gauge 
needle. The blood was centrifuged at 2000 x g for 15 minutes at 25°C. The plasma 
was aliquoted into 1.5 ml Eppendorfs tubes and frozen at -70°C until assay.
6.2.2 Human plasma activation and prekallikrein activation assays
Human plasma and prekallikrein activation assays were performed in polystyrene 
96-well plates with Hepes buffer (10 mM Hepes, 137 mM NaCI, 4 mM KCI, 11 mM 
D-glucose, 0.5 mg/ml RIA grade Bovine serum albumin, pH 7.4). Two hours prior to 
initiation of each assay, the 96-well plates were coated with 1% polyethylene glycol. 
All proteins to be used in an assay were exposed to 0.1 mM of the serine protease 
inhibitor (4-amidinophenyl)-methanesulfonylfluoride (AMPSF) in 4 mM sodium 
acetate buffer (pH 5.5) for 15 minutes, then diluted in Hepes buffer and allowed to 
equilibrate for 45 minutes, as stated in chapter 2.5.3.
Enzyme activity was measured by spectrophotometry at a wavelength of 405 nm 
with S-2302, 0.3 mM. All reactions were performed in duplicate and were repeated 
at least three times. The concentration of icatibant used in these studies were 
chosen on the basis of previously published data (Dear et al., 1996).
High molecular weight kininogen (HMWK), Hageman Factor (Factor XII/FXII) and 
Zn2+ are all important co-factors in the activation of prekallikrein in human plasma. 
In addition to these co-factors, proteins present on the surface of endothelial cells, 
such as heat shock protein 90 (HSP90) and hyaluronic acid binding protein (HABP), 
also aid the activation of prekallikrein. Therefore, endothelial cell homogenate, 
HSP90, HABP, HMWK, FXII and Zn2+ were all added to prekallikrein activation 
buffers to aid the conversion of human plasma prekallikrein to human plasma 
kallikrein.
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6.2.2.1 The kinetics of prekallikrein activation in the presence and absence of 
Zn2+ and F X II
Hepes buffer, 105 pi, was added to the 96-well microtiter plate, followed by: 35 j.il of 
high molecular weight kininogen (HMWK), 62.5 nM; 35 pi of human plasma 
prekallikrein, 62.5 nM; 35 pi of Hageman factor (FXII), 62.5 nM, or Hepes buffer. 
The 96-well plate was then incubated at 37°C for 15 minutes. The reaction was 
initiated by the addition of 20 pi of ZnCI2, 0.625 mM, or Hepes buffer and 20 pi of S- 
2302, 3.75 mM, dissolved in distilled water. Spectrophotmetric readings were taken 
at 50-second intervals with Soft Max Pro3 (plate reader software).
6.2.2.2 Activation of prekallikrein by Heat Shock Protein 90
Hepes buffer, 120 pi, was added to the 96-well microtiter plate, followed by: 35 pi of 
high molecular weight kininogen (HMWK), 250 nM, or Hepes buffer; 35 pi of human 
plasma prekallikrein, 250 nM, or Hepes buffer and; 20 pi of Human Heat Shock 
Protein 90 (HSP90), 125 nM, or Hepes buffer. The 96-well plate was then incubated 
at 37°C for 15 minutes. The reaction was initiated by the addition of 20 pi of ZnCI2, 
0.625 mM, or Hepes buffer and 20 pi of S-2302, 3.75 mM, dissolved in distilled 
water. Spectrophotmetric readings were taken at 50-second intervals with Soft Max 
Pro3.
6.2.2.3 The effect of icatibant on prekallikrein activation in the presence of 
HSP90
Icatibant, aprotinin or soybean trypsin inhibitor dissolved in Hepes buffer were 
added to the 96-well microtiter plate followed by: 35 pi of high molecular weight 
kininogen (HMWK), 250 nM, or Hepes buffer; 35 pi of human plasma prekallikrein, 
250 nM, or Hepes buffer; 20 pi of Human Heat Shock Protein 90 (HSP90), 125 nM, 
or Hepes buffer. The 96-well plate was then incubated at 37°C for 15 minutes. The 
reaction was initiated by the addition of 20 pi of ZnCI2, 0.625 mM and 20 pi of S- 
2302, 3.75 mM, dissolved in distilled water. Spectrophotmetric readings were taken 
at 50-second intervals with Soft Max Pro3.
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6.2.2A Activation of prekallikrein by hyaluronic acid binding protein and FXII
Hepes buffer, 85 pi, was added to the 96-well microtiter plate, followed by: 35 pi of 
high molecular weight kininogen (HMWK), 250 nM; 35 pi of human plasma 
prekallikrein, 250 nM; 35 pi of Hageman factor (FXII), 250 nM, or Hepes buffer; 20 
pi hyaluronic acid binding protein (HABP), 66.6 pg/ml, or Hepes buffer. The 96-well 
plate was then incubated at 37°C for 15 minutes. The reaction was initiated by the 
addition of 20 pi of ZnCI2, 0.625 mM, or Hepes buffer and 20 pi of S-2302, 3.75 mM, 
dissolved in distilled water. Spectrophotmetric readings were taken at 50-second 
intervals with Soft Max Pro3.
6.2.2.5 The effect of icatibant on prekallikrein activation in the presence of 
FXII
Icatibant, aprotinin or soybean trypsin inhibitor dissolved in Hepes buffer were 
added to the 96-well microtiter plate, followed by: 35 pi of high molecular weight 
kininogen (HMWK), 250 nM; 35 pi of human plasma prekallikrein, 250 nM; 35 pi of 
Hageman factor (FXII), 250 nM, or Hepes buffer. The 96-well plate was then 
incubated at 37°C for 15 minutes. The reaction was initiated by the addition of 20 pi 
of ZnCI2, 0.625 mM and 20 pi of S-2302, 3.75 mM, dissolved in distilled water. 
Spectrophotmetric readings were taken at 50-second intervals for a duration of 10 
minutes with Soft Max Pro3.
6.2.2.6 Potentiation of prekallikrein activation by FXII with endothelial cell 
lysate
Hepes buffer, 85 pi, was added to the 96-well microtiter plate, followed by: 35 pi of 
high molecular weight kininogen (HMWK), 250 nM; 35 pi of human plasma 
prekallikrein, 250 nM; 35 pi of Hageman factor (FXII), 250 nM; 20 pi endothelial cell 
lysate or Hepes buffer. The 96-well plate was then incubated at 37°C for 15 
minutes. The reaction was initiated by the addition of 20 pi of ZnCI2, 0.625 mM and 
20 pi of S-2302, 3.75 pM, dissolved in distilled water. Spectrophotmetric readings 
were taken at 50-second intervals with Soft Max Pro3.
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6.2.2.7 Prekallikrein activation with endothelial cell lysate and without FXII or 
Zn2+
Hepes buffer, 85 pi, was added to the 96-well microtiter plate, followed by: 35 pi of 
high molecular weight kininogen (HMWK), 250 nM; 35 pi of human plasma 
prekallikrein, 250 nM; 35 pi of Hageman factor (FXII), 250 nM, or Hepes buffer; 20 
pi endothelial cell lysate or Hepes buffer. The 96-well plate was then incubated at 
37°C for 15 minutes. The reaction was initiated by the addition of 20 pi of ZnCI2, 
0.625 mM, or Hepes buffer and 20 pi of S-2302, 3.75 mM, dissolved in distilled 
water. Spectrophotmetric readings were taken at 50-second intervals with Soft Max 
Pro3.
6.2.2.8 The effect of icatibant on prekallikrein activation in the presence of 
FXII and endothelial cell lysate
Icatibant, aprotinin or soybean trypsin inhibitor dissolved in Hepes buffer were 
added to the 96-well microtiter plate, followed by: 35 pi of high molecular weight 
kininogen (HMWK), 250 nM; 35 pi of human plasma prekallikrein, 250 nM; 35 pi of 
Hageman factor (FXII), 250 nM, or Hepes buffer; 20 pi endothelial cell lysate or 
Hepes buffer. The 96-well plate was then incubated at 37°C for 15 minutes. The 
reaction was initiated by the addition of 20 pi of ZnCI2) 0.625 mM, or Hepes buffer 
and 20 pi of S-2302, 3.75 mM, dissolved in distilled water. Spectrophotmetric 
readings were taken at 50-second intervals with Soft Max Pro3.
6.2.2.9 Activation of human plasma by endothelial cell lysate and Zn2+
Hepes buffer, 123.5 pi, was added to the 96-well microtiter plate, followed by 7.5 pi 
of human plasma and 20 pi of endothelial cell lysate. The 96-well plate was then 
incubated at 37°C for 15 minutes. The reaction was initiated by the addition of 25 pi 
of ZnCI2, 8 mM, or Hepes buffer and 25 pi of S-2302, 2.4 mM, dissolved in distilled 
water. Spectrophotmetric readings were taken at 50-second intervals with Soft Max 
Pro3.
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6.2.2.10 The effect of icatibant on the activation of human plasma in the 
presence of Zn2+ and endothelial cell lysate
Icatibant, aprotinin or soybean trypsin inhibitor dissolved in Hepes buffer were 
added to the 96-well microtiter plate, followed by 7.5 pi of human plasma and 20 pi 
of endothelial cell lysate. The 96-well plate was then incubated at 37°C for 15 
minutes. The reaction was initiated by the addition of 25 pi of ZnCI2, 8 mM and 25 pi 
of S-2302, 2.4 mM, dissolved in distilled water. Spectrophotmetric readings were 
taken at 50-second intervals with Soft Max Pro3.
6.2.3 Human pancreatic trypsin enzyme assay
Trypsin was incubated in a 96-well plate with the appropriate Tris-HCI buffer (as 
mention in chapter 2.5.2.3), with or without an antagonist or inhibitor present, for 15 
minutes at 37°C. Reactions were initiated by the addition of the chromogenic 
substrate S-2765 and reading the change in optical density with a 
spectrophotometer at 9-second intervals and 405 nm. All reactions were performed 
in duplicate and were repeated at least three times.
6.2.4 Data analysis
Enzyme velocity graphs were fitted to a second order polynomial equation as they 
fitted the data better than any other function.
Polynomial equation (equation 6.1):
OD(t) = A + Bt + Ct2
Where:
OD(t) is the optical density at time 1.1 is time. A, B and C are kinetic constants.
Unfortunately, the parameters of these equations could not be used to obtain a 
kinetic constant for the rate of the reaction.
The rate of each reaction was calculated by using a tangent to determine the 
gradient of the change in optical density versus time graph after any lag phase 
which may have occurred. The initial velocity of each assay was calculated by linear
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regression using SoftMax Pro3 (96-well plate reader software) or with GraphPad- 
Prism 4 software with assays exceeding 10 minutes in duration. Log10[dose]- 
response curves were created from the initial velocity of each assay and fitted to the 
appropriate equation using GraphPad. A Wilcoxon sign-rank (nonparametric, paired 
test), Friedman (nonparametric, paired test) and Dunn’s test (non-parametric, post 
hoc test) were used to determine statistical differences in enzyme activity. A p value 
less than 0.05 (p<0.05) was taken as statistically significant.
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6.3 Results
6.3.1 The kinetics of prekallikrein activation in the presence and absence of 
Zn2+ and FXII
S-2302, 0.3 mM, was cleaved in the presence of prekallikrein (8.75 nM), HMWK 
(8.75 nM), FXII (8.75 nM) and Zn2+ (50 pM) (figure 6.1). There were two phases to 
the enzyme activity, an exponential phase, followed by a linear phase with a 
constant rate of enzyme activity. Removal of either FXII or Zn2+ from the assay 
generated a 20-minute delay in observable enzyme activity, increased the duration 
of the exponential phase and significantly reduced the initial rate of S-2302 
cleavage. The linear phase of the reaction was reduced by 87% and 89.7% with the 
removal of Zn2+ and FXII respectively. There was no observable enzyme activity in 
the absence of Zn2+ and FXII. Data for this investigation was fitted to equation 6.1.
6.3.2 Activation of prekallikrein by Heat Shock Protein 90
The cleavage of S-2302, 0.3 mM, only occurred in the presence of prekallikrein and 
after a delay of 45 minutes. The enzyme activity exhibited two distinct phases, an 
exponential phase which lasted for approximately 55 minutes, followed by a linear 
phase with a constant rate of S-2302 cleavage (figure 6.2A). The rate of S-2302 
cleavage, during the linear phase, was greatest when Heat Shock Protein 90 
[HSP90] (10 nM), Zn2+ (50 pM) HMWK (35 nM) and prekallikrein (35 nM) were 
present. Removal of HSP90, Zn2+, HMWK or prekallikrein reduced the rate of 
kallikrein activity by 67.2%, 77.9%, 99.4% and 100% respectively (figure 6.2B). The 
duration of the exponential phase was not affected by any of the prekallikrein co­
factors, however, the amplitude of its activity was reduced by the removal of 
HSP90, Zn2+ and HMWK. Data for this investigation was fitted to equation 6.1.
6.3.3 The effect of icatibant on prekallikrein activation in the presence of 
HSP90
The cleavage of S-2302, 0.3 mM, by active prekallikrein (plasma kallikrein), in the 
presence of HSP90, Zn2+ and HMWK was significantly inhibited (p<0.05, Friedman 
test) by aprotinin (1 pM) and SBTI (1 pM) but not icatibant (10 pM) (p>0.05, Dunn’s 
test). Enzyme activity was reduced by 95%, 99.9% and 16.28% by aprotinin, SBTI 
and icatibant respectively (figure 6.3).
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Figure 6.1) The hydrolysis of S-2302 (0.3 mM) in the presence of plasma prekallikrein (8.75 
nM) and HMWK (8.75 nM) and the effect of addition of FXII (8.75 nM) and Zn2+ (50 jiM). The 
hydrolysis of S-2302 was measured by spectrophotometry at 405 nm and 37° C for a 
duration of 65 minutes. Results are the mean and standard error of 3 experiments. FXII is 
unactive Hageman factor. HMWK is high molecular weight kininogen.
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Figure 6.2) The kinetics (A) and the percentage change in the non-exponential cleavage of 
S-2302, 0.3 mM (B) in the presence and absence of plasma prekallikrein (35 nM), HSP90 
(10 nM), Zn2+ (50 pM) and HMWK (35 nM). The hydrolysis of S-2302 was measured by 
spectrophotometry at 405 nm and 37°C for a duration of 150 minutes. Results are the mean 
and standard error of 3 experiments. HSP90 is Heat Shock Protein 90. HMWK is High 
Molecular Weight Kininogen. PK is prekallikrein.
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Control + Icatibant Aprotinin
Figure 6.3) HSP90-potentiated prekallikrein (35 nM) activation in the presence of icatibant 
(10 pM), aprotinin (1 pM) and soybean trypsin inhibitor (1 pM). All wells 
contained prekallikrein (35 nM), HSP90 (10 nM), Zn2+ (50 pM) and HMWK (35 nM) and S- 
2302 (0.3mM). The hydrolysis of S-2302 was measured using spectrophotometry at 37°C 
and 405 nm for 150 minutes. Results are the mean and standard error of 3 experiments. 
SBTI is soybean trypsin inhibitor. HMWK is high molecular weight kininogen. HSP90 is Heat 
Shock Protein 90. *A significant reduction in enzyme activity compared to control (p<0.05, 
Friedman test).
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6.3.4 Activation of prekallikrein by hyaluronic acid binding protein and FXII
Cleavage of S-2302, 0.3 mM, occurred in under 10 minutes after initiation of the 
assay with FXII (17.5 nM), Zn2+ (50 M), HMWK (17.5 nM), hyaluronic acid binding 
protein [HABP] (5.33 jig/ml) and PK (17.5 nM) (figure 6.4). Removal of HABP, FXII, 
PK, HMWK or Zn2+ from the assay resulted in -7%, 99.8%, 100%, 98.9%, or 
98.28% reduction in enzyme activity respectively.
6.3.5 The effect of icatibant on prekallikrein activation in the presence of
The cleavage of S-2302, 0.3 mM, by active prekallikrein (plasma kallikrein), in the 
presence of FXII, Zn2+ and HMWK was significantly inhibited (p<0.05, Friedman 
test) by aprotinin (1 pM) and SBTI (1 pM) and icatibant (10 pM). Enzyme activity 
was reduced by 82.6%, 95.34% and 21.2% by aprotinin, SBTI and icatibant 
respectively (figure 6.5).
6.3.6 Potentiation of prekallikrein activation by FXII with endothelial cell
Cleavage of S-2302, 0.3 mM, in the presence of prekallikrein (8.75 nM), FXII (8.75 
nM), HMWK (8.75 nM) and Zn2+ (50 pM) was significantly augmented by the 
addition of whole cell lysate (1.2 mg/ml of protein), supernatant lysate (0.89 mg/ml 
protein) and pellet endothelial lysate (0.59 mg/mi protein) (figure 6.6A). This effect 
was dose-dependent (figure 6.6B). The [protein]-potentiation curves were fit to 
equation 6.2. The Hill coefficients for whole cell, supernatant and pellet fractions of 
the endothelial lysate curves were determined as 0.92 ± 0.51, 1.30 ± 0.43 and 1.18 
± 2.45 respectively.
Vmax is the maximum augmentation of the initial velocity of the enzyme at saturating 
substrate concentrations. Vj is the initial velocity of the. K<j is the dissociation equilibrium 
constant.
FXII
lysate
V,. =  V„
Equation 6.2: m a x
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Figure 6.4) Hydrolysis of S-2302 (0.3 mM) in the presence and absence of plasma 
prekallikrein (8.75 nM), HMWK (8.75 nM), HABP (5.33 fig/ml), FXII (8.75 nM) and Zn2+ (50 
pM). The hydrolysis of S-2302 was measured by spectrophotometry at 405 nm and 37°C for 
a duration of 10 minutes. Results are the mean and standard error of 3 experiments. HABP 
is Hyaluronic acid binding protein. HMWK is High Molecular Weight Kininogen. PK is 
prekallikrein. FXII is unactive Hageman factor.
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Control + Icatibant Aprotinin
Figure 6.5) FXII-potentiated prekallikrein (8.75 nM) activation in the presence of icatibant 
(10 pM), soybean trypsin inhibitor (1 pM) and aprotinin (1 pM). All wells contained 
prekallikrein (8.75 nM), FXII (8.75 nM, Zn2+ (50 pM), HMWK (8.75 nM) and S-2302 (0.3 
mM). The hydrolysis of S-2302 was measured by spectrophotometry at 405 nm and 37°C 
for a duration of 10 minutes. Results are the mean and standard error of 3 experiments. *A 
significant reduction in enzyme activity compared to control (p<0.05, Friedman test). SBTI is 
soybean trypsin inhibitor. HMWK is high molecular weight kininogen. FXII is unactive 
Hageman Factor.
206
Chapter 6 The effect o f icatibant on prekallikrein activation
300
250
200
150
-  100
Control Whole cell Supernatant Pellet
Lysate
225n
200
co 150
Whole Cell
Supernatant
Pellet
(Q
c 125
I  100
75
50
y
i l . i r25
0.1 1 10 100 1000
[Protein], ug/ml
Figure 6.6) The rate of hydrolysis of S-2302, 0.3 mM (A) and Log10[dose]-potentiation 
curves (B) in the presence of Zn2+ (50 pM), prekallikrein (8.75 nM), HMWK (8.75 nM), FXII 
(8.75 nM) with whole (EA.hy926) cell, supernatant and pellet lysate. The protein 
concentration in the whole cell lysate, supernatant and pellet of (A) are 1.2 mg/ml, 0.89 
mg/ml and 0.59 mg/ml respectively. Enzyme activity was measured by spectrophotometry at 
405 nm and 37°C for 10 minutes. Results are the mean and standard error of 4 
experiments. HMWK is high molecular weight kininogen. FXII is unactive Hageman Factor.
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6.3.7 Prekallikrein activation with endothelial cell lysate and without FXII or 
Zn2+
S-2302, 0.3 mM, was cleaved at a rate of 89.4x1 O'3 OD/min in the presence of FXII 
(8.75 nM), Zn2+ (50 pM), HMWK and prekallikrein (figure 6.7). Removal of FXII or 
Zn2+ from the assay caused an 80.5% and 82.2% reduction in amidolytic activity 
respectively. In the absence of Zn2+ and FXII, S-2302, 0.3 mM, was cleaved at a 
rate of 15 x10'3 OD/min. The addition of whole cell EA.hy926 lysate to the assay 
(1.2 mg/ml) increased the rate of prekallikrein activation 2.8-fold in the presence of 
Zn2+, HMWK, FXII and prekallikrein. Removal of either FXII or Zn2+ from the assay, 
with whole cell endothelial lysate present, reduced the rate of S-2302 cleavage to 
21 x1 O'3 OD/min or less.
6.3.8 The effect of icatibant on prekallikrein activation in the presence of 
FXII and endothelial cell lysate
Aprotinin (1 pM), SBTI (1 pM) and the removal of the endothelial supernatant lysate 
(with 1.44 mg/ml of protein) from the assay significantly inhibited the cleavage of S- 
2302, 0.3 mM, in the presence of prekallikrein, HMWK, Zn2+, FXII (p<0.05, 
Friedman test) (figure 6.8). Icatibant, 10 pM, failed to significantly inhibit the 
activation of prekallikrein (p>0.05, Dunn’s test).
6.3.9 Activation of human plasma by endothelial cell lysate and Zn2+
Amidolytic activity was generated 20 minutes after initiation of the assay and was 
reduced by 97.3% in the absence of Zn2+ (figure 6.9). S-2302, 0.3 mM, was cleaved 
by human plasma at the rate of 23.3 x10'3 OD/min in the presence of 3.74 pg/ml of 
endothelial whole cell lysate protein and Zn2+ (1 mM). Data for this investigation was 
fitted to equation 6.1.
6.3.10 The effect of icatibant on the activation of human plasma in the presence 
of Zn2+ and endothelial cell lysate
Icatibant (10 M), SBTI (1 pM) and aprotinin (1 pM) significantly inhibited the 
cleavage of S-2302, 0.3 mM, in the presence of Zn2+ (1 mM), by human plasma 
(p<0.05, Friedman test) (figure 6.10). However, icatibant alone failed to significantly
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Figure 6.7) The rate of S-2302, 0.3 mM, hydrolysis by prekallikrein (8.75 nM), with HMWK 
(8.75 nM), in the presence and absence of FXII (8.75 nM), Zn2+ (50 pM) and 1.2 mg/ml of 
protein from whole (EA.hy926) cell endothelial lysate. The hydrolysis of S-2302 was 
measured by spectrophotometry. Readings were taken at 37°C and 405 nm. Results are the 
mean and standard error of 3 experiments. HMWK is high molecular weight kininogen. FXII 
is unactive Hageman factor.
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Figure 6.8) The inhibition of prekallikrein activation in the presence of icatibant (10 pM), 
soybean trypsin inhibitor (1 pM) and aprotinin (1 pM). All wells also contained prekallikrein 
(8.75 nM), FXII (8.75 nM), Zn2+ (50 pM), HMWK (8.75 nM), S-2302 (0.3 mM) and 1.44 
mg/ml of protein from the supernatant of EA.hy926 cell lysate. The hydrolysis of S-2302 was 
determined by spectrophotometry at 37°C and 405 nm for 10 minutes. Results are the mean 
and standard error of 3 experiments. *A significant reduction in enzyme activity compared to 
control (p<0.05, Friedman test). SBTI is soybean trypsin inhibitor. HMWK is high molecular 
weight kininogen.
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Figure 6.9) The kinetics (A) and the rate of S-2302 (0.3 mM) hydrolysis (B) by human 
plasma activated by 3.74 mg/ml of protein from EA.hy926 whole cell lysate in the presence 
and absence of Zn2+ (1 mM). The hydrolysis of S-2302 was measured by 
spectrophotometry. Readings were taken at 37°C and 405nm for 50 minutes at 5 minute 
intervals. Results are the mean and standard error of 3 experiments. *A significant increase 
in enzyme activity compared to control (p<0.05, Wilcoxon sign-rank test).
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Figure 6.10) The effect of icatibant (10 pM), SBTI (1 pM) and aprotinin (1 pM) on the 
hydolysis of S-2302 (0.3 mM) by human plasma activated in the presence of the protein 
(3.74 mg/ml) from EA.hy926 whole cell lysate and Zn2+ (1 mM). The hydrolysis of S-2302 
was measured at 37°C and 405 nm for 50 minutes at 5 minute intervals. Results are the 
mean and standard error of 4 experiments. HMWK is high molecular weight kininogen. *A 
significant reduction in enzyme activity compared to control (p<0.05, Friedman test). FXII is 
unactive Hageman factor. SBTI is soybean trypsin inhibitor.
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inhibit the enzyme activity of human plasma (p>0.05, Dunn’s test).
6.3.11 The effect of S-2765 concentration on human pancreatic trypsin enzyme 
activity
Trypsin, 1.81 nM, displayed Michaelis-Menten kinetics in the presence of increasing 
concentrations of S-2765 (figure 6.11A). Enzyme activity was saturable, with a 
single value for Vmax and KM. Data was fitted to the Michaelis-Menten equation:
Vmax is the maximum augmentation of the initial velocity of the enzyme at saturating 
substrate concentrations, y is the initial velocity of the. Kd is the Michaelis-Menten constant. 
[S] is the concentration of the substrate in the assay.
Vmax, Km and kcat were calculated to be 109.2 ±1.58 Aoptical density x10'3/min, 40.66 
±2.01 pM and 148.19 s‘1 respectively.
6.3.12 The effect of kinin receptor ligands on human pancreatic trypsin enzyme
The cleavage of S-2765, 20 pM, by human pancreatic trypsin was determined in the 
presence of the following kinin receptor ligands: Icatibant, NPC 567, [Ad]-Bk, WIN 
64338 (kinin B2 receptor antagonists); bradykinin (a kinin B2 receptor agonist); des- 
arg10-kallidin (a kinin Bi receptor agonist); des-arg10-leu9-kallidin (a kinin Bi receptor 
antagonist) (figure 6.11B). The concentration of S-2765 was chosen on the basis of 
the Km obtained from figure 6.11 A. Trypsin enzyme activity was not affected by the 
presence of any of the kinin receptor ligands at ligand concentrations up to and 
including 1 pM. At ligand concentrations above 1 pM trypsin enzyme activity was 
potentiated.
m a x
activity
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Figure 6.11) Human pancreatic trypsin, 1.81 nM, activity in the presence of increasing 
concentrations of S-2765 (A) and in the presence of kinin receptor ligands (B). Percentage 
changes were normalised to the control (mean of 30.01 x10"3 OD/minute, standard error of 
the mean 16.6 OD x10'3/minute. Data represent the means from 3 experiments with 
duplicate samples.
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6. 4 Discussion
Incubation of prekallikrein with HMWK, Zn2+ and FXII resulted in the immediate 
hydrolysis of S-2302 (figure 6.1). Removal of either FXII or Zn2+ from the assay 
significantly reduced the rate of prekallikrein activation, while removal of HMWK 
from the assay completely abrogates prekallikrein activation (figure 6.2).
The mechanism by which HMWK acts as a cofactor in prekallikrein activation is not 
known but it is likely to be aided by (1) HMWKs ability to bind simultaneously to 
prekallikrein and cell surface receptors, such as the receptor for the globular head 
of complement fragment 1q (gC1qR) (Thompson et al., 1979; Kaplan et al., 2002), 
and (2) HMWKs ability to potentiate the activation of FXII (Meier et al., 1977). The 
latter observation would suggest that FXII binds directly to HMWK, however, to 
date, no binding sites for HMWK have been mapped out on FXII or vice versa.
Zn2+ is also an essential cofactor for the activation of prekallikrein in vitro. It is 
required for the binding of FXII and HMWK to cell surface receptors such as gC1qR 
(Joseph et al., 2002). It has been reported that Zn2+ induces a conformational 
change in gC1qR which results in the re-arrangement of hydrophobic amino acids 
present within its HMWK-binding site. This conformational change increases the 
affinity of HMWK for gC1qR (Kumar et al., 2002). Zn2+ also appears to be important 
in the activation of prekallikrein which occurs independently of cell surface receptors 
(figure 6.1; figure 6.2; figure 6.4). Therefore, it is likely that Zn2+ also binds to one or 
more of the proteins involved in the activation of prekallikrein to aid prekallikrein 
activation.
Initial studies on the activation of prekallikrein in human plasma using artificial 
surfaces, such as kaolin, suggested that FXII was responsible for the activation of 
prekallikrein in plasma as FXII-deficient plasma did not activate upon contact with 
artificial surfaces (Proud and Kaplan, 1988). However, studies on endothelial 
surfaces have revealed that FXII-deficient human plasma is activated when 
incubated with Zn2+and HUVECs (Joseph et al., 2001) and (2) purified prekallikrein 
is activated when incubated with HMWK, Zn2+ and HUVECs in the absence of FXII 
(Rojkjaer et al., 1998). Consequently, FXII is now believed to be a potentiator, and 
not activator, of prekallikrein in vivo. As a result of this it is also believed that
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another protein found on cells may be responsible for the activation of prekallikrein 
in vivo. One candidate is Heat Shock Protein 90 (HSP90).
Prekallikrein (35 nM) is autoactivated after a delay of 40 minutes when incubated 
with Zn2+ (50 pM) and HMWK (35 nM) (figure 6.2). The addition of HSP90, 10 nM, 
to the assay significantly enhanced the rate of prekallikrein activation without 
altering the 40-minute delay in plasma kallikrein activity. Previous studies on the 
activation of prekallikrein in the presence of HSP90 suggest that HSP90 is an 
activator, and not potentiator, of prekallikrein activation as prekallikrein was not 
activated in the absence of HSP90, it was only activated in the presence of HSP90 
(Joseph et al., 2002). In addition to activating prekallikrein, HSP90 also plays a role 
in signal transduction and protein degradation (Sreedhar et al., 2004). These effects 
are believed to be dependent on its ability to induce protein folding within cells. 
However, the mechanism behind HSP90’s ability to potentiate the activation of 
prekallikrein is not known, but it may be dependent on its protein folding ability as 
the binding of HMWK to prekallikrein requires a conformational change in the 
structure of HMWK (Lin et al., 1996). Alternatively, HSP90 may display proteolytic 
activity similar to that of FXIIa. This theory is supported by the fact that HSP90’s 
ability to activate prekallikrein, like FXII, is potently inhibited by the protein corn 
trypsin inhibitor (Joseph et al., 2002). Secondly, HPS90, like FXII, requires Zn2+ and 
an intact single chain of HMWK to potentiate the activation of prekallikrein (figure 
6.2; figure 6.4)(Joseph et al., 2002).
Unsurprisingly, the serine protease inhibitors aprotinin and soybean trypsin inhibitor 
(SBTI) significantly inhibited the hydrolysis of S-2302, 0.3 mM, in the presence of 
prekallikrein, Zn2+, HMWK and HSP90 (figure 6.3). However, icatibant, 10 pM, failed 
to inhibit HSP90-induced potentiation of prekallikrein activation.
Although FXII may not be responsible for the activation of prekallikrein in vivo it 
does plays a major role in the generation of plasma kallikrein activity in vitro (figure 
6.4). Incubation of icatibant, 10 pM, with prekallikrein, HMWK, Zn2+ and FXII failed 
to significantly impede the activation of prekallikrein (figure 6.5) suggesting that 
icatibant does not reduce the recovery of kinin from human nasal airways by 
impeding the progression of FXII-potentiated activation of prekallikrein.
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The cell surface receptors gC1qR, cytokeratin 1 (CK1) and urokinase plasminogen 
activator receptors (u-PAR) are now regarded as physiological activators of 
prekallikrein (Joseph et al., 1996; Hasan et al., 1998; Joseph et al., 1999; Mahdi et 
al., 2001). The precise mechanism by which activation is brought about is not 
understood but of the three proteins gC1qR (also known as hyaluronic acid binding 
protein [HABP]) is responsible for the majority of HMWK binding to HUVECs 
(Joseph et al., 2001). The addition of cloned gC1qR to enzyme assays containing 
prekallikrein, Zn2+, HMWK and FXII, dose-dependently potentiates S-2302 
hydrolysis. Potentiation of prekallikrein activation by gC1qR is not seen in the 
absence of FXII (Joseph et al., 2001). Unfortunately, these results could not be 
reproduced with HABP. It failed to potentiate the activation of prekallikrein in the 
presence of FXII, Zn2+ and HMWK (figure 6.4). This lack of efficacy could be due to 
an insufficient concentration of HABP, a lack of purity or species variation (as HABP 
was obtained from affinity-purified bovine nasal cartilage).
Replacement of HABP with endothelial cell lysate, resulted in significant 
potentiation of prekallikrein activation in the presence of FXII, Zn2+ and HMWK 
(figure 6.6). Removal of either FXII or Zn2+ from reactions assays with endothelial 
lysate, prekallikrein and HMWK significantly attenuated the amidolytic activation 
observed (figure 6.7). This result is corroborated by other reports in which the 
activation of prekallikrein on the surface of HUVECs is only potentiated in the 
presence of FXII, Zn2+ and HMWK (Joseph et al., 2001). Icatibant, 10 pM, was 
incubated with this assay to determine if it was capable of inhibiting prekallikrein 
activation by interfering with the interaction between the FXII or Zn2+ and the 
endothelial lysate proteins. However, icatibant, 10 pM failed to inhibit the activation 
of prekallikrein (figure 6.8).
Human plasma was activated when incubated with endothelial cell lysate and Zn2+ 
(figure 6.9). Compared to assays with purified proteins, a relatively high 
concentration of Zn2+ was required to induce amidolytic activity. This is likely to be 
due the presence of plasma proteins such as albumin which act as chelators of 
Zn2+. This result is corroborated by reports which have shown that high 
concentrations of Zn2+ are required for human plasma to be activated on the surface 
of HUVECs (Rojkjaer et al., 1998). Incubation of icatibant, 10 pM, also failed to 
significantly inhibit the activation of human plasma (figure 6.10).
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The enzyme or cofactors responsible for the activation of tissue prokallikrein within 
the human nasal airway have not been identified. Investigations in vitro have 
revealed that the serine proteases trypsin and human plasma kallikrein are capable 
of activating tissue prokallikrein (Takada et al., 1985). However, the inhibition of 
human plasma kallikrein by icatibant is not likely to account for the reduction in 
recovery of kinins from the nasal airway of PAF-challenged individuals, as shown in 
chapter 4. In addition the inability of icatibant (and other kinin B2 receptor 
antagonists) to inhibit the enzyme trypsin (figure 6.11B) suggests that icatibant does 
not reduce the recovery of kinin kinins from the nasal airway by inhibiting trypsin or 
trypsin-like enzymes thought to be present within the human airway.
In summary, icatibant, 10 p.M, failed to significantly inhibit the activation of 
prekallikrein or human plasma in vitro. Icatibant, 10 pM, also failed to inhibit the 
enzyme activity of trypsin. This suggests that inhibition of prekallikrein activation or 
trypsin-like enzyme activity in vivo is not likely to be a plausible explanation for 
icatibant’s ability to inhibit the recovery of kinins from human nasal airways as 
previous reports have shown that icatibant, 10 pM, abolishes the binding of [125l]- 
icatibant to kinin B2 receptors on human nasal turbinates with an inhibition constant 
of 0.48 ± 0.02 nM (Dear et al., 1996).
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6. 5 Summary
(1) The activation of human plasma prekallikrein and human plasma were 
measured by the cleavage of S-2302, 300 pM (at pH 7.4, 37°C and 405 nm).
(2) The activation of human plasma prekallikrein (35 nM) was potentiated by 
presence of Heat Shock Protein 90 (10 nM) in the presence of Zn2+ (50 pM) and 
HMWK (35 nM).
(3) Heat shock protein 90-induced potentiation of prekallikrein activation was not 
inhibited by incubation with icatibant (10 pM) but it was significantly inhibited by the 
plasma kallikrein inhibitors aprotinin (1 pM) and SBTI (1 pM).
(4) The activation of human plasma prekallikrein (8.75 nM) was potentiated by 
presence of FXII (8.75 nM) in the presence of Zn2+ (50 pM) and HMWK (8.75 nM).
(5) Hageman Factor-induced potentiation of prekallikrein activation was not 
inhibited by icatibant (10 pM) but it was significantly inhibited by the plasma 
kallikrein inhibitors aprotinin (1 pM) and SBTI (1 pM).
(6) The activation of human plasma prekallikrein (8.75) was potentiated by 
EA.hy926 cell lysate in the presence of FXII (8.75 nM), Zn2+ (50 pM) and HMWK 
(8.75 nM).
(7) The activation of human plasma prekallikrein (8.75 nM) was not inhibited by 
icatibant (10 pM) but it was significantly inhibited by the plasma kallikrein inhibitors 
aprotinin (1 pM) and SBTI (1 pM).
(8) The activation of human plasma in the presence of Zn2+ (1 mM) and EA.hy926 
cell lysate (3.74 mg/ml) was not inhibited by icatibant (10 pM) but it was significantly 
inhibited by the plasma kallikrein inhibitors aprotinin (1 pM) and SBTI (1 pM).
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(9) The kinin B2 receptor antagonists, WIN 64338, NPC-567, icatibant and [1- 
adamantaneacetyl-D-Arg°, Hyp3-(2-thienyl)-Ala5,8, D-Phe7]-bradykinin did not inhibit 
the enzyme activity of human pancreatic trypsin.
(10) The inhibition of human plasma prekallikrein activation or trypsin-like enzyme 
activity is not likely to be a plausible mechanism by which icatibant impedes the 
recovery of kinins from the nasal airway of non-atopic individuals challenged with 
PAF.
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CHAPTER 7
THE ROLE OF KININ Bi AND B2 RECEPTORS 
IN AIRWAY HYPER-REACTIVITY IN THE 
HUMAN NASAL AIRWAY
7.1 Introduction
Intranasal challenge with PAF mimics the symptoms of allergic rhinitis by causing 
nasal blockage, nasal discomfort, sneezing and an increase in vascular 
permeability. PAF is found in the nasal lavages of allergic individuals challenged 
intranasally with allergen (Touqui, 1994; Chilton et al., 1996). At doses considerably 
lower than that required to mimic symptoms of allergic rhinitis PAF also causes an 
increase in kinin production (Turner et al, 2000b) and induces airway hyper­
reactivity to allergen (Andersson et al., 1988), histamine and bradykinin (Austin and 
Foreman, 1993; Turner et al., 2000b). Intranasal pre-treatment with the kinin B2 
receptor antagonists, icatibant and [1-adamantaneacetyl-D-Arg°, Hyp3, beta-(2- 
thienyl)-Ala5,8-D-Phe7]-bradykinin abolishes all of these PAF-induced effects. 
Therefore, the capacity of kinins to induce hyper-reactivity in human nasal airway is 
thought to be of significance.
Nasal lavages recovered, from individuals with perennial allergic rhinitis and 
challenged with house dust mite have been found to contain kinins (Dear et al., 
1996). It has been established that these kinins are also subject to further 
degradation by aminopeptidase enzymes which cause them to form high affinity 
kinin B  ^ receptor agonists (Proud et al., 1987). The use of kinin B•, receptor agonists 
and antagonists in models of allergic asthma augments and impedes, respectively, 
the development of airway hyper-reactivity (Huang et al., 1999; Gama Landgraf et 
al., 2003; Sugahara et al., 2003). However, kinin BA receptors have not been found 
in the airway of non-atopic individuals, they have only been found within the upper 
airway of atopic individuals (Christiansen et al., 2002). If, indeed, kinin Bi receptors 
play a role in allergic rhinitis, the ability of icatibant to block airway hyper-reactivity 
may also result from its ability to weakly antagonize kinin B1 receptors (Burkard et 
al., 1996; Stewart et al., 1999).
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Unilateral allergen challenge of individuals with seasonal allergic rhinitis causes 
bilateral rhinorrhea and an elevation in the secretory IgA content of nasal lavage 
fluid recovered from both nasal cavities (Raphael et al., 1991). This is primarily 
believed to be due to the activation of sensory neurones by mediators such as 
histamine and bradykinin which are produced as a result of intranasal allergen 
challenge (Raphael et al., 1989b; Riccio and Proud, 1996). However, unilateral 
challenge of non-atopic individuals with bradykinin and histamine only causes 
ipsilateral blockage, implying that its congestive-inducing effects are restricted to 
the cavity to which it is introduced. It is yet to be determined whether this remains 
true after pre-treatment with PAF.
In this chapter the role of PAF, bradykinin and des-arg10-kallidin are investigated in 
human nasal airway hyper-reactivity and the effect of PAF on mediator production 
is also determined.
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7.2 Experimental protocol
All experiments were performed single-blind, on non-atopic individuals.
7.2.1 The effect of bradykinin and captopril on histamine-induced nasal 
blockage
The aim of this study was to determine whether inhibition of angiotensin converting 
enzyme (ACE), in conjunction with intranasal challenge with bradykinin, would 
enhance the half-life of bradykinin in the nasal airway and subsequently enhance 
histamine-induced nasal blockage. Subjects were challenged bilaterally with a 100 
pi spray of saline, histamine, 200 pg, and then bradykinin, 250 pg. The minimum 
cross- sectional area of the nasal airway (Amin) was measured immediately prior to, 
2, 5, and 10 minutes after all three challenges. Immediately after the last acoustic 
rhinometric measurement subjects were given captopril orally, 12.5 mg, or nothing 
(negative control). Both treatments were given randomly in a single blind cross-over 
manner at least 72 hours apart. One, two, four and six hours after receipt of 
captopril or control, subjects were re-challenged with bradykinin, 250 pg. Histamine, 
200 pg, was re-administered 6.5 hours after receipt of captopril or control. Amin was 
measured immediately prior to, 2, 5, and 10 minutes after all five challenges apart 
from the 2 and 4 hour time-points. The protocol of this investigation is summarized 
in figure 7.1:
Captopril/Control
Saline Histamine Bradykinin Bradykinin Bradykinin Bradykinin Bradykinin Histamine
_J I
Time: t=  - 1.5 hrs t=  -1 .0  hrs t = -0.5 hrs t= 0 h r s  t=  1 hr t=  2 hrs t=  4 hrs t=  6 hrs t=  6.5 hrs
Amin.
T T  T"
Amin. !Amin. Amin Amin. Amin.
Figure 7.1) Protocol for investigating the effect of captopril and bradykinin on histamine- 
induced nasal blockage.
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7.2.2 The duration of PAF-induced airway hyper-reactivity
The aim of this study was to determine the duration of PAF-induced nasal airway 
hyper-reactivity to histamine. Subjects were challenged bilaterally with a 100 pi 
spray of saline, followed by a bilateral 100 pi spray with histamine, 200 pg, thirty 
minutes later. The minimum cross-sectional area of the nasal airway (Amin.) was 
measured immediately prior to, 5, 10 and 15 minutes after both challenges. Half an 
hour after receipt of histamine, subjects were treated intranasally with a 100 pi 
spray of PAF, 60 pg, or saline. Both treatments were administered randomly in a 
single blind cross-over manner at least a week apart. Four, six and eight hours after 
treatment with PAF or saline, subjects were re-challenged bilaterally with histamine. 
Amin was measured immediately prior to, 5, 10 and 15 minutes after challenge with 
histamine at all three time points. The doses and time-course used were based 
upon pilot studies and previous publications (Austin and Foreman, 1993). The 
protocol of this investigation is summarized in figure 7.2:
Saline
Saline /  PAF 
Histamine Histamine Histamine Histamine
Time: t=  -1.0 hrs t=  -0.5 hrs t=  0 hrs 4 hrs t=  6 hrs
y ^ ^ ^ yi t w ^ y^ y ^
Amin. Amin.
T~TT
t=  8 hrs
Amin.
4\ ^  / t /k t  t  A
Amin. Amin.
Figure 7.2) Protocol for investigating duration of PAF-induced airway hyper-reactivity.
7.2.3 The role of kinin Bi receptors in PAF-induced nasal airway hyper­
reactivity
The aim of this study was to determine whether intranasal pre-treatment with PAF 
alters nasal responsiveness to challenge with the kinin receptor agonist, des- 
arg10-kallidin. Subjects were challenged bilaterally with 100 pi sprays of saline; 
bradykinin, 100 pg; des-arg10-kallidin, 200 pg; and des-arg10-kallidin, 400 pg. Each 
challenge was performed in a random order and at thirty-minute intervals. 
Immediately prior to, 2, 5, 10 and 15 minutes after each nasal challenge, the
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minimum cross-sectional area (Amin) of the nasal airway was determined by 
acoustic rhinometry. Half an hour after receipt of the last drug subjects were treated 
intranasally with a 100 pi spray of PAF, 60 pg, or saline. Both treatments were 
administered randomly in a single blind cross-over manner at least a week apart. 
Four hours after receipt of PAF or saline subjects were re-challenged bilaterally with 
100 pi sprays of bradykinin, 100 pg; des-arg10-kallidin, 200 pg; and des-arg10- 
kallidin, 400 pg. Each challenge was performed in a random order and at thirty- 
minute intervals. Amin. were determined immediately prior to, 2, 5, 10 and 15 
minutes after all three challenges. The protocol of this investigation is summarized 
in figure 7.3:
Saline / PAF
DAKD
Saline Bradykinin (200 ug)
1_____i
DAKD 
(400 ug)
DAKD DAKD 
Bradykinin (200 ug) (400 ug)
Time: t= -2 .0  hrs t= -1 .5  hrs t= -1.0 hrs t= -0 .5  hrs t=  0  hrs t=  4 hrs t=  4 .5  hrs
i ,  ^  A A *  i A ^  ^  A A f  ^  f  ' k Jk ijk A  * h ^  ^  ^  Ai i r  ^  ‘A '^ -  a
Amin. | Amin. | | Amin. Amm. | Amin. Amin.
=  5  hrs
A A A A
Amin. ~]
Figure 7.3) Protocol for investigating the effect of PAF pre-treatment on challenge with a 
kinin B-i receptor agonist. DAKD is des-arg10-kallidin.
7.2.4 The effect of unilateral pre-treatment with PAF on contralateral 
histamine-induced nasal blockage
The aim of this study was to determine whether unilateral pre-treatment with PAF 
alters histamine-induced nasal blockage in the contralateral nostril. Subjects were 
challenged unilaterally (in the left nostril) with a 100 pi spray of saline. The minimum 
cross-sectional area of the nasal airway (Amin) was measured immediately prior to, 
2, 5, 10 and 15 minutes after challenge with saline. Thirty minutes after receipt of 
saline, subjects were treated in the contralateral nostril (right nostril) with a 100 pi 
spray of PAF, 80 pg, or saline. It must be noted that the dose of PAF used in this 
investigation does not cause nasal congestion (Maniscalco et al., 2000). Subjects 
were then re-challenged in the left nostril (contralateral to the nostril which PAF or 
saline was administered to 6 hours prior) with a 100 pi spray of histamine, 200 pg. 
Amin. was measured (in both nostrils) immediately prior to, 2, 5, 10 and 15 minutes
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after challenge with histamine. This protocol was repeated at least a week apart in 
a single blind crossover manner (Part 1).
This investigation was repeated again in a single blind cross-over manner at least 
one week apart but with each subject receiving PAF, 80 jug, or saline in the right 
nostril, and histamine in the left nostril (Part 2). The protocol of these investigations 
are summarized in figure 7.4A and 7.4B respectively:
Saline 
(Left nostril)
Time:
Saline / PAF 
(Right nostril)
t=  -0.5 hrs t=  0 hrs
Histamine 
(Left nostril)
t=  6 hrs
A ^ *i St ^  ^ 4 \
Amin. Amin.
B
Saline 
(Right nostril)
Time: t=  -0.5 hrs
Saline / PAF 
(Left nostril)
t= 0 hrs
Histamine 
(Right nostril)
t=  6 hrs
4 \ ^ ^  ^  4t 4V ^ 4 \
Amin. Amin.
Figure 7.4A and 7.4B) Protocol for investigating the effect of unilateral pre-treatment with 
PAF on contralateral histamine-induced nasal blockage.
7.2.5 The effect of unilateral pre-treatment with PAF on contralateral 
bradykinin-induced nasal blockage
The aim of this study was to determine whether unilateral pre-treatment with PAF 
alters bradykinin-induced nasal blockage in the contralateral nostril. Subjects were 
challenged unilaterally (in the left nostril) with a 100 pi spray of saline. The minimum
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cross-sectional area of the nasal airway (Amin) was measured immediately prior to, 
2, 5, 10 and 15 minutes after challenge with saline. Thirty minutes after receipt of 
saline, subjects were treated in the contralateral nostril (right nostril) with a 100 pi 
spray of PAF, 80 pg, or saline. It must be noted that the dose of PAF used in this 
investigation is not sufficient enough to nasal congestion (Maniscalco et al., 2000). 
Subjects were then re-challenged in the left nostril (contralateral to the nostril which 
PAF or saline was administered to 6 hours prior) with a 100 pi spray of bradykinin, 
100 pg. Amjn. was measured (in both nostrils) immediately prior to, 2, 5, 10 and 15 
minutes after challenge with bradykinin. This protocol was repeated at least a week 
apart in a single blind crossover manner (Part 1).
This investigation was repeated in a single blind cross-over manner at least a week 
apart but with each subject receiving PAF, 80 pg, or saline in the right nostril, and 
bradykinin in the left nostril (Part 2). The protocol of these investigations are 
summarized in figure 7.5A and 7.5B respectively:
Saline 
(Left nostril)
Time:
Saline / PAF 
(Right nostril)
t= -0.5 hrs t= 0 hrs
Bradykinin 
(Left nostril)
t= 6 hrs
A ^  ^  ^  i < >
Amin. Amin.
Figure 7.5A and 7.5B) Protocol for investigating the effect of unilateral pre-treatment with 
PAF on contralateral bradykinin-induced nasal blockage.
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B
Saline 
(Right nostril)
Time: t=  -0.5 hrs
Saline / PAF 
(Left nostril)
t=  0 hrs
Bradykinin 
(Right nostril)
t=  6 hrs
4 \ ^ 4t A
Amin. Amin.
Figure 7.5A and 7.5B) Protocol for investigating the effect of unilateral pre-treatment with 
PAF on contralateral bradykinin-induced nasal blockage.
7.2.6 The effect of bilateral challenge with PAF on unilateral histamine- 
induced nasal blockage
The aim of this study was to determine whether bilateral pre-treatment with PAF 
alters nasal patency in the unchallenged nostril after unilateral challenge with 
histamine. Subjects were challenged unilaterally (in the right nostril) with a 100 pi 
spray of saline. The minimum cross-sectional area of the nasal airway (Amin.) was 
measured immediately prior to, 2, 5, 10 and 15 minutes after challenge with saline. 
Thirty minutes after receipt of saline, subjects were treated bilaterally with a 100 pi 
spray of PAF, 80 pg, or saline. It must be noted that the dose of PAF used in this 
investigation is not sufficient enough to nasal congestion (Maniscalco et al., 2000). 
Six hours later subjects were re-challenged in the right nostril with a 100 pi spray of 
histamine, 200 pg. Amin was measured (in both nostrils) immediately prior to, 2, 5, 
10 and 15 minutes after challenge with histamine. This protocol was repeated at 
least a week apart in a single blind crossover manner (Part 1).
This investigation was repeated in a single blind, cross-over manner at least a week 
apart but with each subject receiving a bilateral pre-treatment with PAF, 80 pg, or 
saline, and challenge with histamine in the left nostril (Part 2). The protocol of these 
investigations are summarized in figure 7.6A and 7.6B respectively:
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Saline 
(Right nostril)
Time:
Saline / PAF 
(Both nostrils)
t=  -0.5 hrs t= 0 hrs
Histamine 
(Right nostril)
t=  6 hrs
A  ^  ^  ^  /
Amin. Amin.
7.6A) Protocol for investigating the effect of bilateral pre-treatment with PAF on nasal 
blockage after unilateral challenge with bradykinin.
B
Saline 
(Left nostril)
Time:
Saline / PAF 
(Both nostrils)
t=  -0.5 hrs
T T T ~
Amin.
t=  0 hrs
Histamine 
(Left nostril)
t=  6 hrs
t  t f
Amin.
7.6B) Protocol for investigating the effect of bilateral pre-treatment with PAF on nasal 
blockage after unilateral challenge with bradykinin.
7.2.7 Data analysis
The minimum cross-sectional area (Amin ) of each nasal cavity was determined by 
acoustic rhinometry. Values of Amin. obtained after each nasal challenge were 
normalised against the basal value of Amin. A normalised Amin versus time graph 
was plotted and the area under the curve (AUC) was calculated. Data were 
analyzed statistically using a Wilcoxon sign-rank test. A p value less than 0.05 
(p<0.05) was taken as statistically significant.
Note: Data in figure 7.9B were calculated by determining the area under the “area 
under Amin. vs time curve” (figure 7.9A) at time points 4, 6 and 8 hours after 
challenge with PAF or saline.
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Data in figure 7.7B were calculated by determining the area under the “area under 
Amin. vs time curve” (figure 7.7A) at time points 1 and 6 after treatment with captopril 
or placebo.
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7.3 Results
7.3.1 The effect of bradykinin and captopril on histamineinduced nasal 
blockage
Intranasal challenge with bradykinin, 250 jug, caused a significantly greater 
reduction in nasal patency compared to the change in nasal patency caused by 
challenge with saline (p<0.05, Wilcoxon sign-rank test) (figure 7.7). Re-challenge 
with bradykinin 1 hour after receipt of captopril, 12.5 mg, resulted in significant 
potentiation of nasal blockage (p<0.05, Wilcoxon sign-rank test). Nasal blockage 
caused by intranasal challenge with histamine 6.5 hours after pre-treatment with 
captopril and repeated challenges with bradykinin was not significantly different 
from the histamine-induced nasal blockage generated after repeated challenges 
with bradykinin without oral captopril (figure 7.8).
7.3.2 The time-course of PAF-induced airway hyper-reactivity
Nasal challenge with 200 pg of histamine, 0, 4, 6 and 8 hours after pre-treatment 
with saline caused a significant reduction in nasal patency compared to challenge 
with saline (figure 7.9A) (p<0.05, Wilcoxon-sign rank test). Histamine-induced nasal 
blockage generated 4, 6 and 8 hours after pre-treatment with PAF, 60 pg, was 
significantly greater than the nasal blockage obtained after pre-treatment with saline 
(figure 7.9B) (p<0.05, Wilcoxon-sign rank test).
7.3.3 The role of kinin Bi receptors in PAF-induced nasal airway hyper­
reactivity
Bradykinin, 100 pg, caused a reduction in nasal patency which was significantly 
enhanced by pre-treatment with PAF, 60 pg, 6 hours prior, compared to the 
reduction in nasal patency observed after pre-treatment with saline (p<0.05, 
Wilcoxon sign-rank test). Des-arg10-kallidin, 200 pg and 400 pg,
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Figure 7.7) (A) A graph showing the change in nasal patency after challenges with
bradykinin, 250 pg, prior and post receipt of captopril or placebo. Amjn was measured in
triplicate before 2, 5 and 10 min after each challenge. Values were normalised by
expressing Amin. as a percentage decrease in Amln. from baseline for each subject, following
which the area under normalised Amjn. versus time curve (AUC) was determined. (B) Area
under “ area under Amin. vs time curve” at time points 1 and 6 hours. Data are means from 5
subjects, displayed as mean ± standard error of the mean. *Significant reduction in the AUC
post captopril treatment and challenge with bradykinin (at time points 1 and 6 hours)
compared with the reduction in AUC caused by challenge with bradykinin(at time points 1
+
and 6 hours) (p<0.05, Wilcoxon sign-rank test). Significant reduction in the AUC caused by
bradykinin challenge compared with the reduction in AUC caused by challenge with saline 
(p<0.05, Wilcoxon sign-rank test). The dotted line corresponds to unchanged nasal patency.
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Figure 7.8) A graph showing the change in nasal patency after challenge with histamine, 
200 pg, 6.5 hours after receipt of captopril, 12.5 mg, or control followed by repetitive 
challenges with bradykinin, 250 pg, 6.5 hours after receipt of captopril or control. A,™ was 
measured in triplicate before 2, 5 and 10 min after each challenge. Values were normalised 
by expressing Amin as a percentage decrease in Amin. from baseline for each subject, 
following which the AUC was determined. Data are means from 5 subjects, displayed as 
mean ± standard error of the mean. The dotted line corresponds to unchanged nasal 
patency.
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Figure 7.9(A) A graph showing the change in nasal patency after challenge with histamine, 
200 jug, at 0, 4, 6 and 8 hours after treatment with saline or PAF, 60 pg. Amin. was measured 
in triplicate immediately prior, 5, 10 and 15 min after each challenge. Values were 
normalised by expressing Amjn as a percentage decrease in Amin from baseline for each 
subject, following which the area under the normalised A,™. versus time curve (AUC) was 
determined. (B) Area under “ area under Amln. vs time curve” at time points 4, 6 and 8 hours. 
Data are means from 7 subjects, displayed as mean ± standard error of the mean.
+Significant reduction in the AUC caused by histamine after PAF pre-treatment compared 
with the reduction in AUC caused by histamine after pre-treatment with saline (p<0.05, 
Wilcoxon sign-rank test). * Significant reduction in the nasal patency following histamine 
challenge and pre-treatment with PAF, 60 pg, compared with the reduction in patency 
caused by challenge with histamine after pre-treatment with saline (p<0.05, Wilcoxon sign- 
rank test). The dotted line corresponds to unchanged nasal patency.
Saline 
PAF
saline 0 4 6 8
T im e  a fte r  tre a tm e n t (h o u rs )
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Saline
PAF
Bradykinin DAKD (200 jig) DAK D (400 jig)
Figure 7.10) A graph showing the change in nasal patency after challenge with 100 pg of 
bradykinin and des-arg10-kallidin, 200 p g  and 400 p g , 4 hours after saline or PAF, 60 pg , 
treatment. Amin. was measured in triplicate immediately prior, 2, 5, 10 and 15 min after each 
challenge. Values were normalised by expressing Amjn. as a percentage decrease in Amin. 
from baseline for each subject, following which the area under normalised Amin, versus time 
curve (AUC) was determined. Data are means from 8 subjects, displayed as mean ± 
standard error of the mean. *Significant reduction in the AUC caused by challenge with 
bradykinin post treatment with PAF compared with the reduction in AUC caused by 
challenge with bradykinin post treatment with saline (p<0.05, Wilcoxon sign-rank test). 
DAKD is des-arg10-kallidin. The dotted line corresponds to unchanged nasal patency.
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did not have a significant effect on nasal patency 4 to 5 hours patency after pre­
treatment with PAF compared to pre-treatment with saline (figure 7.10).
7.3.4 The effect of unilateral pre-treatment with PAF on contralateral 
histamine-induced nasal blockage
Part 1: Histamine challenge in the left nostril and PAF pre-treatment in the right 
nostril
Unilateral challenge of the left nostril with saline did not cause a significant change 
in the patency of either nostril (figure 7.11). Unilateral challenge of the left nostril 
with histamine, 200 pg, 6 hours after contralateral pre-treatment with saline caused 
a significant reduction in the left nostril’s patency (p<0.05, Wilcoxon sign-rank test). 
There was no significant effect on the patency of the unchallenged (right) nasal 
cavity. Unilateral challenge of the left nostril with histamine 6 hours after 
contralateral pre-treatment with PAF, 80 pg, did not have a significant effect on the 
patency of the left nasal cavity. The unchallenged nasal cavity (right nostril) 
exhibited a significant reduction in nasal patency 6 hours after ipsilateral pre­
treatment with PAF, 80 pg (p<0.05, Wilcoxon sign-rank test). The reduction in 
patency of the unchallenged nasal cavity occurred as early as 2 minutes after 
contralateral challenge with histamine and peaked at the 10-minute mark (figure 
7.12). The reduction in patency of the left nasal cavity occurred as early as 2 
minutes after challenge with histamine and began to resolve immediately.
Part 2: Histamine challenge in the right nostril and PAF pre-treatment in the left 
nostril
Unilateral challenge of the right nostril with saline did not cause a significant change 
in the patency of either nostril (figure 7.13). Unilateral challenge of the right nostril 
with histamine, 200 pg, 6 hours after contralateral pre-treatment with saline caused 
a significant reduction in the right nostril’s patency (p<0.05, Wilcoxon sign-rank 
test).
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IRight nostril 
ILeft nostril
Saline (R)
(t = -0.5 hours)
Histamine (L) 
post saline (R)
Histamine (L) 
post PAF (R)
(t = 6 hours)
Figure 7.11) A graph showing the change in nasal patency after challenge of the left nasal 
cavity with histamine, 200 pig, 6 hours after contralateral treatment with saline or PAF, 80 
pg. Amin. was measured in triplicate before 2, 5, 10 and 15 min after each challenge. Values 
were normalised by expressing Amin. as a percentage decrease in Amin. from baseline for 
each subject, following which the AUC was determined. Data are means from 9 subjects, 
displayed as mean ± standard error of the mean. (R) is challenge or treatment of the right 
nostril. (L) is challenge or treatment of the left nostril. * Significant reduction in AUC of 
challenged nostril compared to the AUC of the unchallenged nostril. The dotted line 
corresponds to unchanged nasal patency.
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Left nostril (+ histamine)
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Figure 7.12) A normalised Amin. vs. time graph showing the change in nasal patency of the 
left and right nasal cavity after challenge with histamine, 200 pg, in the left nasal cavity and 
treatment with PAF, 80 pg, in the right nasal cavity 6 hours earlier. Amin. was measured in 
triplicate before, 2, 5, 10 and 15 min after challenge with histamine. Values were normalised 
by expressing Amin. as a proportion of baseline Amin for each subject. Data are means from 
9 subjects, expressed as mean ± standard error of the mean. The dotted line corresponds to 
unchanged nasal patency.
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There was no significant effect on the patency of the unchallenged (left) nasal 
cavity. Unilateral challenge of the right nostril with histamine 6 hours after 
contralateral pre-treatment with PAF, 80 pg, caused a significant reduction in the 
patency of the right nasal cavity (p<0.05, Wilcoxon sign-rank test). There was no 
significant effect on the patency of the unchallenged (left) nasal cavity 6 hours after 
ipsilateral pre-treatment with PAF, 80 pg.
7.3.5 The effect of unilateral pre-treatment with PAF on contralateral 
bradykinin-induced nasal blockage
Part 1: Bradykinin challenge in the left nostril and PAF pre-treatment in the right 
nostril
Unilateral challenge of the left nostril with saline did not cause a significant change 
in the patency of either nostril (figure 7.14). Unilateral challenge of the left nostril 
with bradykinin, 100 pg, 6 hours after contralateral pre-treatment with saline caused 
a significant reduction in the patency of the left nasal cavity (p<0.05, Wilcoxon sign- 
rank test). There was no significant effect on the patency of the unchallenged (right) 
nasal cavity. Unilateral challenge of the left nostril with bradykinin 6 hours after 
contralateral pre-treatment with PAF, 80 pg, did not have a significant on the 
patency of the left nasal cavity. The unchallenged nasal cavity (right nostril) 
exhibited a significant reduction in nasal patency 6 hours after ipsilateral pre­
treatment with PAF, 80 pg (p<0.05, Wilcoxon sign-rank test). The reduction in 
patency of the unchallenged nasal cavity occurred as early as 2 minutes after 
contralateral challenge with bradykinin and then slowly began to resolve (figure 
7.15). The reduction in patency of the left nasal cavity occurred as early as 2 
minutes after challenge with bradykinin and began to plateau at the 5-minute mark.
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17 |Right nostril 
iLeft nostril
Saline (R)
(t = -0.5 hours)
Histamine (R) 
post saline (L)
Histamine (R) 
post PAF (L)
(t = 6 hours)
Figure 7.13) A graph showing the change in nasal patency after challenge of the right nasal 
cavity with histamine, 200 pg, 6 hours after contralateral treatment with saline or PAF, 80 
F9- was measured in triplicate before 2, 5, 10 and 15 min after each challenge. Values 
were normalised by expressing Amin. as a percentage decrease in Amjn. from baseline for 
each subject, following which the AUC was determined. Data are means from 9 subjects, 
displayed as mean ± standard error of the mean. (R) is challenge or treatment of the right 
nostril. (L) is challenge or treatment of the left nostril. * Significant reduction in AUC of 
challenged nostril compared to the AUC of the unchallenged nostril. The dotted line 
corresponds to unchanged nasal patency.
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Figure 7.14) A graph showing the change in nasal patency after challenge of the left nasal 
cavity with bradykinin, 100 pg, 6 hours after contralateral treatment with saline or PAF, 80 
pg- Amin was measured in triplicate before 2, 5, 10 and 15 min after each challenge. Values 
were normalised by expressing A,™. as a percentage decrease in Amin. from baseline for 
each subject, following which the AUC was determined. Data are means from 8 subjects, 
displayed as mean ± standard error of the mean. (R) is challenge or treatment of the right 
nostril. (L) is challenge or treatment of the left nostril. * Significant reduction in AUC of 
challenged nostril compared to the AUC of the unchallenged nostril. The dotted line 
corresponds to unchanged nasal patency.
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Figure 7.15) A normalised Amin. vs. time graph showing the change in nasal patency of the 
left and right nasal cavity after challenge with bradykinin, 100 pg, in the left nasal cavity and 
treatment with PAF, 80 pg, in the right nasal cavity 6 hours earlier. Amin was measured in 
triplicate before, 2, 5, 10 and 15 min after challenge with histamine. Values were normalised 
by expressing Amin as a proportion of baseline Amjn. for each subject. Data are means from 9 
subjects, expressed as mean ± standard error of the mean. The dotted line corresponds to 
unchanged nasal patency.
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Part 2: Bradykinin challenge in the right nostril and PAF pre-treatment in the left 
nostril
Unilateral challenge of the right nostril with saline did not cause a significant change 
in the patency of either nostril (figure 7.16). Unilateral challenge of the right nostril 
with bradykinin, 100 pg, 6 hours after contralateral pre-treatment with saline caused 
a significant reduction in the right nostril’s patency (p<0.05, Wilcoxon sign-rank 
test). There was no significant effect on the patency of the unchallenged (left) nasal 
cavity. Unilateral challenge of the right nostril with bradykinin 6 hours after 
contralateral pre-treatment with PAF, 80 pg, caused significant reduction in patency 
of the right nasal cavity (p<0.05, Wilcoxon sign-rank test). There was no significant 
effect on the patency of the unchallenged (left) nasal cavity 6 hours after ipsilateral 
pre-treatment with PAF, 80 pg.
7.3.6 The effect of bilateral challenge with PAF on unilateral histamine- 
induced nasal blockage
Part 1: Histamine challenge in the right nostril
Unilateral challenge of the right nostril with saline did not cause a significant change 
in the patency of either nostril (figure 7.17). Unilateral challenge of the right nostril 
with histamine, 200 pg, 6 hours after bilateral pre-treatment with saline caused a 
significant reduction in the right nostril’s patency (p<0.05, Wilcoxon sign-rank test). 
There was no significant effect on the patency of the unchallenged (left) nasal 
cavity. Unilateral challenge of the right nostril with histamine 6 hours after bilateral 
pre-treatment with PAF, 80 pg, caused a significant reduction in the patency of the 
right nasal cavity compared to the change in patency caused by challenge of the 
right nasal cavity with histamine after bilateral saline pre-treatment (p<0.05, 
Wilcoxon sign-rank test). The unchallenged nasal cavity (left nostril) exhibited a 
significant reduction in nasal patency 6 hours after ipsilateral pre-treatment with 
PAF, 80 pg, compared to the change in patency caused by unilateral challenge with 
saline (p<0.05, Wilcoxon sign-rank test).
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Figure 7.16) A graph showing the change in nasal patency after challenge of the right nasal 
cavity with bradykinin, 100 pg, 6 hours after contralateral treatment with saline or PAF, 80 
F9- Amin was measured in triplicate before 2, 5, 10 and 15 min after each challenge. Values 
were normalised by expressing Amin, as a percentage decrease in Amin from baseline for 
each subject, following which the AUC was determined. Data are means from 8 subjects, 
displayed as mean ± standard error of the mean. (R) is challenge or treatment of the right 
nostril. (L) is challenge or treatment of the left nostril. * Significant reduction in AUC of 
challenged nostril compared to the AUC of the unchallenged nostril. The dotted line 
corresponds to unchanged nasal patency.
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Figure 7.17) A graph showing the change in nasal patency after challenge of the right nasal 
cavity with histamine, 200 pg, 6 hours after bilateral treatment with saline or PAF, 80 pg. 
Amin, was measured in triplicate before 2, 5, 10 and 15 min after each challenge. Values 
were normalised by expressing Amin, as a percentage decrease in Amin. from baseline for 
each subject, following which the AUC was determined. Data are means from 7 subjects, 
displayed as mean ± standard error of the mean. (R) is challenge or treatment of the right 
nostril. (L) is challenge or treatment of the left nostril. * Significant reduction in AUC of 
challenged nostril compared to the AUC of the unchallenged nostril. The dotted line 
corresponds to unchanged nasal patency.
245
Chapter 7 Kinin receptors and airway hyper-reactivity
Part 2: Histamine challenge in the left nostril
Unilateral challenge of the left nostril with saline did not cause a significant change 
in the patency of either nostril (figure 7.18). Unilateral challenge of the left nostril 
with histamine, 200 pg, 6 hours after bilateral pre-treatment with saline caused a 
significant reduction in the left nostril’s patency (p<0.05, Wilcoxon sign-rank test). 
There was no significant effect on the patency of the unchallenged (right) nasal 
cavity. Unilateral challenge of the left nostril with histamine 6 hours after bilateral 
pre-treatment with PAF, 80 pg, caused a significant reduction in the patency of the 
left nasal cavity (p<0.05, Wilcoxon sign-rank test). There was no significant effect 
on the patency of the unchallenged (right) nasal cavity 6 hours after ipsilateral pre­
treatment with PAF, 80 pg.
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Figure 7.18) A graph showing the change in nasal patency after challenge of the left nasal 
cavity with histamine, 200 pg, 6 hours after bilateral treatment with saline and PAF, 80 pg. 
Amin. was measured in triplicate before 2, 5, 10 and 15 min after each challenge. Values 
were normalised by expressing Amin, as a percentage decrease in Amjn. from baseline for 
each subject, following which the AUC was determined. Data are means from 7 subjects, 
displayed as mean ± standard error of the mean. (R) is challenge or treatment of the right 
nostril. (L) is challenge or treatment of the left nostril. *Significant reduction in AUC of 
challenged nostril compared to the AUC of the unchallenged nostril. The dotted line 
corresponds to unchanged nasal patency.
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7.4 Discussion
PAF-induced airway hyper-reactivity is thought to be dependent on PAF’s ability to 
induce kinin production within the human nasal airway. First because the kinin B2 
receptor antagonists, icatibant and [1-adamantaneacetyl-D-Arg°, Hyp3, beta-(2- 
thienyl)-Ala5,8-D-Phe7]-bradykinin, inhibit PAF-induced airway hyper-reactivity in 
non-atopic individuals (Turner et al., 2000b) and, secondly because, long-term use 
of ACE inhibitors, by patients with cardiovascular complications, is associated with 
an increased occurrence of airway hyper-reactivity and coughing (Overlack et al., 
1992; Dicpinigaitis and Dobkin, 1996). Additionally, challenge of unsensitised 
guinea-pigs with bradykinin induces airway hyper-reactivity to ACh in the lower 
airways (Omini et al., 1989). However, repetitive challenge of non-atopic human 
subjects with bradykinin does not appear to induce airway hyper-reactivity to 
histamine in the nasal airway (Turner et al., 2000b). This was suspected to be due 
to bradykinins short half-life in the human nose.
Intranasal challenge with bradykinin, 250 pg, caused a significant reduction in the 
AUC, which is experienced subjectively as nasal blockage (figure 7.7). Re- 
introduction of bradykinin into the nasal airway 1 and 6 hours after treatment with 
the control produced a consistent degree of nasal congestion. This implies that 
there was no tachyphylaxis of the congestive response. Intranasal challenge with 
bradykinin, 250 pg, one hour after receipt of captopril, 12.5 mg, significantly 
enhanced the bradykinin-induced congestive response and its effects were still 
evident a further 5 hours later. However, the reduction in nasal patency caused by 
challenge with histamine, 200 pg, after repetitive challenge with bradykinin and 
receipt of captopril was not significantly different from the congestive response 
obtained in the presence of control (figure 7.8). This finding is in agreement with 
previous studies performed in the upper and lower human airways. Short-term 
treatment with the ACE inhibitors, captopril and lisinopril, failed to potentiate airway 
reactivity to histamine (Overlack et al., 1992; Dicpinigaitis and Dobkin, 1996) and 
the symptoms of the immediate response in the nasal airway of allergen-challenged 
atopic individuals (Proud et al., 1990). However, it must be noted that potentiation 
of bradykinin-induced nasal blockage does not necessarily correspond to an 
increase in the kinin content of the nasal airway. It has been reported that there are 
some circumstances, such as organ bath preparations, in which an accumulation of
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kinins in response to inhibition of ACE cannot be detected even though there is an 
icatibant-sensitive potentiation of the response to bradykinin (Busse and 
Lamontagne, 1991; Hecker et al., 1994). Moreover, reports have shown that 
captopril potentiates the effects of bradykinin in vitro, at concentrations of 
bradykinin expected to desensitise kinin B2 receptors (Hecker et al., 1994). 
Therefore, it is believed that captopril is also capable of potentiating the actions of 
kinins in vivo, independent of kinin-accumulation. However, reports have shown 
that captopril does enhance the recovery of kinins from the nasal airway of allergen- 
challenged atopic individuals (Proud et al., 1990). Nonetheless, captopril does 
potentiate the activity of kinins in vivo but this does not appear to alter nasal 
reactivity to intranasal challenge with histamine.
Intranasal challenge with histamine, 200 pg, caused a significant reduction in nasal 
patency (figure 7.9A). Re-challenge with histamine 4, 6 and 8 hours after pre­
treatment with saline caused a significant congestive response. Intranasal 
challenge with histamine 4, 6 and 8 hours after pre-treatment with PAF, 60 pg, 
significantly potentiated the congestive response (figure 7.9B). This is consistent 
with previous studies on the ability of PAF to induce airway hyper-reactivity in non- 
atopic individuals (Austin and Foreman, 1993; Turner et al., 2000b).
Pre-treatment with PAF, 60 pg, significantly enhanced the congestive response to 
bradykinin, 100 pg (figure 7.10). This also concurs with previous investigations 
(Austin and Forman, 1993). However, des-arg10-kallidin, 200 pg and 400 pg, failed 
to produce a significant change in nasal patency after pre-treatment with PAF, 60 
pg. This suggests that PAF-induced AHR within non-atopic nasal airways is not 
mediated by the expression or activation of kinin receptors.
The expression of kinin Bi receptors in atopic individuals is induced by inflammation 
of the nasal airway. Mediators such as PAF, which is only detectable in the lavages 
of allergen-challenged atopic individuals (Touqui et al., 1994) and known to cause 
inflammation of the nasal airway, may be capable of inducing the expression of 
functional kinin B  ^ receptors in non-atopic airways, as found in rat hind-paws 
(Fernandes et al., 2003). However, intranasal challenge of atopic individuals with 
des-arg10-kallidin does not induce any subjective or objective changes in symptom 
severity, even though the receptors were functional (Christiansen et al., 2002). In
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order for kinin Bi receptors to directly cause nasal blockage they need to be 
expressed on the vascular endothelium. Unfortunately, the cellular location of their 
expression within the human nose has not been determined.
Intranasal unilateral (left nostril) challenge with saline had no effect on the patency 
of the left nostril (figure 7.11). Unilateral challenge of the left nostril with histamine, 
200 pg, 6 hours after pre-treatment of the contralateral cavity (right nostril) with 
saline produced significant ipsilateral (left nostril) nasal blockage, with no significant 
change in patency of the contralateral (right nostril) nasal cavity and a similar result 
was obtained when bradykinin, 100 pg, was used in the place of histamine (figure 
7.14). Previous studies have produced similar findings. Unilateral challenge with 
histamine consistently causes ipsilateral nasal blockage, which is likely to be due to 
the activation of local vascular receptors (Kirkegaard et al., 1983; Birchall et al., 
1993; Sheahan et al., 2005). However, the response of the contralateral nasal 
cavity to challenge with histamine appears to vary. A reduction (Shelton et al., 
1994), increase (Birchall et al., 1993) and no change (Kirkegaard et al., 1983) in 
nasal patency have been observed with unilateral challenges with histamine. 
Therefore it appears that not all histamine’s effects on nasal patency may be 
exerted locally. This is not inconceivable as receptors for histamine are also 
situated on nerves within the human nasal airway (Nakaya et al., 2004). In addition 
to affecting contralateral nasal patency, unilateral challenge with histamine also 
produces a bilateral increase in nasal secretions (Raphael et al., 1989b; Riccio and 
Proud, 1996). Nasal lavage fluid of the unchallenged nasal cavity exhibits a 
significant increase in the production of glandular proteins, indicating that the 
serous glands were activated by the parasympathetic nervous system, CGRP or 
sensory neuropeptides (as mentioned in chapter 1.3.1.2.6; 1.3.1.2.7.1; 1.3.1.2.7.4).
Unilateral (left nostril) challenge with histamine, 200 pg or bradykinin, 100 pg, 6 
hours after contralateral pre-treatment with PAF, 80 pg, failed to cause statistically 
significant blockage in the left nasal cavity (figure 7.11; figure 7.14). The reason for 
this lack of blockage is not known. The PAF-treated (right) nasal cavity exhibited a 
congestive response only once the contralateral cavity was challenged with 
histamine or bradykinin (figure 7.11; figure 7.14). It must be noted that PAF, 80 pg, 
does not cause nasal congestion in the absence of challenge with histamine or 
bradykinin (Maniscalco et al., 2000). The transient nature of this response suggest
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that it may be neuronal in origin (figure 7.12; figure 7.15). This is supported by the 
fact that intranasal challenge with high doses of PAF causes nasal discomfort which 
is indicative of C-fibre activation. Alternatively, nasal blockage could be caused by 
mast cell degranulation in response to the release of tachykinins by C-fibres 
(Devillier et al., 1989; Austin et al., 1996; Baumgarten et al., 1997). However, 
receptors for PAF have not been identified on human nasal neurons (Shirasaki et 
al., 2006) and intranasal challenge with PAF does not cause the production of 
substance P within non-atopic human nasal airways (Turner et al., 1999).
Unfortunately, these results were not reproducible. When investigation 7.24 and 
7.26 were repeated on the same individuals in a cross-over manner, unilateral 
challenge with histamine or bradykinin caused ipsilateral (right nostril) blockage, 
while the PAF-treated (left) nostril did not exhibit any change in nasal patency 
(figure 7.13; figure 7.16).
Previous investigations in which PAF, 60 pg, has been introduced bilaterally into the 
nasal airway of non-atopic individuals have failed to show any sign of tachyphylaxis 
(Austin and Foreman, 1993). Therefore, investigation 7.2.4 was repeated but with 
bilateral pre-treatment with PAF, 80 pg, as opposed to contralateral pre-treatment 
to determine whether PAF’s effects on the nasal airway were reproducible.
Unilateral challenge (right nostril) with histamine, 200 pg, 6 hours after bilateral 
intranasal pre-treatment with PAF, 80 pg caused significant bilateral nasal 
blockage. Histamine-induced reduction of the right nostril’s patency was potentiated 
by pre-treatment with PAF. This concurs with figure 7.11 and previous studies 
(Austin and Foreman, 1993; Turner et al., 2000b). The unchallenged (left) nostril 
also became congested in response to contralateral challenge with histamine, as 
found in figure 7.11. This implies that PAF’s hyperresponsive-inducing effect on the 
nasal airway is not nostril selective. However, when this investigation was repeated 
on the same individuals in a cross-over manner, PAF failed to induce airway hyper­
reactivity in the left nostril (which was challenged with histamine) or congestion in 
the unchallenged (right) nostril in response to contralateral challenge with histamine 
(figure 7.18).
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One possible reason for the lack of reproducibility could be tachyphylaxis. 
Tachyphylactic responses to PAF have previously been reported in animal and 
human airways (Cuss et al., 1986; Rubin et al., 1987; Kioumis et al., 1988; Roberts 
et al., 1988; Popovich et al., 1988; Block et al., 1990; Coyle et al., 1990). The 
reason for its occurrence has not been fully established but it is believed to be 
platelet-dependent, as PAF-induced contraction of canine tracheal strips only 
occurs in the presence of fresh platelets and tachyphylaxis of this response is only 
overcome by replenishment of old platelets (Popovich et al., 1988). Additionally, 
depletion of functional platelets in vivo with an anti-rabbit platelet serum inhibits 
PAF-induced airway hyper-reactivity in rabbit lungs (Coyle et al., 1990). This 
suggests that platelets are not only involved in the onset of tachyphylaxis but they 
may also be involved in inducing airway hyper-reactivity (Pitchford and Page, 
2006). Alternatively, assuming that PAF’s airway hyper-reactivity inducing-effects 
are mediated by sensory neurons, tachyphylaxis may simply occur due to the 
depletion of neuropeptide stores, as observed with the use of high doses of 
capsaicin or repetitive stimulation of sensory neurones (Lundblad et al., 1983; 
Manzini et al., 1993).
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7.5 Summary
(1) Intranasal challenge with bradykinin, 250 pg, caused a significant reduction in 
nasal patency in comparison to the change in patency caused by challenge with 
saline. Re-challenge with bradykinin, 250 pg, 1 and 6 hours later did not show any 
sign of tachyphylaxis.
(2) Pre-treatment with captopril orally, 12.5 mg, potentiated bradykinin-induced 
nasal congestion.
(3) Nasal congestion caused by intranasal challenge with histamine, 200 pg, after 6 
hours of repetitive challenge with bradykinin, 250 pg, was not potentiated by pre­
treatment with captopril, 12.5 mg.
(4) Intranasal pre-treatment with PAF, 60 pg, significantly potentiated histamine- 
induced nasal blockage at the 4, 6 and 8 hour time points.
(5) Intranasal challenge with des-arg10-kallidin, 200 and 400 pg, failed to induce a 
significant change in nasal patency prior or post intranasal pre-treatment with PAF, 
60 pg. Intranasal challenge with bradykinin, 100 pg, 4 hours post intranasal pre­
treatment with PAF, 60 pg significantly potentiated the congestive response.
(6) Intranasal unilateral challenge with histamine, 200 pg, caused bilateral nasal 
blockage 6 hours after pre-treatment of the contralateral nasal cavity with PAF, 80 
pg. Nasal blockage was only observed in the challenged cavity when the 
investigation was repeated in a cross-over manner. A similar result was obtained 
when bradykinin, 100 pg, was used in place of histamine, 200 pg.
(7) Intranasal unilateral challenge with histamine, 200 pg, caused bilateral nasal
blockage, 6 hours after intranasal bilateral pre-treatment with PAF, 80 pg. Nasal
blockage was only observed in the challenged cavity when the investigation was
repeated in a cross-over manner.
253
Chapter 8 General discussion and future aims
CHAPTER 8
GENERAL DISCUSSION AND FUTURE AIMS
Intranasal pre-treatment of non-atopic individuals with the kinin B2 receptor 
antagonist, icatibant, dose-dependently inhibits the recovery of kinins from non- 
atopic individuals intranasally challenged with PAF. The inhibitory effect of icatibant 
on the recovery of kinins from nasal lavage fluid in vivo is extremely potent and is 
comparable to its ability to antagonise bradykinin-induced nasal blockage in vivo 
(Dear et al., 1996).
In chapter 3, icatibant failed to inhibit PAF-induced albumin production within the 
nasal airway and the kallikrein inhibitor, aprotinin, also failed to inhibit PAF-induced 
albumin production, which implies that kinins do not play a major role in the 
induction of PAF-induced increases in vascular permeability. It also suggests that 
icatibant is not likely to inhibit PAF-induced kinin production in vivo by impeding the 
influx of plasma proteins which promote kinin synthesis, such as FXII and HMWK, 
into the nasal airway. Thus, it appears that icatibant’s effect on the recovery of 
kinins from nasal lavage fluid occurs independently of the activation of vascular 
kinin B2 receptors. However, kinin production in rats which have been used to 
model pancreatitis, by intravenous administration of caerulein, is inhibited by pre­
treatment with icatibant (Griesbacher et al., 2003). This was attributed to a 
reduction of vascular permeability, as icatibant also inhibited the recovery of a2- 
macroglobulin (a marker of increased vascular permeability) and kininogen content 
of rat pancreas.
Reports have shown that pre-treatment of individuals, who suffer from perennial 
allergic rhinitis, with a non-selective kallikrein inhibitor impedes the congestive 
response to house dust mite allergen, as well as kinin production (Katori et al., 
1996). Pre-treatment of individuals who suffer from perennial allergic rhinitis with 
the kinin B2 receptor antagonist, icatibant, also potently inhibits the congestive 
response to allergen and inhibits the recovery of kinins from the nasal airway (Dear 
et al., 1996), Consequently, it was speculated that icatibant may act as an inhibitor 
of kallikrein in addition to being a kinin B2 receptor antagonist. However, it is evident
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from chapter 4 that icatibant is a significantly better antagonist of kinin B2 receptors 
than it is an inhibitor of kallikrein. This means it is very unlikely that icatibant inhibits 
the recovery of kinins from PAF-challenged non-atopic individuals or house dust 
mite challenged individuals with perennial allergic rhinitis by inhibiting tissue or 
plasma kallikrein.
The inability to detect an increase in kallikrein-like enzyme activity in the nasal 
lavage fluid of PAF-challenged non-atopic individuals could be due to the possibility 
that kallikrein is not responsible for PAF-induced kinin production. Therefore, in 
chapter 5, the enzyme activity of crude nasal lavage fluid was compared to that of 
purified tissue and plasma kallikrein. Crude nasal lavage fluid exhibited similar 
enzyme kinetics and an inhibitory profile to that of human plasma kallikrein, 
suggesting that the human plasma kallikrein is the enzyme present in crude nasal 
lavage fluid which is responsible for the cleavage of the chromogenic substrates S- 
2302 and S-2266. However, this does not necessarily imply that the enzyme 
present in crude nasal lavage fluid is responsible for PAF-induced kinin synthesis. 
Confirmation of the identity of the enzyme in crude nasal lavage fluid could be 
provided by the use of a western-blot and a kininogenase assay (with HMWK) on 
purified nasal lavage fluid obtained from non-atopic individuals challenged with 
PAF.
In chapter 6, the effect of icatibant on prekallikrein activation was determined. 
Icatibant failed to significantly inhibit the activation of prekallikrein in vitro at a dose 
known to abolish the binding of [125l]-icatibant to kinin B2 receptors of human nasal 
turbinates (Dear et al., 1996). This makes it unlikely that icatibant inhibits the 
recovery of kinins from PAF-challenged individuals in vivo by inhibiting the 
activation of prekallikrein.
As intranasal challenge with PAF causes an increase in vascular permeability, 
shown in chapter 3, it is quite feasible that plasma kallikrein is responsible for PAF- 
induced kinin synthesis within the nasal airway of non-atopic individuals. However, 
the inability of icatibant to inhibit: (1) PAF-induced albumin production (2) the 
activation of prekallikrein and (3) plasma kallikrein enzyme activity (with high 
affinity) suggests that there must be another source of kinins within the nasal airway 
which is sensitive to pre-treatment with icatibant. This other source may be tissue
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kallikrein (Poblete et al., 1993; Proud and Vio, 1993). Tissue kallikrein is stored 
within submucosal glands of the nasal airway and could be released in response to 
challenge with PAF. However, there are no reports present within the literature to 
suggest that PAF is capable of doing so and markers of glandular activation are not 
produced in response to challenge of non-atopic individuals with PAF, as shown in 
chapter 3. Nonetheless, receptors for PAF have been identified on human nasal 
submucosal glands (Shirasaki et al., 2005). Alternatively, submucosal glands may 
be activated by kinins synthesized by plasma kallikrein in response to challenge 
with PAF. While, kinin B2 receptors are not present on submucosal glands within the 
human nasal airway but they are present on nerves within the nasal airway 
(Baraniuk et al., 1990d) and it has been shown that intranasal challenge with 
bradykinin causes glandular activation, via the parasympathetic nervous system, in 
hyper-responsive individuals (Riccio et al., 1996). If this theory holds true, then it is 
likely that PAF-induced kinin production is predominantly synthesised by tissue 
kallikrein which is released in response to indirect innervation of submucosal glands 
(by the sensory-parasympathetic reflex). This theory could be tested by determining 
whether SBTI, an inhibitor of plasma kallikrein, but not tissue kallikrein, inhibits the 
recovery of kinins from PAF-challenged non-atopic individuals. Unfortunately, this 
investigation could not be performed for ethical reasons. Additionally, it would be 
interesting to determine whether intranasal challenge of non-atopic individuals with 
PAF (and atopic individuals with allergen) causes the release of tissue kallikrein 
(identified western blotting and a kininogenase assay) into the nasal airway as well 
as determine whether its release is sensitive to pre-treatment with icatibant.
The ability of icatibant to inhibit PAF-induced kinin production and AHR suggests 
that kinins may play a role in the induction of AHR. However, repetitive intranasal 
challenge of non-atopic individuals with bradykinin does not alter nasal 
responsiveness to challenge with histamine and there is no sign of tachyphylaxis to 
bradykinin-induced congestion, as shown in chapter 7. This remains true even in 
the presence of an ACE inhibitor, as shown in chapter 7.
Two possible explanations for bradykinins inability to induce AHR to histamine in 
vivo are firstly, that it is not responsible for the development of AHR, it may simply 
be responsible for the maintenance of AHR while another mediator, such as PAF, 
initiates the hyper-reactive response or secondly, bradykinin is not the only
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mediator responsible for initiating AHR, it may need to work in conjunction with 
another mediator to induce airway AHR.
As shown in chapter 7, unilateral challenge with histamine (or bradykinin) results in 
bilateral nasal blockage when the contralateral nasal cavity is pre-treated with PAF. 
However, the inability to reproduce these results in individuals which have already 
been treated with PAF suggests these results are questionable. One possible 
reason for the lack of reproducibility could be tachyphylaxis. An ideal experiment to 
address this possibility would be to reproduce these investigations 7.2.4 -  7.2.6 in 
an unpaired, as opposed to paired, manner.
In conclusion this study has shown that PAF induces kinin production within the 
human nasal airway which is impeded by pre-treatment with the high affinity kinin B2 
receptor antagonist icatibant. Multiple enzymes appear to be involved in the 
production of kinins within the nasal airway, one of which is plasma kallikrein. This 
study has also shown that icatibant does not inhibit the enzyme activity of tissue or 
plasma kallikrein potently enough to suggest that it may play a role in relief of 
symptoms of nasal allergy in vivo. Further charactersisation of the effects of PAF in 
vivo would aid the understanding of how PAF induces AHR and kinin production 
within the human nasal airway, as well as how icatibant impedes these effects.
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